Development of an oral drug delivery platform formulation for the targeted delivery of celecoxib for the chemoprevention and treatment of colorectal cancer. by McDonald, Bernard
  
 
Development of an oral drug 
delivery platform formulation for 
the targeted delivery of celecoxib 
for the chemoprevention and 
treatment of colorectal cancer  
 
A dissertation submitted for the degree of Ph.D. 
By 
Bernard McDonald  
B.Sc. Biotechnology  
M.Sc. Pharmaceutical Technology  
 
Under the supervision of Prof. Ian W. Marison  
School of Biotechnology, 
Dublin City University 
 
 
External Supervisor: Dr. Ivan Coulter, Sigmoid Pharma Ltd. 
 
January 2015
 I 
 
Declaration 
 
‘I hereby certify that this material, which I now submit for assessment on the 
programme of study leading to the award of Doctor of Philosophy is entirely my own 
work, and that I have exercised reasonable care to ensure that the work is original, and 
does not to the best of my knowledge breach any law of copyright, and has not been 
taken from the work of others save and to the extent that such work has been cited and 
acknowledged within the text of my work’ 
 
Signed: ___________________________ Date: _______________________ 
I.D. Number: 98016326
 II 
 
Table of Contents 
Declaration……………………………………………………………………………...I 
Table of Contents......…………………………………………………………………...II 
Abstract………………………………………………………………………………...VI 
Publications……………………………………………………………………………VII 
Acknowledgements…………………………………………………………………...VIII 
 
CHAPTER 1 Introduction: Colorectal cancer, celecoxib and oral drug delivery .... 1 
1.1 Background ............................................................................................................. 2 
1.2 Colorectal cancer (CRC) ......................................................................................... 3 
1.3 Celecoxib and CRC ................................................................................................. 8 
1.4 Oral drug delivery and Celecoxib ......................................................................... 14 
1.5 Nomenclature ........................................................................................................ 20 
1.6 References ............................................................................................................. 21 
 
CHAPTER 2 Pre-formulation ..................................................................................... 31 
2.1 Abstract ........................................................................................................... 32 
2.2 Introduction ..................................................................................................... 32 
2.2.1 Background ................................................................................................. 32 
2.2.2 Lipid based formulations............................................................................. 33 
2.2.3 Characterization of release from LBBDS (release testing) ......................... 46 
2.2.4 Objectives .................................................................................................... 47 
2.3 Material and methods ...................................................................................... 48 
2.3.1 Materials ...................................................................................................... 48 
2.3.2 Methods ....................................................................................................... 49 
2.4 Results and discussion .................................................................................... 52 
2.4.1 Solubility screening studies......................................................................... 52 
2.4.2 CLX liquid formulations ............................................................................. 56 
2.4.3 CLX microbead production feasibility study .............................................. 68 
2.5 Conclusions ..................................................................................................... 71 
2.6 Nomenclature .................................................................................................. 72 
2.7 Acknowledgements ......................................................................................... 73 
2.8 References ....................................................................................................... 73 
 
 III 
 
CHAPTER 3 In-vitro cell study ................................................................................... 77 
3.1 Abstract ................................................................................................................. 78 
3.2 Introduction ........................................................................................................... 78 
3.2.1 Background .................................................................................................... 78 
3.2.2 HT29 CRC carcinoma cell line ...................................................................... 79 
3.2.3 Cell viability (MTT Assay) ............................................................................ 80 
3.2.4 Cell viability and apoptosis (Flow cytometry assay) ..................................... 81 
3.2.5 Cancer metastasis (scratch wound healing assay) .......................................... 86 
3.2.6 Objectives ....................................................................................................... 87 
3.3 Materials and methods .......................................................................................... 88 
3.3.1 Materials ......................................................................................................... 88 
3.3.2 Methods .......................................................................................................... 89 
3.4 Results and discussion .......................................................................................... 93 
3.4.1 CLX liquid formulations ................................................................................ 93 
3.4.2 Effects of CLX formulations on the viability of HT29 cells ......................... 94 
3.4.3 Effects of CLX formulations on cell viability and apoptosis ......................... 98 
3.4.4 Effects of CLX formulations on the motility of HT29 cells ........................ 103 
3.4.5 In-vitro drug release studies on CLX liquid formulations ........................... 105 
3.5 Conclusions ......................................................................................................... 107 
3.6 Nomenclature ...................................................................................................... 109 
3.7 Acknowledgments ............................................................................................... 109 
3.8 References ........................................................................................................... 110 
 
CHAPTER 4 Microbead Development ..................................................................... 114 
4.1 Abstract ............................................................................................................... 115 
4.2 Introduction ......................................................................................................... 115 
4.2.1 Background .................................................................................................. 115 
4.2.2 Microencapsulation ...................................................................................... 117 
4.2.3 Microencapsulation techniques .................................................................... 118 
4.2.4 Desired CQAs of CLX formulation/technology .......................................... 125 
4.2.5 Objectives ..................................................................................................... 128 
4.3 Materials and Methods ........................................................................................ 129 
4.3.1 Materials ....................................................................................................... 129 
4.3.2 Methods ........................................................................................................ 130 
 IV 
 
4.4 Results and discussion ........................................................................................ 134 
4.4.1 Development and optimisation of CLX microbeads .................................... 134 
4.4.2 Optimised CLX microbead formulations ..................................................... 151 
4.4.3 Physical characterisation of optimised microbead formulations ................. 157 
4.4.4 Selection of optimal CLX microbead formulation....................................... 162 
4.4.5 CLX 136/B – optimal CLX microbead formulation .................................... 170 
4.5 Conclusions ......................................................................................................... 172 
4.6 Nomenclature ...................................................................................................... 174 
4.7 Acknowledgements ............................................................................................. 174 
4.8 References ........................................................................................................... 175 
 
CHAPTER 5 Colon targeting of microbeads for an in-vivo animal study ............ 179 
5.1 Abstract ............................................................................................................... 180 
5.2 Introduction ......................................................................................................... 180 
5.2.1 Background .................................................................................................. 180 
5.2.2 Animal models for CRC............................................................................... 182 
5.2.3 Colon targeting ............................................................................................. 189 
5.2.4 Objectives ..................................................................................................... 198 
5.3 Materials and Methods ........................................................................................ 199 
5.3.1 Materials ....................................................................................................... 199 
5.3.2 Methods ........................................................................................................ 200 
5.4 Results and Discussion ........................................................................................ 206 
5.4.1 Coated CLX microbead formulations .......................................................... 206 
5.5 Conclusions ......................................................................................................... 216 
5.6 Nomenclature ...................................................................................................... 218 
5.7 Acknowledgements ............................................................................................. 219 
5.8 References ........................................................................................................... 220 
 
 
 
 
 
 
 V 
 
CHAPTER 6 Encapsulation scale-up, coating optimisation and application of 
formulation platform to other actives ....................................................................... 226 
6.1 Abstract ......................................................................................................... 227 
6.2 Introduction ................................................................................................... 227 
6.2.1 Background ............................................................................................... 227 
6.2.2 Mechanical-aided dripping techniques ..................................................... 229 
6.2.3 Coating Optimisation ................................................................................ 235 
6.2.4 Objectives .................................................................................................. 241 
6.3 Materials and methods .................................................................................. 242 
6.3.1 Materials .................................................................................................... 242 
6.3.2 Methods ..................................................................................................... 243 
6.4 Results and discussion .................................................................................. 247 
6.4.1 Encapsulation scale-up .............................................................................. 247 
6.4.2 Coating optimisation to meet mouse TPP ................................................. 254 
6.4.3 Coating optimisation to meet human TPP ................................................ 257 
6.4.4 Application of the platform formulation to other APIs ............................. 263 
6.5 Conclusions ................................................................................................... 273 
6.6 Nomenclature ................................................................................................ 275 
6.7 Acknowledgements ....................................................................................... 275 
6.8 References ..................................................................................................... 276 
 
CHAPTER 7 Conclusions and perspectives ............................................................. 280 
7.1 Conclusion and perspectives ............................................................................... 281 
7.2 Nomenclature ...................................................................................................... 293 
7.3 References ........................................................................................................... 294 
 VI 
 
Abstract 
 
Development of an oral drug delivery platform formulation for the targeted 
delivery of celecoxib for the chemoprevention and treatment of colorectal cancer 
Bernard McDonald 
 
The anti-inflammatory drug celecoxib (CLX) has been shown to exert protective effects 
in colorectal cancer (CRC) therapy. The primary objective of this study was to develop 
and characterize a novel CLX multiparticulate drug delivery technology suitable for use 
in the treatment and prevention of CRC which has the potential to minimize the side 
effects associated with CLX. Liquid CLX formulations were developed as precursors to 
CLX microbeads and the effect of formulated CLX samples on the viability and motility 
of a CRC cell line was examined. CLX liquid formulations were shown for the first 
time to have an enhanced effect in comparison to the marketed CLX product Celebrex®. 
Liquid CLX formulations were translated into an optimized CLX microbead 
formulation which met a number of pre-defined critical quality attributes. A sustained 
release coat was applied to the beads. An in-vivo study was performed to compare the 
effect of the coated CLX microbeads versus Celebrex® in the attenuation of CRC 
tumours and inflammation in a CRC mouse model. Whilst the level of CRC tumour 
attenuation and inflammation was comparable between both formulations, the CLX 
microbead statistically outperformed Celebrex®. Microbead production was scaled-up 
and subsequent coating optimisation studies were performed resulting in products that 
met pre-defined target product profiles for both murine and human colon delivery. 
Finally a screening study to assess the applicability of the platform formulation to a 
range of APIs other than CLX was performed with 50% of the actives screened being 
successfully incorporated into microbeads. In summary, the in-vitro and in-vivo results 
described in this thesis present a significant step forward in CRC therapy using CLX, as 
the microbead formulation developed poses the possibility of presenting CLX in a 
format that has the potential to minimize GI and CV side effects whilst enhancing the 
effectiveness of the treatment. 
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CHAPTER 1                     
Introduction: Colorectal cancer, 
celecoxib and oral drug delivery 
 2 
 
1.1 Background 
 
Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide 
with more than 1 million new cases of CRC diagnosed each year (Siegel et al., 2014). 
CRC is a heterogeneous disease, including at least three major forms; hereditary, 
sporadic, and colitis-associated CRC. Together with familial adenomatous polyposis 
(FAP) and hereditary nonpolyposis colorectal cancer (HNPCC), chronic inflammation 
is among the top three high risk conditions for CRC (Wang and Dubois 2010). 
Significant research has been dedicated to identify novel drug targets for CRC 
prevention and treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) are one 
group of compounds that have been found to decrease the risk of CRC (Ruder et al., 
2011). NSAIDs target and inhibit the cyclooxygenase (COX) enzymes, COX-1 and 
COX-2. Since elevated COX-2 expression has been found in approximately 50% of 
colorectal adenomas and 85% of colorectal adenocarcinomas (Wang and Dubois 2010), 
it is hypothesised that NSAIDs may exert some of their anti-inflammatory and anti-
tumour effects through inhibition of COX-2. Given this hypothesis, and the fact that 
many of the unwanted GI side effects associated with NSAIDs are related to COX-1 
inhibition, there has been a focus on the use of COX-2 selective NSAIDs for the 
treatment and prevention of CRC. Celecoxib (CLX) is a COX-2 selective inhibitor. 
CLX has also demonstrated significant chemopreventative activity in colon 
carcinogenesis (Maier et al., 2004, Reddy et al, 2000 and Kawamori et al., 1998), 
however the administration of CLX is associated with the potential risk for serious CV 
side effects and also some serious GI adverse events despite being COX-2 selective 
(Sostres et al., 2010 and Pfizer Important Safety Information for Celebrex®, 2013). 
The overall objective of this project was to develop a novel CLX formulation for use in 
the treatment and prevention of CRC that would offer a more effective and safer 
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alternative to the currently marketed CLX product Celebrex®. The five subsequent 
results chapters broadly describe the following work packages involved in meeting the 
stated objective; a) pre-formulation development of lipid based CLX formulation, b) an 
assessment of the CLX lipid formulations in an in-vitro CRC cell culture model, c) 
translation of the lipid-based CLX formulations into a multiparticulate microbead, d) 
colonic targeting of the microbeads and a subsequent in-vivo assessment in an animal 
model and e) optimisation of the microbead including an assessment of the platform 
formulation with respect to other active ingredients. Each chapter outlined above 
includes a detailed introduction on the subject matter of that chapter, therefore this 
initial introduction will serve as an overview of CRC, CLX and the use of CLX in the 
treatment and prevention of CRC and finally the challenges with respect to the oral drug 
delivery of CLX. 
 
1.2 Colorectal cancer (CRC) 
 
CRC develops in the colon or the rectum which is also known as the large intestine (See 
Figure 1.1 below). The colon and rectum are parts of the digestive system, also called 
the gastrointestinal (GI) tract. The digestive system processes food for energy and also 
eliminates solid waste from the body. After food is chewed and swallowed, it travels 
through the oesophagus to the stomach. In the stomach, food is partially broken down 
before entering the small intestine via the pylorus. In the small intestine (consisting of 
the duodenum, jejunum and ileum) digestion continues and most of the nutrients are 
absorbed. The small intestine joins the large intestine in the lower right abdomen at the 
ileocecal junction. The first and longest part of the large intestine is the colon, a 
muscular tube which is approximately 1.5 meters in length. Water and mineral nutrients 
are absorbed from the food matter in the colon, whereas the leftover waste (the faeces) 
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passes into the rectum (the final 15 cm of the large intestine) and is then expelled from 
the anus. Cancer develops much less often in the small intestine than in the colon or 
rectum (American Cancer Society, 2014). The colon is divided into four sections; a) the 
ascending colon (extends upward on the right side of the abdomen), b) the transverse 
colon (crosses the body from the right to the left side), c) the descending colon 
(descends on the left side) and d) the sigmoid colon were the colon joins the rectum 
(sigmoid colon is in the shape of an “S”). The ascending and transverse sections are 
collectively referred to as the proximal colon, while the descending and sigmoid colon 
are referred to as the distal colon. Colorectal cancers have different characteristics based 
on their location within the colon or rectum (Iacopetta, 2002). In the case of women and 
older patients, proximal tumours are more prevalent, whereas distal tumours are more 
common among men and younger patients (Matanoski et al., 2006 and Nawa et al., 
2008).  
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Figure 1.1 Diagram depicting the gastrointestinal tract, including the colon and rectum. (Adapted from 
American Cancer Society, 2014). 
 
 
Most cancers of the colon begin as a noncancerous growth called a polyp that develops 
on the inner lining of the colorectum (colon/rectum). The most common kind of polyp is 
called an adenomatous polyp or adenoma. Adenomas arise from glandular cells in the 
mucosa (which produce mucus to lubricate the colorectum) as a result of a multistep 
process in which normal crypts are initiated to form foci of aberrant crypts (ACF) that 
proliferate by crypt fission to form microadenoma (De Robertis et al., 2011). The 
microadenomas enlarge to give macroscopic adenomas and eventually adenomatous 
polyps (Figure 1.2). It is estimated one-third to one-half of all individuals will 
eventually develop one or more adenomas (Bond, 2000 and Schatzkin et al., 1994).  
Some people are more likely to develop polyps than others such as those with a family 
history of polyps and/or colorectal cancer. Despite the fact that adenomas have the 
capacity to become cancerous, less than 10% are estimated to progress to invasive 
cancer (Levine and Ahnen, 2006 and Riso, 2010), however there is an increased 
tendency for cancers to evolve as adenomas become larger (Pickhardt et al., 2013). 
These cancers are refered to adenocarcinomas (Figure 1.2) and account for 96% of all 
colorectal cancers (Stewart et al., 2006). Adenocarcinomas can ultimately metastasize 
and spread to other organs via the blood or lymph system. The colorectal cancer 
description outlined above relates to the most common colorectal cancer sequence (i.e., 
adenoma-carcinoma sequence type or sporadic cancer), however as eluded to in Section 
1.1, there exists a number of other colorectal sequence types (i.e., hereditary and colitis-
associated cancer types) with their own unique histopathological features (Tanaka, 
2012). For example, in contrast to the involvement of adenomas in the case of sporadic 
cancer, colitis associated cancer involves another precancerous condition of the 
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colorectal tissue known as dysplasia which is characterised by abnormal cell growth and 
inflammation. Tissue exhibiting dysplasia can often be benign but similar to adenomas 
it can also turn malignant (Johns Hopkins Medicine Colorectal Cancer, 2014).  
In addition to understanding the histopathology of CRC (sporadic, hereditary and colitis 
associated), scientists have also been able to trace colon cancer progression at a 
molecular level. Despite differences in the stepwise mutations in oncogenes and tumour 
suppressor genes and the expression of key proteins and enzymes, there is considerable 
overlap in the genetic and signalling pathways involved in the pathogenesis of the 
different types of colorectal cancers. For example the expression of the following genes 
and associated proteins, K-ras, APC, p-53 and β-catenin, and also the enzymes such as 
COX-2 (cyclooxygenase 2) have been shown or suggested to play a role play in both 
sporadic and colitis-associated CRC (Tanaka, 2012, Terzic et al., 2010 and De Robertis 
et al., 2011). 
 
 
                      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Diagram depicting development of CRC from small adenoma (polyp) to metastatic 
adenocarcinoma (Adapted from American Cancer Society, 2014). 
 
Adenomatous 
polyp 
Microadenoma 
 
Adenocarcinoma 
 
Spread to other 
organs 
 
Macroadenoma 
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Whilst a small percentage of human colorectal cancers are associated with defined 
familial syndromes (e.g., FAP and HNPCC), the vast majority of malignant colorectal 
cancers arise out of benign adenomatous polyps over a course of several decades 
(Johnson and Fleet, 2013). In the case of non-familial colorectal cancers, malignancy 
can develop spontaneously or as a late complication of a chronic inflammatory state (De 
Robertis et al., 2011). Many of the risk factors (including environmental causes) 
associated with cancer (including CRC) are associated with some form of chronic 
inflammation. Up to 20% of cancers are linked to chronic infections, 30% can be 
attributed to tobacco smoking and inhaled pollutants and 35% can be attributed to 
dietary factors (De Robertis et al., 2011). In the case of CRC, chronic inflammation as a 
result of inflammatory bowel disease (IBD) greatly increases the risk of the disease (van 
Hogezand et al., 2002). IBD is a complex class of immune disorders that have been 
grouped into two major forms, ulcerative colitis (UC) and Crohn’s disease (CD). 
Colitis-associated CRC (CACRC) is the subtype of CRC that is associated with IBD, it 
is difficult to treat and has a high mortality (Feagins et al., 2009). More than 20% of 
IBD patients develop CACRC within 30 years of disease onset and >50% will die from 
CACRC (Lakatos and Lakatos, 2008).  
 
It is important to note that although the clearest link between inflammation and colon 
cancer is seen in patients with IBD (Fukata et al., 2007), colorectal tumours not 
associated with IBD have also been shown to display robust inflammation and increased 
expression of proinflammatory cytokines, which highlights the key role that 
inflammation plays regardless of the colorectal cancer type (Terzic et al., 2010). 
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1.3 Celecoxib and CRC 
 
Given the role that inflammation plays in CRC, there has been a lot of focus on the use 
of anti-inflammatory drugs for the treatment and prevention of CRC and in particular 
there has been a focus on the role of COX and specifically COX-2 with respect to 
inflammation and CRC progression. Two isoforms of COX have been identified: COX-
1 and COX-2. Both of these enzymes are encoded by separate genes located on different 
chromosomes and catalyze the conversion of arachidonic acid and other fatty acids to 
prostaglandins (lipid inflammatory mediators) (Gonzalez-Angulo et al., 2002). 
Evidence has revealed that although both COX-1 and COX-2 catalyze the same 
reaction, COX 1 produces metabolites that play a central role in maintaining 
homeostatic functions, including platelet aggregation, renal blood flow and gastric 
cytoprotection, whereas, COX-2 is an inducible enzyme expressed in response to a 
variety of physiological stimuli such as inflammation, fever, wound healing, and 
neoplasia (Gonzalez-Angulo et al., 2002). COX-2 is also understood be be induced 
physiologically in the heart and therefore plays a vital role in opposing platlet ahhesion 
and aggregation (Funk and Fitzgerald, 2007). The mechanism of action of COX-1 and 
COX-2 is illustrated in Figure 1.3 below. 
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Figure 1.3 Mechanism of action of COX-1 and COX-2 enzymes. COX-1 and COX-2 catalyse conversion 
of arachidonic acid into different prostaglandins.  Prostaglandins resulting from the COX 1 pathway are 
responsible for homeostatic functions whereas COX-2 prostaglandins primarily play a role in 
inflammation, fever and pain. COX-1 is referred to as constitutive enzyme as it is produced by cells under 
all types of physiological conditions, whereas COX-2 is an inducible enzyme produced only under 
specific conditions such as inflammation. 
 
Expression of COX-2 has been found to be increased at sites of inflammation and also 
in approximately 85% of CRCs and 50% of colorectal adenomas (Eberhart et al., 1994, 
Marnett and Dubois, 2002, Wang and Dubois 2010). The COX-2 protein is found in the 
cytoplasm of neoplastic colonic epithelial cells and to a lesser extent in stromal cells, 
whereas normal epithelium is negative for COX-2 (De Robertis et al., 2011). It is 
postulated that COX-2 may contribute to tumour development by modulating apoptosis, 
angiogenesis, and tumour invasiveness and also that COX-2 has a role in the 
progression of cancer via activation of metalloproteases, thereby increasing the 
invasiveness of colon cancer cells (Tsujii and Dubois, 1995). The tumorigenic effect of 
COX-2 on the development of colorectal tumours has been well documented not only in 
the sporadic (Oshima et al., 1996) but also in the colitis-associated model of CRC 
(Tanaka et al., 2003 and Kim et al., 2008). It is however noted that there exists some 
discord with respect to this as a number of other studies cast doubt on the role that 
COX-2 plays in the progression of CRC (Grosch et al., 2001, Ishikawa and Herschman, 
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2010, Arber, 2008, Sade et al., 2012 and Sacchetti, 2013). Although the mechanism for 
cancer protection by COX-2 inhibitors is unknown, it is speculated that it may relate to 
an altered synthesis of arachidonic acid metabolites which, as previously discussed, may 
play a role in apoptosis, angiogenesis, and tumour invasiveness, however it is also 
possible that COX-2 inhibitors act by COX-2 independent mechanisms with respect to 
colorectal cancer (Arber, 2008).  Regardless of the role that COX-2 plays in CRC 
progression there is a large body of evidence that anti-inflammatory drugs and 
specifically COX inhibitors have a role to play with respect to the prevention and 
treatment of CRC. The past three decades have witnessed more than 200 well-
conducted, randomized, single-blind, placebo-controlled animal studies that showed the 
consistent preventive effect of NSAIDs on carcinogen-induced colorectal neoplasia in 
rodents (Arber, 2008). In a review by Gonzalez-Angulo and colleagues (Gonzalez-
Angulo et al., 2002), a list of twenty three COX inhibitors successfully used (to varying 
degrees) in animal studies for the prevention of colon carcinogenesis is provided. The 
review includes two studies by Kawamori and colleagues (Kawamori et al., 1998) and 
Reddy and colleagues (Reddy et al., 2000) on the chemopreventative effects and the 
chemotherapeutic effects of CLX (selective COX-2 inhibitor) with respect to CRC. 
These studies demonstrated the inhibitory activity of CLX during the initiation and 
post-initiation stages of carcinogenesis (Kawamori et al., 1998) but also that CLX can 
inhibit tumour growth during the promotion/progression stage of carcinogenesis when 
premalignant lesions have developed (Reddy et al., 2000). The study by Reddy and 
colleagues is of particular interest as it suggests that colon tumour development can also 
be achieved even when the treatment is delayed and it subsequently prompted the 
clinical use of CLX in secondary prevention of colon cancer in patients with FAP and 
also patients with sporadic polyps (details of these clinical studies are outlined later). As 
eluded to above, in addition to a review of animal studies, Gonzalez-Angulo and 
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colleagues also cite several epidemiological studies and clinical trials involving aspirin, 
sulindac (non-selective COX-1 and COX-2 inhibitors) and CLX (selective COX-2 
inhibitor) which illustrate the anti-cancer effect of these NSAIDs. The studies cited 
reported a) a decreased risk of CRC (epidemiological study involving aspirin) and b) a 
suppression of adenomatous polyp formation/regression of existing polyps (FAP 
clinical studies involving CLX and sulindac). Despite evidence regarding the 
chemopreventative effects of aspirin and other conventional nonselective NSAIDs (e.g., 
ibuprofen, sulindac, naproxen and diclofenac), their long-term use may result in serious 
side effects, with the most significant side effect being their serious gastrointestinal 
toxicity which includes dyspepsia, peptic ulcer disease, and significant bleeding with 
associated increased mortality These side effects associated with nonselective NSAIDs 
are thought to result from gastric cytoprotective COX-1 inhibition (Gonzalez-Angulo et 
al., 2002). Therefore a lot of attention has focused on the use of selective COX-2 
inhibitors (which display reduced GI side effects) with respect to their ability to prevent 
the development and progression of CRC. As previously described CLX, is an example 
of one such selective COX-2 inhibitor. CLX is weakly acidic (pKa 11.1), hydrophobic 
in nature (Log P 3.5) and has a low aqueous solubility of 3—7 μg/ml at 20 °C 
(Avrahami et al., 2007). It is categorised as a BCS (biopharmaceutical classification 
system) class II drug because of its poor aqueous solubility and high membrane 
permeability (Morgen et al., 2012). The structure of CLX is shown in Figure 1.4 below. 
CLX has been shown to be 30 times more selective than COX-2 than COX-1, in 
contrast to other COX-2 inhibtors such as rofecoxib and valdecoxib (both of which have 
been withdrawn from the market) which are 300 times more selective (Marino, 2011). 
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            Figure 1.4 Structure of Celecoxib (adapted from Sigma Aldrich celecoxib product page, 2014)  
 
 
CLX exhibits anti-inflammatory, analgesic and anti-pyretic activities in animals and is 
routinely administered for human therapy as the marketed product Celebrex® in the 
treatment of osteoarthritis, adult rheumatoid arthritis and ankylosing spondylitis. Whilst 
CLX is extensively hepatically metabolised by the liver and these metabolites are in-
active, CLX does not undergo extensive first pass metabolism with approximately 50% 
of the drug remaining in its active form three hours after administration (Paulson et al., 
2000). Although there is no absolute bioavailaity data for Celebrex® in humans due to 
the absence of an intravenous dose, bioavailability studies in dogs have demonstrated an 
absolute bioavailability in the region of 30 %. (Paulson et al., 2000).  As previously 
mentioned, clinical trials have been performed to assess the effect of CLX (Celebrex®) 
on the prevention of both FAP and sporadic (non FAP related) intestinal polyps. In the 
FAP trial, six months of twice-daily treatment of FAP patients with 400 mg of CLX led 
to a significant reduction (~ 30%) in the number of colorectal polyps and was found to 
be more effective than a 100 mg twice daily dose (Steinbach et al., 2000). This 
subsequently resulted in the European approval of Pfizer’s CLX Onsenal®) product for 
the treatment of FAP. At the same time, Celebrex® was approved by the FDA (Food and 
Drug Administration) for the treatment of FAP (Cancer Network, 2002). In the EMA 
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(European Medicines Agency) approval report for Onsenal® the following mode of 
action for the product was described; ‘the active substance in Onsenal®, celecoxib, is an 
NSAID that belongs to the group of COX-2 inhibitors. It blocks the COX-2 enzyme, 
resulting in a reduction in the production of prostaglandins, substances that are 
involved in processes such as inflammation and the activity of smooth muscle (muscle 
that performs automatic tasks such as the opening and closing of blood vessels). COX-2 
is found at high levels in adenomatous colorectal polyps. By blocking the activity of 
COX-2, celecoxib helps to slow down the formation of polyps by stopping them 
developing their own blood supply and by increasing the rate of cell death’ (EMA 
Onsenal® Approval Report, 2003 and Pfizer Withdrawal Notice for Celebrex for FAP 
indication, 2012). The approval for Onsenal® and Celebrex® (for the treatment of FAP 
only) was subsequently withdrawn in 2011 as a result of Pfizer being unable to recruit 
sufficient patients to support clinical trials to prove the clinical benefits of the product 
(EMA Onsenal® Withdrawal Notification, 2011). Two further clinical trials, referred to 
as the APC (Adenoma Prevention with Celecoxib) and the PreSAP (Prevention of 
Spontaneous Adenomatous Polyps) trials were launched in 2000 to assess the effect of 
Celebrex® in reducing the proportion of subjects with new colorectal adenomas post 
baseline polypectomy after 1 and 3 years of study drug administration. The trials 
targeted patients at a high risk of recurrent adenomas. The APC trial (CLX 200 mg or 
400 mg twice daily) and the PreSAP trial (CLX 400 mg once daily) tested the efficacy 
and safety of CLX against placebo. The two trials were discontinued in 2004 based on 
an analysis that revealed that patients taking CLX were at increased risk for 
cardiovascular (CV) events (Soloman et al., 2006). For APC and PreSAP trials 
combined, 83 patients (out of a total of 3853 patients) experienced cardiovascular death, 
non-fatal myocardial infarction, non-fatal stroke, or heart failure (Solomon et al., 2006), 
however it is important to note that no excessive cardiovascular toxicity was observed 
 14 
 
for the PreSAP trial where the relative risk on 400 mg of CLX one a day compared to 
the placebo was not significant (Arber, 2008). It is also worth noting that the 200 mg 
twice-daily dosing in the APC trial also demonstrated much less risk than 400 mg 
twice-daily compared with the placebo (Solomon et al., 2006). Despite the 
discontinuation of the trials, the data analysis for the trials demonstrated that in the 
PreSaP trial (in which 80% of patients had completed their 3 year treatment and follow 
up period) that the use of 400 mg of CLX once daily was shown to significantly reduce 
the occurrence of colorectal adenomas within three years after polypectomy (Arber et 
al., 2006). In the APC trial (in which 77% of patients had completed their 3 year 
treatment and follow up period) it was demonstrated that the use of CLX by patients at 
high risk for colorectal neoplasia significantly reduced the proportion of patients with 
adenomas detected during a three-year study. Additionally the trial documented a 
prevention of premalignant adenomas with CLX, although the trial was not designed to 
assess effectiveness of the drug for the prevention of colorectal cancer (Bertagnolli et 
al., 2006). Although the trials were discontinued due to CV toxicity, it has been 
reported that the trials exhibited a dose-related increase in CV events and blood pressure 
which therefore raises the possibility that lower doses or other dose intervals may be 
associated with less CV risk (Solomon et al., 2006). 
1.4 Oral drug delivery and Celecoxib 
 
Based on the information outlined above, it was planned to develop a colonic specific 
CLX formulation for the treatment and prevention of CRC, in the belief that targeting a 
lower dose of the drug to the colon would allow for a safe and more effective therapy. 
There are many ways to deliver drugs into the body including; oral delivery (through 
swallowing), sub-mucosal delivery (through buccal and sublingual mucosa), parenteral 
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delivery (through injection), transdermal delivery (through skin) and pulmonary 
delivery (through inhalation). Among these routes of delivery, oral delivery is the most 
widely accepted by patients with respect to compliance (Gupta et al., 2009). As 
previously stated CLX is a poorly soluble drug. Poorly water-soluble drugs are 
becoming more prevalent as candidates for oral drug delivery and it has been estimated 
that approximately 60–70 % of newdrug molecules are insufficiently soluble in aqueous 
media and/or have very low permeability to allow for their adequate and reproducible 
absorption from the gastrointestinal tract (GIT) following oral administration (Gupta et 
al., 2013). Drug development scientists have adopted various strategies to enhance the 
solubility of these molecules to ultimately enhance their absorption. These strategies 
can be broken down into two broad methods. The first method involves chemically 
altering the structure of the molecule in order to render it more soluble. The second 
method is described as a ‘formulation approach’ in which the active material is 
physically altered or combined with other materials that result in the solubilisation of 
the active, but critically the chemical structure of the molecule is not altered. In the case 
where the chemical structure of the molecule is altered, the outcome is a new chemical 
entity with its own toxicological profile. When addressing the solubility of a poorly 
soluble drug, the ‘formulation approach’ is usually the preferred option, primarily due 
to the significant regulatory implications involved in bringing a new chemical entity to 
the market. An example of a ‘formulation approach’ involves particle size reduction of 
crystalline compounds via micronisation (e.g., Elan’s Nanocrystal® technology) which 
can increase the surface area and hence the dissolution rate of the drug, however this 
approach may not be desirable in situations where poor wettability and handling 
difficulties are experienced for very fine powders (Gupta et al., 2013). Another 
‘formulation approach’ is that of ‘amorphous formulations’ including ‘solid solutions’ 
which can be formed using a variety of technologies including spray drying and melt 
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extrusion in which the drug is rendered amorphous and therefore more soluble. A 
drawback of ‘amorphous formulations’ is that they can display stability issues over time 
as they revert back to the crystalline form (Singh et al., 2011). Lipid based drug 
delivery systems (LBDDSs) are one of the most promising ‘formulation approaches’ for 
addressing the challenges associated with poorly soluble drugs and confers many 
advantages over other drug delivery systems (Gupta et al., 2013). Although the 
intention of this project was not to enhance the absorption of CLX, one of the key 
formulation objectives was to enhance the solubility of CLX to allow the drug to be 
available in a freely molecular form in order for the drug to be optimally available to 
interact with colonic tissue. The efficacy of an anti-cancer agent in a patient depends 
both on its potency but also on the application of an effective drug delivery system to 
ensure the drug is targeted to the site of action (Venkatesan et al., 2011).  On this basis, 
a LBDDS in which the drug is delivered in a pre-solubilized form was selected as the 
most appropriate formulation approach for this project (refer to Chapter 2 for further 
details on LBDDSs). The second key formulation objective was to present the drug in a 
multiparticulate pellet format based on the following advantages of multiparticulate 
dosage forms (Sharma and Chaurasia, 2013, Asghar and Chandran, 2006 and Porter, 
2013); 
 
• Multiparticulates/pellets are less susceptible to dose dumping than single unit 
bolus formulations (e.g., tablets, soft gelatine capsules or powder filled hard 
gelatine capsules) 
 
• Multiparticulates reduce intra and inter-subject variability by reducing variations 
in gastric residence times and GI transit times 
 17 
 
o Particles smaller than 2 mm can pass through the constricted pyloric 
sphincter even during the gastric phase of the digestion process and 
distribute themselves more readily throughout the distal part of the 
gastrointestinal tract  
o Multiparticulates are also retained longer in the colon (thereby allowing 
for a more prolonged period of action) 
 
• Multiparticulates disperse freely in the GI tract thereby allowing for more 
widespread interaction with GI tissue 
 
• Multiparticulates can minimise irritant effects 
o Single unit dosage forms can potentially lodge in restrictions within the 
gastrointestinal tract, causing the release of drug to be localized and thus 
cause mucosal damage should the drug possess irritant effects. This 
potentially harmful effect can be minimized with multiparticulates since 
their small size reduces the likelihood of such entrapment, while the drug 
concentration is spread out over a larger number of discrete particles. 
 
• The spherical nature of pellets allows for the improved application of controlled 
release coating and also enhances flow properties 
 
The combination of these key formulation objectives required the development of a 
multiparticulate formulation that was amenable to the encapsulation of lipids and the 
application of controlled release polymers. Conventional LBDDSs such as soft gelatine 
capsules were therefore not considered given that they represent a single unit dosage 
form and are not broadly amenable to coating. The selection and development of a 
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suitable formulation technology to meet the requirements outlined is described in detail 
in Chapter 4. 
As referred to earlier, CLX is currently administered for the treatment of osteoarthritis, 
adult rheumatoid arthritis and ankylosing spondylitis as the marketed formulation 
Celebrex® and was previously administered for the treatment of FAP as the marketed 
product Onsenal® (both Pfizer products). Based on a review of the available literature it 
would appear that Celebrex® and Onsenal® are equivalent products marketed under 
different brand names (FDA Oncologic Drugs Advisory Committee Briefing Document, 
2005 and MHRA Safety Advisory Notice, 2011). In the EMA scientific discussion for 
the approval of Onsenal®, the manufacturing method is outlined. It describes a product 
which is wet granulated (to improve its flow properties) followed by milling (to reduce 
the particle size and increase the surface area to aid dissolution) (EMA Scientific 
Discussion for the Approval of Onsenal®, 2004). The manufacturing method and 
product description for Onsenal® corresponds to the visual appearance of Celebrex® (a 
fine powder filled into hard gelatine capsule). Although Celebrex® is not approved for 
use in the prevention or treatment of CRC, its efficacy has been shown in the various 
clinical trials previously described. The primary drawback of Celebrex® is its CV side 
effects and despite being COX-2 selective, Celebrex® is also associated with GI toxicity 
(Silverstein FE et al., 2000, Pfizer Celebrex® Monograph 2014).  The CV side effects 
associated with COX-2 inhibitors is understood to be a result of the inhibition of the 
physiological induction of COX-2 in the heart (Funk and Fitzgerald, 2007). In the case 
of GI side effects, COX-2 is produced in the intestinal epithileum in response to tissue 
injury which accounts for aspects of the toxicity associated with drugs such as CLX 
when administered in combination with non-slective COX inhibitors such as aspirin 
which supress the mucosal defence (Wallace, 2000). A literature review in relation to 
Celebrex® identified the unwanted side effects of Celebrex® to be a) dose related (CV 
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and GI side effects) and b) dosage form related (GI side effects) (Sacchetti, 2013, 
Soloman et al., 2005 and FDA labelling Revision for Celebrex® Capsules, 2008). Aside 
from COX inhibition, direct damage to the mucus layer and cytotoxicity to the 
gastrointestinal epithelia has been observed with different NSAIDs, including CLX 
(Tomisato et al., 2004). In the case of COX-2 inhibitors such as CLX, it is postulated 
that this direct toxicity might occur in spots of higher vulnerability where the protective 
mucus is weakened by COX-1 inhibition, pre-existing lesions and incipient damage 
(Tomisato et al., 2004, Lichtenberger et al., 2006, Scarpignato and Hunt, 2010 Pfizer 
Celebrex® Monograph 2014). 
A central hypothesis of this study was that by presenting pre-dissolved CLX in 
multiparticulate form, the GI irritation effects of the current dosage form could 
potentially be alleviated and in tandem by addressing the solubility issues associated 
with the drug it would potentially allow for the opportunity of administering a lower 
dose thereby reducing the potential for both GI and CV side effects. Celebrex® was used 
throughout the project as a formulation comparator with respect to physicochemical 
performance (e.g., in-vitro release testing) and efficacy (in-vitro cell line and in-vivo 
animal studies) in the belief that the development of an enhanced formulation with 
respect to these parameters would then warrant an enhanced safety assessment in human 
volunteers in future studies. 
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1.5 Nomenclature 
Table 1.1 List of abbreviations which are listed according to their appearance in the text. 
 
Abbreviation Definition 
CRC  Colorectal cancer  
FAP Familial adenomatous polyposis  
HNPCC Hereditary nonpolyposis colorectal cancer 
NSAIDs Non-steroidal anti-inflammatory drugs  
COX Cyclooxygenase  
CLX Celecoxib 
GI Gastrointestinal 
ACF Aberrant crypt foci 
IBD Inflammatory bowel disease 
UC Ulcerative colitis 
CD Crohn’s Disease 
CACRC Colitis associated colorectal cancer 
CV Cardiovascular 
BCS Biopharmaceutics classification system 
EMA European medicines agency  
LBDDS Lipid based drug delivery system 
MHRA Medicines and healthcare products regulatory agency 
FDA Food and drug administration 
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2.1 Abstract 
 
The purpose of this phase of the project was to develop a lipid-based celecoxib (CLX) 
liquid formulation which would act as a precursor for the development of a suitable oral 
drug delivery formulation designed to deliver pre-solubilised CLX to the 
gastrointestinal (GI) tract and more specifically to the colon for the treatment of 
colorectal cancer (CRC). The solubility of CLX in a range of lipids, surfactants and 
cosolvents was evaluated. CLX was solubilised in mixtures of these vehicles to produce 
liquid formulations. The in-vitro release of these liquid formulations was assessed and 
compared to the marketed CLX product Celebrex® with optimised liquid CLX 
formulations demonstrating a greater release performance to Celebrex®. A successful 
feasibility study was performed in which the potential for converting liquid CLX 
formulations into CLX microbeads was assessed.  
 
2.2 Introduction 
2.2.1 Background  
 
The challenges of orally delivering poorly soluble drugs such as CLX to the colon for 
the treatment and prevention of CRC were outlined in Chapter 1, which concluded that 
a multiparticulate lipid based drug delivery system (LBDDS) in which the drug is 
delivered in a pre-solubilized form was the optimal formulation type for CLX for this 
indication. Over the past several decades, LBDDSs (emulsions, microemulsions, mixed 
micelles etc.) have been explored for resolving a variety of drug delivery challenges 
(Cannon and Long, 2008, Kalepu et al., 2013).  Most frequently LBDDSs for oral use 
are designed to present a poorly soluble drug in a solubilized format to eliminate 
dissolution of crystalline material as the rate limiting step of absorption (Pouton, 2000). 
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For this project the intention was to develop a lipid based formulation in which the 
dissolution of CLX in the GI tract would be eliminated as a rate limiting step, thereby 
allowing for the drug to be delivered to colonic tissue in a free molecular form. 
2.2.2 Lipid based formulations  
 
Lipids are one of the most versatile excipient classes available to formulation scientists 
for improving the solubility of poorly water soluble drugs. The formulation options 
include lipid suspensions, solutions, emulsions, microemulsions, mixed micelles, 
SEDDs (self-emulsifying drug delivery systems), SMEDDS (self-microemulsifying 
drug delivery systems), thermo-softening matrices and liposomes. When designing one 
of these lipid based drug delivery systems there are hundreds of potential excipients 
from which to choose, however despite the number of possibilities there are only a 
relatively small subset of lipids which have found application in clinical development 
due to a lack of regulatory approval (Gibson, 2007). Typically lipid classes used for 
pharmaceutical applications include the following; a) fatty acids, b) natural oils/fats, c) 
semi-synthetic mono-, di- and triglycerides, d) mixtures of glycerides/glyceride 
polyethylene glycol (PEG) derivatives and fatty acid esters of PEG and e) polyglyceryl 
fatty acid esters. A brief background to each of these lipid classes is included here. 
Surfactants and co-solvents play a key role in lipid formulations and are also described. 
Finally, a brief overview of the most common lipid based formulations is provided. 
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2.2.2.1 Lipids 
 
A. Fatty acids 
 
Fatty acids are monocarboxylic acid derivatives of saturated or unsaturated (carbon- 
carbon double bond) aliphatic hydrocarbons. Saturated fatty acids with eight or fewer 
carbons are flowable liquids at room temperature whilst those fatty acids of 10 or more 
carbons in chain length are semi-solid at room temperature and possess melting points 
that increase in proportion to the hydrocarbon chain length but which decrease with 
increasing degree of unsaturation. Fatty acids find pharmaceutical application primarily 
as solubilizing vehicles for poorly water soluble drugs (Gibson, 2007 and Saxena et al., 
2013). The structure of oleic acid is provided in Figure 2.1 below as an example of a 
fatty acid. The abbreviated name for oleic acid is C18:1, which describes a fatty acid of 
18 carbons containing one carbon-carbon double bond.  
 
 
Figure 2.1 Structure of oleic acid (C18:1) (Adapted from Chemspider oleic acid technical information 
page, 2014) 
 
B. Natural oils and fats 
 
Naturally occurring oils and fats are comprised of mixtures of various triglycerides (TG) 
and are more commonly (but rarely) referred to as triacylglycerols since chemically they 
are fatty acid tri-esters of glycerol. Naturally occurring triglycerides contain fatty acids 
of varying chain lengths and degrees of unsaturation. Based on the length of their 
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component fatty acids, triglycerides can be classified as short (< 5 carbons), medium (6-
12 carbons) or long chain (> 12 carbons) (Gibson, 2007 and Boyd et al., 2011). The 
structure of a glyceryl trioleate (a major component of olive oil) is provided in Figure 
2.2 below as an example of a long chain triglyceride. 
                  
Figure 2.2 Structure of a glyceryl trioleate (Adapted from Sigma Aldrich glyceryl trioleate product page 
2014). 
 
C. Semi-synthetic mono-, di-, and triglcerides 
 
In addition to naturally occurring triglycerides, there also exists a wide range of semi-
synthetic mono-, di- and triglycerides which contain one, two and three fatty ester 
groups respectively. The primary advantage of semi-synthetic glycerides compared to 
naturally occurring glycerides is that they offer more uniform compositions with respect 
to fatty acid content, however it should be acknowledged that semi-synthetic glycerides 
still exhibit a certain amount of compositional variability (e.g., with respect to fatty acid 
content and the position of fatty acids on the glycerol backbone). The compositional 
variability of semi-synthetic glycerides can vary depending on the excipient brand and 
from batch to batch, therefore careful consideration should be employed as part of the 
selection process. In Table 2.1, the composition of Miglyol® 810N is shown as an 
example of a semi-synthetic medium chain triglyceride (Gibson, 2007). 
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                                 Table 2.1 Composition of Miglyol® 810N (Gibson, 2007). 
Fatty Acid Composition (%) 
Caproic (C6) ≤ 2 
Caprylic (C8) 65-80 
Capric (10) 20-35 
Lauric (C12) ≤ 2 
Myristic (C14) ≤ 1 
 
 
D. Mixtures of glycerides/glyceride PEG derivatives and fatty acid esters of 
PEG 
 
Another common class of lipid excipients are mixtures of mono-, di- and triglycerides/ 
glyceride PEG derivatives and fatty acid esters of PEG. These excipients are commonly 
used as solubilising vehicles, surfactants, wetting agents and as emulsifiers in 
SEDDS/SMEDDS. Some typical examples of this excipient class are detailed in Table 
2.2 below. These excipients range from being highly lipophilic (e.g., Labrafil® M 1944 
CS – HLB of 3–4) to being water soluble (e.g., Cremophor® RH-40 – HLB of 14–16). 
See Section 2.2.2.2 for further details on hydrophile-lipophile balance (HLB). 
 
Table 2.2 Examples of mixtures of glycerides/glyceride PEG derivatives and fatty acid esters of PEG 
Chemical name Composition Trade name 
PEG-32 glyceryl 
laurate 
Mono-, di-, and trilauric (C12:0) acid esters of glycerol plus 
mono- and difatty acid esters of PEG 1500 Gelucire
®
  44/14 
PEG-32 glyceryl 
palmitosterate 
Mono-, di-, and tripalmitic acid (C16:0) and steraic acid 
(C18:0) esters of glycerol plus mono- and difatty acid esters of 
PEG 1500 
Gelucire®  50/13 
PEG-8 glyceryl 
caprylate/caprate 
Mono-, di-, and tricaprylic acid (C8:0) and capric acid (C10:0) 
esters of glycerol plus mono- and difatty acid esters of PEG 
1500 
Labrasol®   
PEG-6 glyceryl 
oleate 
Mono-, di- and trioleic acid (C18:1) esters of glycerol and 
mono and diesters of PEG 300 
Labrafil® M 1944 
CS 
PEG-6 glyceryl 
linoleate 
Mono-, di- and trilinoleic acid (C18:2) esters of glycerol and 
mono and diesters of PEG 300 
Labrafil® M 2125 
CS 
PEG-35 castor oil Mixtures of glyceryl PEG ricinolate with fatty acid esters of PEG, free PEGs and ethoxylated glycerol Cremophor
®
 EL 
PEG-40 
hydrogenated 
castor oil 
Hydrogenated glyceyl PEG ricinoleate with 40 moles of 
ethylene oxide per mole of castor oil 
Cremophor® RH-
40 
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E. Polyglyceryl fatty acid esters  
 
The final lipid classification that was considered as part of this project was polyglyceryl 
fatty acid esters. Polyglyceryl fatty acid esters are composed of a chain of glycerol 
molecules linked together by ether linkages, which are esterified with one or more fatty 
acid molecules. Similar to the previous category described, these excipients find 
application as solubilising vehicles and surfactants and also as crystallisation inhibitors. 
An example of a polyglyceryl fatty acid ester is Plurol® Oleique which is an octasteraic 
acid (18:0) ester of a 6 glycerol unit chain (Gibson, 2007). 
 
F. Propylene glycol fatty acid esters 
 
Propylene glycol fatty acid esters are another group of substances closely related to 
glycerides but which do not fit into the classical lipid classifications described in 
Section 2.2.2. They are chemically derived from propylene glycol and fatty acids. 
Although they have surfactant properties, they are most commonly employed as 
solubilisers. Some typical examples of this excipient class are detailed in Table 2.3 
below. 
 
                       Table 2.3 Examples of propylene glycol fatty acid esters. 
 
Chemical name Trade name(s) 
Propylene glycol 
monolaurate 
Lauroglycol ® FCC  
Capmul® PG-12 
Lauroglycol 90® 
Propylene glycol 
dicaprylate/dicaprate Labrafac
®
 PG 
Propylene glycol 
monocaprylate 
Capryol® PGMC 
Capryol® 90 
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2.2.2.2 Surfactants 
 
Lipid based formulations often contain surfactants to facilitate dispersion of the drug 
and formulation components after ingestion. Conventional or traditional surfactants are 
made up of distinct regions; a hydrophobic portion referred to as the ‘tail’ and a 
hydrophilic ‘head’ group. The hydrophobic portion of these surfactants is commonly 
made up of straight- or branched- hydrocarbon chains, which may include aromatic 
moieties. The hydrocarbon tails are normally flexible, and when aggregated present a 
fluid hydrocarbon environment for the solubilisation of hydrophobic materials 
Surfactant structures other than the conventional head/tail arrangement also exist, for 
example, bile salts have a less common planar structure where the steroidal backbone 
presents a hydrophobic face and the reverse face is hydrophilic (Liu et al., 2008). 
Surfactants are often classified according to their hydrophile-lipophile balance (HLB) 
number. The HLB balance of a surfactant is a measure of the degree to which it 
is hydrophilic or lipophilic. Surfactants with low HLB values (1–9) are more lipophilic 
and tend to be lipid soluble, whereas those with high HLB values (>10) are more 
hydrophilic and often form transparent micellar solutions when added to water. A blend 
of low and high HLB surfactants are often used in the preparation of oil-in-water 
emulsions to ensure a maximum resistance to phase separation and a high degree of 
dispersion (Gibson, 2007 and Cannon and Long, 2008). 
In the case of traditional surfactants, the chemical nature (i.e., the charge) of the 
hydrophilic head group is also used to classify surfactants into four distinct groups; 
nonionic (no charge), anionic (negatively charged), cationic (positively charged) and 
zwitterionic (negatively and positively charged – pH dependent).  
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Nonionic surfactants are the most widely used surfactants in pharmaceutical systems 
due to their low toxicity and excipient compatibility and were therefore the focus with 
respect to surfactants in this project. The head groups of nonionic surfactant molecules 
contain no charged moieties, with their hydrophilc properties attributed to the presence 
of hydroxyl groups. All of the lipids listed in Section 2.2.2.1 D with the exception of 
Labrafil® M 1944 CS and Labrafil® M 2125 CS are classified as nonionic surfactants. 
Other nonionic surfactants include the following categories; sorbitan fatty acid esters, 
PEG-ylated sorbitan fatty acid esters, PEG fatty acid esters and vitamin E PEG esters. 
The most common nonionic surfactants used in the pharmaceutical industry (including 
their HLB values) are detailed in Table 2.4 below. The non-ionic surfactants from 
section 2.2.2.1 D are also included. Figure 2.3 below shows the structure of Solutol® 
HS-15, a PEG fatty acid ester. Solutol® HS-15 (also referred to as Kolliphor® HS-15) is 
a non-ionic solubiliser and surfactant obtained by reacting 15 moles of ethylene oxide 
with 1 mole of 12-hydroxy stearic acid. The resulting product consists of PEG mono- 
and di-esters of 12 hydroxystearic (primary lipophilic component) and of about 30% of 
free PEG. Solutol® HS-15 is a yellowish white paste at room temperature that becomes 
liquid at approximately 30ºC. It is soluble in water and its critical micelle concentration 
lies between 0.005 and 0.02% (BASF Solutol®HS-15 technical information sheet, 
2012). 
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                                 Table 2.4 Examples of nonioinc surfactants. 
 
Classification Chemical Name HLB Trade name 
Sorbitan fatty 
acid esters 
Sorbitan monooleate 4 Span® 80 
Sorbitan trioleate 2 Span® 85 
Sorbitan monolaurate 8 Span® 20 
PEG-ylated 
sorbitan fatty acid 
esters 
Polyoxyethylene sorbitan 
monolaurate 17 Tween
®
 20 
Polyoxyethylene sorbitan 
monopalmitate 16 Tween
®
 40 
Polyoxyethylene sorbitan 
monosterate 15 Tween
®
 60 
Polyoxyethylene sorbitan 
monooleate 15 Tween
®
 80 
Polyethylene 
glycol fatty acid 
esters 
Polyethylene glycol-15-
hydroxystearate 15 
Solutol® HS-
15 
Vitamin E PEG 
esters Tocopherol PEG succinate 13 
Vitamin E 
TPGS 
Mixtures of 
glycerides/ 
glyceride PEG 
derivatives and 
fatty acid esters 
of PEG 
 
PEG-32 glyceryl laurate 14 Gelucire
®
  
44/14 
PEG-32 glyceryl 
palmitosterate 13 
Gelucire®  
50/13 
PEG-8 glyceryl 
caprylate/caprate 14 Labrasol
®
 
PEG-35 castor oil 13 Cremophor
®
 
EL 
PEG-40 hydrogenated 
castor oil 15 
Cremophor® 
RH-40 
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Figure 2.3 Structure of primary lipophilic component of Solutol® HS-15 (Adapted from BASF 
Solutol®HS-15 technical information sheet, 2012).  
 
 
2.2.2.3 Cosolvents 
 
Hydrophilic cosolvents may be used in lipid-based formulations to improve drug 
solubilisation. A second advantage of cosolvents is their ability to aid dispersion of lipid 
formulations by facilitating water ingress into the formulation. When cosolvents are 
employed on their own (i.e., single component systems), drug precipitation is likely due 
to rapid dissipation of the cosolvent, however when formulated with lipids, the lipids 
remain post cosolvent dissipation thereby preventing precipitation (Cannon and Long, 
2008). The amount of cosolvent employed in a formulation is generally limited by its 
compatibility with other formulation excipients (e.g., gelatine in the case of soft gelatine 
capsules). Table 2.5 below lists some common cosolvents used in the pharmaceutical 
industry. 
 
 
 
 
 
Monoester 
 
 
Diester 
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                                 Table 2.5 Examples of cosolvents.  
 
Chemical Name 
Abbreviated or 
Trade Name 
 
Ethanol EtOH 
Dimethyl Acetamide DMA 
Polyethylene Glycol 300 PEG 300 
Polyethylene Glycol 400 PEG 400 
Polyethylene Glycol 200 PEG 200 
Polyethylene Glycol 1000 PEG 1000 
Polyethylene Glycol 4000 PEG 4000 
Diethylene glycol monoethyl 
ether Transcutol
®
 P 
 
 
2.2.2.4 Lipid formulations 
 
Of the various lipid formulations listed in Section 2.2.2, emulsions/SEDDS, 
microemulsions/SMEDDS and micelle formulations are among the most common 
formulation approaches (Hauss, 2007 and Lui, 2008). A brief description of these 
formulation types is provided below.   
 
A. SEDDS and SMEDDS 
 
SEDDS are drug delivery systems consisting of drug, oils and surfactants and may also 
include cosolvents. On addition to water (e.g., in the GI tract) and with gentle agitation, 
the system will form an emulsion (i.e., a dispersion of droplets of one liquid in another 
immiscible liquid (e.g., oil in water)) (Grove and Mullertz, 2007 and Cannon and Long, 
2008). SEDDS are more practical for oral applications than ready-to-use emulsions (i.e., 
those that contain water) due to volume considerations, easier formulation into dosage 
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forms such as soft gelatine capsules and also enhanced chemical stability (due to the 
absence of water in the formulation) (Date et al., 2010). SEDDS are essentially 
emulsion preconcentrates. SMEDDS are those self-emulsifying systems that form 
microemulsions on addition to water and gentle agitation. The term microemulsion 
implies an emulsion with a very fine droplet size, however microemulsions are not 
actually emulsions (Cannon and Long, 2008). Microemulsions form spontaneously on 
mixing with little or no mechanical energy whereas for emulsions homogenisation is of 
critical importance. In comparison to emulsions, microemulsions have a much smaller 
droplet size (6-80 nm) and are visually transparent or translucent, whereas the drops of 
the dispersed phase in an emulsion are generally large (> 0.1 µm) so that they often take 
on a milky, rather than a translucent appearance (Cannon and Long, 2008). In contrast 
to emulsions, microemulsions are thermodynamically metastable. In emulsions the 
average drop size grows continuously with time so that phase separation ultimately 
occurs under gravitational force (i.e., they are thermodynamically unstable and their 
formation requires input of energy as described above). The marketed cyclosporine 
formulations Sandimmune® (SEDDS) and Neoral® (SMEEDS) are examples of 
formulations which yield emulsions and microemsulions respectively on dilution with 
the aqueous environment of the GI tract (Narang et al., 2007). 
 
B. Micelles 
 
The ability of surfactants to enhance the solubility of poorly water soluble compounds 
in an aqueous environment is widely known and is used in many aspects of drug 
formulation development (Liu et al., 2008). This enhancement of the aqueous solubility 
by surfactants occurs as a result of the dual nature of surfactant molecules (i.e., their 
discrete hydrophobic and hydrophilic regions). The term surfactant describes a surface-
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active agent. The hydrophobic (nonpolar) and hydrophilic regions (polar) of these 
surface-active agents allow them to orientate at polar-nonpolar interfaces (e.g., water/air 
or water/oil).  Once the interface is saturated, the surfactants then self-associate to form 
micelles and other aggregates, whereby their hydrophobic regions are minimized and 
shielded from aqueous contact by their hydrophilic regions. This creates a discrete 
hydrophobic environment suitable for solubilisation of many hydrophobic compounds 
(Lui et al., 2008). Alternatively, the poorly aqueous soluble drug may be solubilized 
within the head group layer at the surface or in the palisade portion of the micelle (the 
portion between the surface and the core) (Rangel-Yagui et al., 2005). In the case of 
dilute surfactant solutions, the polar head groups of the surfactant molecules are 
generally arranged in an outer spherical shell, while the hydrocarbon chains are 
orientated towards the center forming a spherical micelle (Figure 2.4 A) which are 
usually between 3–50 nm in size (Paul and Prud’homme, 2001). Depending on the type 
of surfactant employed and the solution conditions, the aggregates may form structures 
other than micelles such as lamellar bilayers (Figure 2.4 B) or spherical bilayers 
(vesicles) containing an encapsulated aqueous phase (Figure 2.4 C). As micelles 
become larger they have been shown to become more asymmetric with their shape 
changing from spherical to cylindrical and lamellar. As stated above, surfactants self-
associate in aqueous media to minimize the area of contact between their hydrophobic 
tails and the aqueous solution. The concentration of surfactant at which this 
phenomenon occurs is referred to as the critical micelle concentration (CMC) (Liu et al, 
2008). At surfactant concentrations below the CMC, the surfactant molecules exist 
predominantly as monomeric units (no micelles) whereas at surfactant concentrations 
above the CMC, micelles exist. 
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Figure 2.4 Structure of surfactant aggregates: A) spherical micelle, B) lamellar bilayer and C) spherical 
bilayer (vesicle) (Adapted from Mc Clements, 2007).  
 
Surfactant mixtures (forming mixed micelles) are commonly used in pharmaceutical 
applications as they often perform better than a single surfactant system. In addition to 
enhancing drug solubilisation, the use of mixed micelles can result in a synergy 
whereby the total concentration of required surfactant required is reduced (Liu et al. 
2008).  
As with SEDDS and SMEDDS, micelle formulations are usually formulated in the 
absence of water (i.e., they are micelle pre-concentrates). Due to incompatibility with 
encapsulation materials (e.g., gelatine) in current technologies, micelle pre-concentrates 
are less common than SEDDS and SMEDDS however given the number of components 
in SEDDS and SMEDDS, it is expected that several dispersion mechanisms are 
operating in parallel in these type of formulations (including the presence of micelles 
and mixed micelles) (Narang et al., 2007 and Grove and Mullertz, 2007). Examples of 
LBDDS which are predominantly surfactant based and thereby could be referred to as 
micelle pre-concentrates are a) the amprenavir formulation Agenerase®, b) the 
cyclosporine formulation Gengraf®, c) the fenofibrate formulation Fenogal® and d) the 
ibuprofen formulation Solufen®-Gé (Liu et al., 2008 and Strickley, 2007). 
 
 
A 
B 
C 
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2.2.3 Characterization of release from LBBDS (release testing) 
 
The characterisation of the release of an API (active pharmaceutical ingredient) is 
usually performed for a number of reasons; a) to compare formulation candidates during 
the development of a drug, b) to predict the performance of a formulation in-vivo and c) 
to act as a quality control (QC) tool (to distinguish between different batches, to assess 
formulation changes, to assess product quality during a products shelf life etc.). 
Characterisation of release from LBDDS is performed via in-vitro release testing. The 
primary focus of in-vitro release testing in the context of this stage of the project was to 
compare formulation candidates and to a lesser extent their potential in-vivo 
performance. LBDDS present special challenges in the design of release tests 
(Dressman, et al., 2007). Unlike the majority of other oral dosage forms in which the 
API is present in a solid format (e.g., tablets and granules) and which therefore undergo 
dissolution testing the drug in LBDDS is usually pre-dissolved, therefore despite the 
fact that the same medthodies are employed (i.e, use of dissolution test apparatus, 
dissolution media etc.), the use of standard dissolution terminology is not appropriate to 
describe the results of these experiments. In the cases of LBDDS, these tests are 
performed as a measure of how well the drug disperses or releases into the chosen 
media rather than a measure of how the drug dissolves1. When designing a release 
experiment for the testing of lipophilic dosage forms, the contents of the dissolution 
medium are important when trying to mimic in-vivo conditions. For example, in the GI 
tract, dispersion of the formulation will occur via emulsification in the stomach and 
small intestine (Dressman et al., 2007) and therefore it is important to mimic the 
                                                 
1
 Given that the methodologies involved include the use of standard dissolution apparatuses, dissolution 
media etc., the term ‘dissolution’ will be used to describe the methodologies where appropriate, however 
the term ‘release’ will be used to describe the release/dispersal of drug from the dosage various forms into 
the media.   
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components of the intestinal fluids to simulate this emulsification process (i.e., the use 
of biorelevant dissolution media). An alternative approach to the release testing of lipid 
based dosage forms and the approach that was adopted here is to test the lipophilic 
dosage forms in simple aqueous media such as Purified Water (PW), Simulated Gastric 
Fluid (SGF – pH 1.2) and Simulated Intestinal Fluid (SIF – pH 6.8) on the basis that the 
formulation should be as robust as possible with respect to the physiology of the GI 
tract (i.e., not reliant on GI conditions).  
 
2.2.4 Objectives 
 
Bioavailability studies have shown CLX to be a poorly soluble, highly permeable drug, 
(i.e., class II of the Biopharmaceutical Classification System), in which the 
bioavailability of the drug is limited by its poor solubility (Paulson et al., 2001). This 
poor aqueous solubility and consequent poor dissolution in gastric fluids is considered 
to be a  major drawback of celecoxib therapy (Rawat and Jain, 2004). The poor 
solubility of the drug reduces its effectiveness in treating the diseases for which it is 
indicated. In order to counteract this poor bioavailability the drug is administered in 
high doses, however these high doses result in a greater incidence of severe adverse side 
effects (FDA labelling revision for Celebrex®, 2008). It is also postulated that the 
effectiveness of CLX in the prevention and treatment of CRC is prohibited by the 
presentation of the current dosage form (powder filled capsule) which is not amenable 
to widespread interaction with colonic tissue in a free molecular form. 
The primary goal of this phase of the project was to develop a formulation for 
improving the solubility of CLX using a combination of excipients that were suitable 
for oral administration and ultimately the incorporation of the resultant formulations 
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into a suitable drug delivery technology for oral delivery. The primary aims/objectives 
of this stage of the project to meet the stated goal were as follows: 
 
 
A. The first objective of the study was to screen a range of vehicles (lipids, 
surfactants and co-solvents) and identify those in which CLX was readily 
soluble. It was proposed that by employing lipids and surfactants in the 
formulation, that the solubility of CLX would be enhanced, thereby increasing 
its oral effectiveness in the local treatment of CRC. 
 
B. The second objective was to use data collected from the initial screening studies 
to form the basis for the design of liquid formulations. The drug release 
performance (in-vitro release testing) of these liquid formulations would then be 
compared to the currently marketed CLX product Celebrex®. The drug release 
performance of the liquid formulations would also be compared to each other to 
assess the impact of changing excipient types and ratios. 
 
C. The third objective was to perform an initial feasibility trial on selected liquid 
formulations to assess if the liquid formulations selected were amenable to 
incorporation into microbeads (Refer to Chapter 4 for development and 
optimisation of microbeads).  
 
D. The fourth and final objective was to select optimal liquid formulations for 
progression to a CRC cell culture study (Refer to Chapter 3). 
 
2.3 Material and methods 
2.3.1 Materials 
Solubilisation studies were performed using a wide range of vehicles consisting of 
lipids, surfactants and cosolvents. The vehicles used here were as follows; corn oil, 
soybean oil, olive oil, oleic acid, linoleic acid, stearaic acid, Span® 80, Span® 85, Span® 
20, (all Sigma Aldrich, USA), Incromega® TG3322 (Croda, UK) Mineral Oil, Tween® 
 49 
 
20, Tween® 40, Tween® 60, Tween® 80, EtOH, DMA, PEG 300, PEG 400, PEG 200 
(Merck, Germany), Miglyol® 810, Miglyol® 812, Miglyol® 829 (all Sasol, South 
Africa), Labrafrac®,  Lipophile WL1349, Capryol® PGMC, Capryol® 90, Lauroglycol® 
FCC, Lauroglycol® 90, Labrafac® PG, Plurol Oleique® CC497, Gelucire® 44/14 
Gelucire® 50/13, Transcutol® P, Labrafil® M2125, Labrafil® M1944 CS, Gelucire® 
33/01, Labrasol®, Maisine® 35-1, Peceol (all Gattefosse, France), Captex® 300, 
Capmul® MCM, Capmul® PG-12 (all Abitec, USA), Imwitor® 308, Imwitor® 742 (both 
Cremer, Germany), Cremophor® RH40, Cremophor® EL, Solutol® HS-15 (all BASF, 
Germany) and Vitamin E TPGS (Eastman, USA). Microbeads were prepared using 
these vehicles in combination with porcine gelatin (Nitta Gelatin, Japan) and sorbitol 
(Neosorb®) (Roquette, Franace). A sample of CLX API was kindly provided by 
Erregierre (Italy). The purity of the API was 99.6% based on the COA provided by the 
supplier. All chemicals used for the release experiments, HPLC and UV testing were of 
laboratory grade. 
2.3.2 Methods 
2.3.2.1 Solubility measurements 
 
CLX was added to measured quantities of a range of lipids, surfactants and cosolvents 
in glass vials (minimum of n =2 measurements). These mixtures were stirred at room 
temperature (20°C) (except in the case of excipients which were solid at room 
temperature, in which case the solubilisation measurements were performed at elevated 
temperatures) using a magnetic stirrer.  Additional amounts of CLX were added to 
samples and were allowed to stir for periods of five min prior to observations being 
made.The solubility of CLX in the liquid vehicles was recorded as the range between 
which the samples transgressed from transparent to cloudy. 
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2.3.2.2 CLX liquid formulations 
 
CLX liquid formulations were prepared by dissolving measured quantities of CLX into 
measured quantities of liquids. Formulations were prepared as one, two or three 
component systems (i.e., containing a single liquid vehicle or mixtures of liquid 
vehicles). 
 
2.3.2.3 In-vitro release testing 
 
Release testing of CLX API was performed at 37°C in SIF (pH 6.8), SGF (pH 1.2) and 
PW (pH 7) to determine whether pH had an impact on the dissolution of CLX. The 
protocols for SIF and SGF were taken from the United States Pharmacopoeia (United 
States Pharmacopeia, 2010). A high throughput drug release screening study (n=1) was 
then performed on CLX liquid formulations at 37°C in PW.  For optimal liquid 
formulations, these release experiments were repeated (n=3). All release experiments 
were performed out using either a Varian/Vankel VK7010 dissolution apparatus 
(VanKel, USA) or a Distek Evolution 6300 (Distek, USA) equipped with standard glass 
vessels and USP type II paddles. Paddle rotating speed in all experiments was 75 rpm. 
Formulations containing 50 mg of dissolved CLX were weighed and added to 1000 mL 
of the relevant dissolution medium (SIF, SGF or PW). At specified times 1.8 mL 
samples were withdrawn, filtered through a 70 µm pore filter (QLA, USA) and analysed 
using either a high performance liquid chromatography (HPLC) method or an 
ultraviolet (UV) spectrophotometric method analysis. The % of drug released at 
particular time points was determined from peak areas which were calculated against a 
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single point external reference standard in the case of the HPLC method, whereas a 
standard curve was used for the UV method. 
 
2.3.2.4 HPLC and UV Analysis 
 
The HPLC method for the analysis of the release and assay samples was adapted from 
Saha and colleagues (Saha et al., 2002). The HPLC column used was a reverse phase 
4.6 x 250 mm Inertsil® C8 column (Inertsil, The Netherlands) with 5 µm particles. The 
mobile phase was acetonitrile:water (65:35). The isocratic method used a flow rate of 
1.25 ml/min and ultraviolet (UV) detection at 230 nm. The injection volume was 20 µl 
and the retention time was 8 min. The HPLC apparatus that was used for the analysis 
were Thermo Finnigan (Thermo Electron Corporation, USA) and Waters (Waters, 
USA) HPLC systems (and associated Chromquest and Empower software). The UV 
method for the analysis of the release samples was also adapted from Saha and 
colleagues (Saha et al. 2002). The spectrophotometer used was a A Genesys 10 series 
UV-visible spectrophotometer (Thermo Electron Corporation, USA). Absorbance was 
read at a wavelength of 251 nm. 
 
2.3.2.5 Microbead manufacture feasibility study 
 
A microbead manufacture feasibility study was performed on the basis of the CLX 
liquid formulation produced. Microbeads containing CLX were prepared via a manual 
’dripping’ method. The microbeads were manufactured by combining the ‘surfactant 
phase premix’ (drug dissolved in various combinations of surfactants, lipids and co-
solvents) with a ‘gelatine phase premix’ (mixture of gelatin, water and sorbitol) and 
mixing at approximately 60°C. Droplets of the mixture were then allowed to fall into a 
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bath of cooling/hardening oil (Miglyol® 810N) at approximately 10°C. The resultant 
beads were then air dried for 24 h (over this time the water in the formulation 
evaporated). Further details on microbead manufacture are provided in Chapter 4. Shape 
and surface morphology of freshly prepared and dried microbeads were observed under 
a Nikon (Nikon, Japan) Eclipse Ti optical microscope mounted with a digital camera. 
 
2.4 Results and discussion 
2.4.1 Solubility screening studies 
Solubility screening studies were performed to identify excipients which had the 
capacity to dissolve CLX. The excipients included a range of lipids, surfactants and 
cosolvents. The range of lipids, surfactants and cosolvents were chosen based on a 
literature review of the various grades of vehicles available (Hauss, 2007 and Lui, 
2008). 
 
2.4.1.1 Excipient screening - lipids 
 
The solubility of CLX in a range of lipids is provided in Table 2.6. Long chain and 
medium chain triglycerides demonstrated a poor capacity for dissolving CLX. Mixtures 
of monoglycerides and diglycerides proved to be efficient solubiliers for CLX. Capmul® 
MCM (glyceryl caprylate/caprate) was the best solubiliser within this class. The best 
solubilisers of CLX within the lipids tested were the propylene glycol esters. Capryol® 
90 from Gattefosse had the best solubilising power. The solubility of CLX in Capryol® 
90 was determined to be 58–64 mg/g.  
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Table 2.6 Solubility of CLX in a range of lipids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification 
 
Common name/Trade name  
 
 
 
Measured Solubility  
(mg/g) 
 
Fatty Acids 
Oleic acid 1–1.6 
Linoleic acid 1–2 
Stearic acid 6–7 
Natural Oils/Fats 
Corn Oil 2–3 
Soybean Oil 2–3 
Olive Oil 1–2 
Incromega® TG3322 
(Omega 3 oil)  < 7 
Mineral Oil < 4 
Semi-synthetic mono-, di- 
and triglycerides 
Miglyol® 810 6–9 
Miglyol® 812 8–11 
Miglyol® 829 15–19 
Captex® 300 9–11 
Labrafrac® Lipophile 
 WL1349 6–9 
Capmul® MCM 67–72 
Peceol® 21–28 
Maisine® 35–1 14–20 
Imwitor® 308 42 
Imwitor® 742 40 
Gelucire® 33/01 7–13 
 
Propylene glycol fatty esters 
Capryol® PGMC 49–56 
Capryol® 90 58–64 
Lauroglycol® FCC 22–28 
Lauroglycol® 90 27–32 
Labrafac® PG 14–21 
Capmul® PG-12 23–39 
Polyglyceryl fatty acid esters Plurol Oleique® CC497 21–28 
Mixtures of  
glycerides/glyceride PEG 
derivatives and fatty acid 
esters of PEG  
Labrafil® M 1944 CS 31–39 
Labrafil® M 2125 CS 30–60 
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2.4.1.2 Excipient Screening – surfactants 
 
The solubility of CLX in a range of surfactants is provided in Table 2.7. The sorbitans 
(Spans®) and the vitamin E PEG ester demonstrated a poor capacity for dissolving 
CLX. The best results for the solubilisation of CLX were found within the 
glyceride/PEG ester mixtures, the PEG-ylated sorbitan fatty acid esters and the PEG 
esters. Among the excipients with the best solubilisation capacity were Cremophor® EL, 
Tween® 20 and Solutol® HS-15 (Solutol required melting at approximately 30°C) which 
had solubilisation capacities for CLX of 264–330, 233–269 and 320–356 mg/g 
respectively. 
 
Table 2.7 Solubility of CLX in a range of nonionic surfactants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Classification HLB Trade name Measured solubility (mg/g) 
Sorbitan fatty acid esters 
4 Span® 80 <17 
2 Span® 85 <24 
8 Span® 20 <17 
PEG-ylated sorbitan fatty 
acid esters 
17 Tween® 20 270–300 
16 Tween® 40 280–310 
15 Tween® 60 248–275 
15 Tween® 80 233–269 
PEG fatty acid esters 15 Solutol® HS–15 320–356 
Vitamin E PEG esters 13 Vitamin E TPGS 41–59 
Mixtures of glycerides/ 
glyceride PEG derivatives 
and fatty acid esters of PEG 
 
14 Gelucire®  44/14 300-330 
13 Gelucire®  50/13 316-342 
14 Labrasol® 311-354 
13 Cremophor® EL 264-330  
15 Cremophor® RH-40 240-250 
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2.4.1.3 Excipient Screening – cosolvents 
 
The solubility of CLX in a range of cosolvents is provided in Table 2.8. The solubility 
of CLX was found to be high in all of the solvents tested with the exception of ethanol 
where the maximum solubility was determined to be between 100–125 mg/g. CLX 
demonstrated high solubility in diethylene glycol monoethyl ether (Transcutol® P). The 
solubility of CLX in Transcutol® P was 345-390 mg/g. Although the solubility of CLX 
in the high molecular weight PEGs appear to be very high, these PEGs required the 
input of heat (~45°C for PEG 1000 and ~65°C for PEG 4000) therefore it is difficult to 
determine whether the solubility of CLX is full attributable to the excipient or to the 
heat input or a combination of both (Note: it was difficult to control the heat on the 
hotplate magnetic stirrer). 
 
                     Table 2.8 Solubility of CLX in a range of cosolvents. 
 
Chemical name 
Trade name /Common 
name 
 
Measured 
Solubility (mg/g) 
Ethanol EtOH 100–125 
Dimethyl Acetamide DMA 152–288 
Polyethylene Glycol 300 PEG 300 310–362 
Polyethylene Glycol 400 PEG 400 282–324 
Polyethylene Glycol 200 PEG 200 313–362 
Polyethylene Glycol 
4000 PEG 4000 615–660 
Polyethylene Glycol 
1000 PEG 1000 601–625 
Diethylene glycol 
monoethyl ether Transcutol
®
 P 345–390 
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2.4.2 CLX liquid formulations  
 
Liquid formulations containing CLX dissolved in one, two and three component 
systems (i.e., in combinations oils/surfactants/cosolvents) were prepared on the basis of 
the results of the screening studies above. The composition of these liquid formulations 
is provided in the following sections. In-vitro release testing was performed on these 
formulations to assess and compare their performance. In-vitro testing was also 
performed on the CLX API and the marketed product Celebrex®. 
 
2.4.2.1 In-vitro release testing of CLX API 
 
A release test was performed on 50 mg of CLX API in PW, SIF and SGF (Figure 2.5). 
The release of the API was very poor in all media with a maximum release of 4 % after 
6 hours in PW. The drug release performance of the drug was shown to be independent 
of the pH of the dissolution media. 
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Figure 2.5 Percentage of drug released from release testing of CLX API in PW, SGF and SIF. The data 
presented are mean values ± STDEV (n=3). 
 
2.4.2.2 In-vitro release of Celebrex® 
 
A release test was performed on 50 mg Celebrex® capsules in PW, SGF and SIF (Figure 
2.6). Celebrex® wassupplied as 100 mg capsules. The contents of each capsule was 
removed and weighed. Fifty percent of the contents were then placed into empty 
capsules so that the content of CLX was equal to 50 mg.  The release of the Celebrex® 
was very poor in all three media (SGF, SIF and PW) with a maximum release of 6 % 
achieved (in PW). The drug release performance of the drug product was shown to be 
independent of the pH of the dissolution media in the range from pH 1.2 to 6.8 
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 Figure 2.6 Percentage of drug released from release testing of Celebrex® in PW, SIF and SGF. The data 
presented are mean values ± STDEV (n=3). 
 
2.4.2.3 In-vitro release performance of preliminary CLX liquid formulations 
in comparison to CLX API and Celebrex® 
 
Two liquid formulations, CLX 001/L and CLX 002/L (Table 2.9) were prepared by 
dissolving CLX in Capryol® 90 and Tween® 20 respectively. A set quantity of both 
formulations equating to 50 mg of CLX were filled into empty gelatine capsules and 
were added to the dissolution medium. PW was chosen as the dissolution media as 
previous results demonstrated that the release of CLX was independent of the pH of the 
media (Figure 2.7).  
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                Table 2.9 Comparison of the composition of formulations CLX 001/L and CLX 002/L. 
Formulations CLX 001/L 
CLX 
002/L 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
 
Celecoxib 50.0 24.39 
 
Capryol® 90 950.0 - 
Tween® 20 - 975.61 
 
 
 
Figure 2.7 Percentage of drug released from release testing of CLX 001/L, CLX 002/L, 
Celebrex® and CLX API in PW. The data presented are mean values ± STDEV (n=3). 
 
The release of the CLX 002/L was greaterthanCLX API and the Celebrex® capsules. 
The release of CLX 002/L was 92 % after 1 hour. This test demonstrated that the release 
of CLX could be dramatically increased by formulating the drug in a lipophilc format. 
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The results from formulation CLX 001/L demonstrated the importance of release testing 
with respect to assessing the performance of the liquid formulations. Although the CLX 
was completely dissolved in the Capryol® 90 in formulation CLX 001/L, this was not 
sufficient to enable the drug to disperse within the dissolution media. This is a common 
problem for drugs which are formulated as liquids in solid oral dosage forms (e.g., soft 
gelatine capsules). Although the drug is presented in a solubilised form, there is often 
no or insufficient components in the formulation to allow for the dispersal of the drug 
(e.g., a surfactant). This is due to the fact that the current technologies are not 
compatible with surfactants when used at significant levels. 
 
2.4.2.4 In-vitro release comparison of CLX liquid formulations  
 
A further six formulations (CLX 004/L to CLX 009/L) were prepared and their release 
performance was compared to that of CLX 002/L. These formulations consisted of CLX 
dissolved in various combinations of Transcutol® P, Capryol® 90, Tween® 20, Miglyol® 
810N and Solutol® HS-15 (Table 2.10). Although the maximum release of these 
formulations (ranging from 5.5 to 14%) were greater than that of Celebrex® and CLX 
API, their performance were poor in comparison to CLX 002/L (Figure 2.8). The 
primary difference between these formulations and CLX 002/L was the level of 
surfactant employed (Table 2.10). 
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Table 2.10 Comparison of the composition of formulations CLX 002/L, CLX 004/L, CLX 005/L, CLX 
006/L, CLX 007/L, CLX 008/L and CLX 009/L. 
Formulations CLX 002/L 
CLX 
004/L 
CLX 
005/L 
CLX 
006/L 
CLX 
007/L 
CLX 
008/L 
CLX 
009/L 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g)  Celecoxib 24.39 320.51 141.84 141.84 319.49 194.17 233.64 
 
Transcutol® P - 679.49 - 428.37 335.46 219.42 378.50 
 
Capryol® 90 - - 429.79 429.79 - 388.35 - 
 
Tween® 20 975.61 - 428.37 - 345.05 198.06 - 
 
Miglyol® 810 N - - - - - - 154.21 
Solutol® HS-15 - - - - - - 233.64 
 
                            
 
 
Figure 2.8 Percentage of drug released from release testing of CLX 004/L, CLX 005/L, CLX 006/L, 
CLX 007/L, CLX 008/L and CLX 009/L tested in PW. This was a high throughput screening study (n=1). 
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CLX 002/L comprised a surfactant concentration of 975.61 mg/g (Tween® 20), whereas 
the maximum surfactant concentration for the formulations described in Table 2.10 was 
for formulation CLX 005/L (428.37 mg/g of Tween® 20). The results also suggested 
that the type of surfactant employed was also of major importance as CLX 009/L 
achieved the highest % of drug released (aside from CLX 002/L) despite its surfactant 
(Solutol® HS-15) concentration being less than that of the other formulations tested. It 
was also observed and noted that precipitation of CLX was more prevalent in 
formulations containing Transcutol® P. 
 
2.4.2.5 Comparison of CLX liquid formulations with increasing 
concentrations of Tween 20® 
 
Liquid formulations CLX 010/L, CLX 011/L, CLX 012/L, CLX 013/L and CLX 014/L 
(Table 2.11) were all prepared by dissolving CLX in  increasing concentrations of 
Tween® 20  to allow for comparisons with formulation CLX 002/L. It was observed 
(Figure 2.9) that the percentage of drug released was greater for formulations containing 
increasing concentrations of Tween® 20. These results demonstrated that there was a 
critical surfactant concentration required to fully disperse the drug in the dissolution 
media. In the case Tween® 20, this was > 961.54 mg/g (conc. of Tween® 20 in CLX 
012/L).  
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Table 2.11 Comparison of the composition of formulations CLX 002/L, CLX 010/L, CLX 011/L, CLX 
012/L, CLX 013/L and CLX 014/L 
 
Formulations CLX 002/L 
CLX 
010/L 
CLX 
011/L 
CLX 
012/L 
CLX 
013/L 
CLX 
014/L 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
 
(m
g/
g) 
Celecoxib 24.39 150.00 90.91 38.46 142.86 30.30 
Tween® 20 975.61 369.00 909.09 961.54 857.14 969.70 
 
               
 
 
Figure 2.9 Percentage of drug released from release testing of CLX 002/L, CLX 010/L, CLX 011/L, 
CLX 012/L, CLX 013/L and CLX 014/L tested in PW. This was a high throughput screening study (n=1). 
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2.4.2.6 Comparison of CLX liquid formulations comprising different 
surfactants  
 
Liquid formulations CLX 015/L, CLX 016/L and CLX 017/L were prepared by 
dissolving CLX in different concentrations of Solutol® HS-15 (Table 2.12). 
Formulations CLX 018/L, CLX 019/L and CLX 020/L were prepared by dissolving 
CLX in various concentrations of Labrasol® (Table 2.12). Release testing in PW was 
performed on all six formulations (Figure 2.10). Overall the percentage of CLX released 
was greater for formulations containing Solutol® HS-15 in comparison to those 
containing Labrasol®.  These results demonstrated that the degree to which the CLX 
dispersed in the dissolution media was dependent on the type of surfactant employed 
and also the concentration of surfactant employed. For example, CLX 017/L and CLX 
020/L comprised of an equal concentration of surfactant (i.e., 937.50 mg/g), however 
the maximum percentage of CLX released was 69 % in the case of CEL 017/L 
(formulation containing Solutol® HS-15), whereas it was 38 % in the case of CLX 
020/L (formulation containing Labrasol®). In the case of the formulations containing 
Solutol® HS-15), when the concentration of Solutol® HS-15 was reduced to 800 mg/g 
(CLX 015/L), the maximum percentage of celecoxib released dropped to 24 %. 
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Table 2.12 Comparison of the composition of formulations CLX 015/L, CLX 016/L, CLX 017/L, CLX 
018/L, CLX 019/L and CLX 020/L.  
 
Formulations CLX 015/L 
CLX 
016/L 
CLX 
017/L 
CLX 
018/L 
CLX 
019/L 
CLX 
020/L 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 200.00 100.00 62.50 200.00 100.00 62.50 
Solutol® HS-15 800.00 900.00 937.50 - - - 
Labrasol® - - - 800.00 900.00 937.50 
 
 
             
 
Figure 2.10 Percentage of drug released from release testing in PW of CLX 015/L, CLX 016/L, 
CLX 017/L, CLX 018/L, CLX 019/L and CLX 020/L. This was a high throughput screening 
study (n=1). 
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Following a review of the results obtained to date, it was observed that the most 
effective surfactants employed in the CLX liquid formulations to date were Solutol® 
HS-15 and Tween® 20. A further six formulations were prepared (CLX 021/L to CLX 
026/L - Table 2.13) containing Solutol® HS-15 or Tween® 20 in combination with 
Miglyol® 810N and Transctol® P. Two additional CLX liquid formulations containing 
Cremophor® EL, which had previously been shown to be an effective solubiliser of 
CLX were also prepared (CLX 028/L and CLX 029/L - Table 2.13). Release testing in 
PW was performed on all eight formulations (Figure 2.11). 
 
 
Table 2.13 Comparison of the composition of formulations CLX 021/L, CLX 022/L, CLX 023/L, CLX 
024/L, CLX 025/L, CLX 026/L, CLX 028/L and CLX 029/L. 
 
Formulations CLX 021/L 
CLX 
022/L 
CLX 
023/L 
CLX 
024/L 
CLX 
025/L 
CLX 
026/L 
CLX 
028/L 
CLX 
029/L 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) Celecoxib 66.67 90.91 90.91 66.67 90.91 90.91 260.00 260.00 
Solutol® HS-
15 600.00 454.55 454.55 - - - - - 
Miglyol ® 
810N 333.33 454.55 227.27 333.33 454.55 227.27 110.00 110.00 
Transcutol® P - - 227.27 - - 227.27 400.00 - 
Tween® 20 - - - 600.00 454.55 454.55 - - 
Cremophor® 
EL - - - - - - 230.00 630.00 
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Figure 2.11 Percentage of drug released from release testing in PW of CLX 021/L, CLX 022/L, 
CLX 023/L, CLX 024/L, CLX 025/L, CLX 026/L, CLX 028/L and CLX 029/L. This was a high 
throughput screening study (n=1). 
 
Overall the percentage of CLX released was greater for formulations containing 
Solutol® HS-15 in comparison to those containing Tween® 20 or Cremophor® EL.  The 
results for CLX 021/L, CLX 022/L and CLX 023/L were particularly interesting when 
compared to that of CLX 015/L. In the case of CLX 015/L, the concentration of 
Solutol® HS-15 was 800 mg/g and the maximum percentage release was 24 %, whereas 
in the case of CLX 021/L, CLX 022/L and CLX 023/L the maximum release 
percentages were 100%, 66 % and 80 % respectively despite lower concentrations of 
Solutol® HS-15 (600 and 454.55 mg/g). These results demonstrated that the addition of 
a lipid component (CLX 021/L contained Miglyol® 810N in addition to Solutol® HS-
15) improved the drug release performance of the lipophilic CLX formulations 
containing Solutol® HS-15 (compared to formulations in Figure 2.10).  
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2.4.3 CLX microbead production feasibility study 
 
On the basis of the liquid formulations that were developed, a microbead production 
feasibility study was performed which involved the preparation of six formulation 
mixtures (mixture of surfactant phase premix and gelatine phase premix) with the 
intention of converting them to microbeads using the method described in section 
2.3.2.5 above. These six formulations are described in Table 2.14 below. Formulations 
CLX 027/B, CLX 028/B, CLX 029/B, CLX 031/B and CLX 032/B were prepared as 
mixtures but were not progressed to microbeads as the drug precipitated in the mixture 
upon contact of the surfactant phase premix with the gelatine phase premix. The 
surfactant phase premix in these formulations contained 26% w/w CLX dissolved in 
various combinations of Solutol® HS-15, Miglyol® 810N, Cremophor® EL and 
Transcutol® P.  
 
Table 2.14 Composition of CLX microbead formulations CLX 027/B, CLX 028/B, CLX 029/B, CLX 
030B, CLX 031/B and CLX 032/B. 
Formulations CLX 027/B 
CLX 
028/B 
CLX 
029/B 
CLX 
030/B 
CLX 
031/B 
CLX 
032/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 100.00 104.00 98.79 23.03 100.41 98.02 
Gelatine 553.85 540.00 558.02 554.40 552.35 560.62 
D-Sorbitol 61.54 60.00 62.00 61.70 61.47 62.39 
Transcutol® P 153.85 160.00 - - - - 
Miglyol® 810N 42.31 44.00 41.80 130.53 42.48 - 
Solutol® HS-15 88.46 - - 230.34 243.29 278.97 
Cremophor® EL - 92.00 239.38 - - - 
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One of the formulations (CLX 030/B) produced during this phase of experiments did 
not result in precipitation on contact and was progressed to the manufacture of 
microbeads. This formulation contained 6% w/w CLX dissolved in 60% w/w of 
Solutol® HS-15 and 34% w/w of Miglyol® 810N. The emulsion produced on the 
combination of the surfactant phase premix and gelatine phase premix was transparent, 
suggesting that it was a microemulsion (i.e., a clear, stable, isotropic liquid mixtures of 
oil, water and surfactant). During the manufacture of the beads it was observed that a 
portion of the microemulsion was dissipating into the cooling solution. The resultant 
beads were roughly spherical and robust and became opaque upon drying. Photographs 
of beads (multiple beads and a single bead) from this batch of microbeads is shown in 
Figure 2.12 below. This preliminary experiment illustrated that it was possible to make 
microbeads from a formulation consisting of CLX dissolved in Solutol® HS-15 and 
Miglyol® 810N. The liquid formulations produced up to this point were reviewed and 
the formulations described in Table 2.15 below were identified as potential candidates 
for an in-vitro CRC cell line study (Chapter 3) principally based on their in-vitro drug 
release performance. It should be noted that formulations containing Tween® 20, 
Cremophor® EL or Labrasol® were excluded from consideration as Solutol® HS-15 had 
been shown to be a better surfactant to these and also that formulations containing 
Transcutol® P were also excluded as precipitation appeared to be more extensive in the 
case of CLX 027/B than for CLX 031/B or CLX 032/B. A comparison of the quality 
attributes of the remaining formulations (Table 2.15) was made to select two 
formulations for progression. 
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Figure 2.12 Photographs of CLX 030/B beads (multiple beads and a single bead). 
 
Table 2.15 Comparison of the quality attributes of formulation candidates for progression to CRC cell 
culture study. 
Formulations 
% Release 
in PW at 1 
h ≥ 50%  
% Release 
in PW at 6 h 
≥ 50%  
High Drug 
Load 
[1] 
Solutol® 
HS-15 
Miglyol® 
810N 
CLX 016/L      
CLX 017/L      
CLX 021/L      
CLX 022/L      
 
[1] High drug load defined as ≥ 8% (w/w). 
 
 
Two candidates were required for progression to the cell culture study. The primary 
criteria for selection for the first candidate was a formulation which demonstrated a high 
% drug release and which remained stable over a period of 6 h. Based on the 
comparison in Table 2.15, formulations CLX 017/L and CLX 021/L met this criteria. 
CLX 021/L was selected as the first candidate on the basis of its greater drug release 
performance compared to CLX 017/L. CLX 021/L represented a two component 
formulation. The selection criteria were revised for the selection of the second 
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formulation to exclude a) two component formulations and b) formulations with low 
drug loadings (i.e., < 8% w/w). These criteria were included to ensure a diverse sample 
set given the preliminary nature of the development work.  CLX 016/L was the only 
remaining formulations that met these two criteria and therefore was selected for 
progression. 
 
2.5 Conclusions 
 
The solubility of CLX in a range of liquid vehicles was assessed. On the basis of this 
assessment, liquid formulations were produced. Optimal liquid formulations produced 
(e.g., CLX 016/L and CLX 021/L) were demonstrated to have a greater drug release 
performance than that of the marketed CLX product Celebrex®. These formulations 
were based on the nonionic surfactant Solutol® HS-15 and the semi synthetic medium 
chain triglyceride Miglyol® 810N. A feasibility study was performed to assess the 
potential for these optimal liquid formulations to be translated into gelatine based 
microbeads. Spherical and robust microbeads were successfully produced which 
represented the first step in the development of a suitable oral drug delivery formulation 
designed to deliver of pre-solubilised CLX to the colon for the treatment of CRC. 
Despite evidence that CLX is a potentially useful drug for the prevention or treatment of 
CRC, a number of questions regarding itssafety  remain (Gonzalez-Angulo et al., 2002).  
A major safety concern relating to CLX is the serious GI side effects associated with 
Celebrex®. It is proposed that the GI side effects are not only dose related but also a 
result of local irritation (Halen et al., 2009) and therefore may be related to the 
presentation of the current dosage form (a powder filled capsule). The work presented 
here in this phase of the project constituted a preliminary but significant step towards 
the possibility of administering CLX for the prevention and/or treatment of CRC in a 
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free molecular form (i.e., fully dissolved) which had a) the potential to reduce the 
known GI side effects and b) the potential to be more efficacious than the current 
marketed dosage form on the basis that the pre-dissolving the drug would enable direct 
interaction with the colonic tissue. The next step of the project (Chapter 3) involved 
testing of this second hypothesis by administering the optimal liquid formulations 
produced here to a CRC cell line and assessing their impact on cell proliferation in 
comparison to cells treated with Celebrex®. 
 
2.6 Nomenclature  
Table 2.16 List of abbreviations which are listed according to their appearance in the text. 
Abbreviation Definition 
CLX Celecoxib 
GI Gastrointestinal 
CRC Colorectal cancer 
LBDDS Lipid based drug delivery system 
SEDDS Self emulsifying drug delivery system 
SMEDDS Self microemulsifying drug delivery system 
PEG Polyethyleneglycol 
HLB Hydrophilic-Lipophilic balance 
QC Quality control 
API Active Pharmaceutical ingredient 
PW Purified water 
SIF Simulated intestinal fluid 
SGF Simulated gastric fluid 
HPLC High performance liquid chromatography 
UV Ultraviolet 
CLX xxx/L 
Celecoxib liquid formulation numbering system where 
xxx is a sequential number and L is liquid 
CLX xxx/B 
Celecoxib bead formulation numbering system where 
xxx is a sequential number and L is liquid 
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CHAPTER 3                                       
In-vitro cell study 
 
 
Publication Status: The work presented in this chapter in addition to data 
from chapters 5 and 6 has been accepted for publication (02-11-14) in the 
Journal of Pharmacy and Pharmacology under the following title ‘In-vitro 
characterization of a novel celecoxib microbead formulation for the 
treatment and prevention of colorectal cancer’.  
 
 
 
 
 
 
 
 
 78 
 
3.1 Abstract 
 
The purpose of this phase of the project was to assess the effect of lipid based celecoxib 
(CLX) liquid formulations on the viability of a cyclooxygenase 2 (COX-2) expressing 
colorectal cancer (CRC) cell line (HT29) and to compare the inhibitory effect to that of 
the marketed CLX product Celebrex®. In-vitro cell viability (measured via MTT and 
flow cytometry assays) and motility (measured via a scratch wound healing assay) were 
shown to be significantly reduced after treatment with CLX liquid formulations relative 
to the control, whereas the results for treatment with Celebrex® were comparable to the 
control. Release experiments and correlation analysis demonstrated that the 
formulations with enhanced and stable drug release (i.e., greater drug release profiles) 
resulted in reduced cell viability and motility.  
 
3.2 Introduction 
3.2.1 Background 
 
A study by Eberhart and colleagues was among the first to demonstrate a significant 
elevation of cyclooxygenase 2 (COX-2) expression in most human colorectal 
carcinomas and also in fifty percent of adenomas (Eberhart et al., 1994). Following this 
observation by Eberhart and colleagues, COX-2 expression was also demonstrated in 
induced tumours from CRC mouse and rat models (Shao et al., 1999 and Boolbol et al., 
1996). These findings, in addition to others as described in Chapter 1, regarding the 
relationship between the COX-2 inhibitor CLX and CRC, have stimulated research 
focusing on studying the effects of COX-2 inhibitors (including CLX) on CRC cell lines 
(Buecher et al., 2005 and Sade et al., 2012).  
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At the conclusion of Chapter 2, a hypothesis was presented that the liquid CLX 
formulations developed had the potential to be more efficacious than the current 
marketed CLX dosage form (Celebrex®) on the basis that pre-dissolving the drug would 
enable direct interaction with the colonic tissue as the drug would be presented in a free 
molecular form (i.e., fully dissolved). The primary aim at the outset of this phase of the 
project (Chapter 3) was to test this hypothesis by administering the optimal liquid 
formulations developed in Chapter 2 (CLX 016/L and CLX 021/L) to a COX-2 
expressing CRC cell line and assessing their impact on cell viability in comparison to 
cells treated with Celebrex®.  
 
3.2.2 HT29 CRC carcinoma cell line 
 
CRC cell lines are useful models for understanding the underlying biological and 
molecular basis for colon cancer and are also useful for assessing the impact of 
chemotherapeutics on colon cancer cells (Rutzky, L.P., and Moyer, M. P., 1990). In a 
review by Ettarh and colleagues (Ettarh et al., 2010), a variety of CRC cell lines that 
have been used in in-vitro investigations on the effects of NSAIDs (non-steroidal anti-
inflammatory drugs) on several aspects of tumour initiation and progression were 
summarised. A review of this summary identified the COX-2 expressing cell line HT29 
as one of the most widely used cell lines for this type of studies. The HT29 cell line was 
also included in the studies cited in Section 3.2.1 (Buecher et al., 2005 and Sade et al., 
2012). HT29 is a human CRC adenocarcinoma cell line with epithelial morphology. 
The cell line was cultured by Jorgen Fogh, and was established in 1964 from the 
primary tumour of a 44 year old female with CRC adenocarcinoma (HT29 Cell Line 
Summary, Memorial Sloan Kettering Cancer Centre, 2014). In addition to the use of the 
HT29 cell line for in-vitro chemotherapeutic studies (such as that described above), the 
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HT29 cell line is also used as a xenograft tumor model for CRC and also as an in-
vitro model to study absorption, transport, and secretion by intestinal cells (HT29 Cell 
Line Summary, Memorial Sloan Kettering Cancer Centre, 2014) 
 
3.2.3 Cell viability (MTT Assay) 
 
As described in Section 3.2.1, the primary aim at the outset of this phase of the project 
was to assess the impact of the optimised CLX formulations on the viability of HT29 
cells following drug treatment and to compare their effect to that of Celebrex®.  There 
are a number of assays available which are designed to measure the viability and 
cytotoxicity of cells in culture after treatment with various stimuli. Assays for cell 
viability may monitor the number of cells over time, the number of cellular divisions, 
metabolic activity, or DNA synthesis (Frei, 2011). An example of an assay which 
measures cell viability via metabolic activity and the assay which was used for this 
study is the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) 
assay. The MTT assay is based on the conversion of the tetrazolium salt (MTT) into 
formazan crystals by living cells, which determines mitochondrial activity. This 
conversion is thought to be facilitated by NADPH (nicotinamide adenine dinucleotide 
phosphate-oxidase) or NADH (nicotinamide adenine dinucleotide phosphate) produced 
by dehydrogenase enzymes in metabolically active cells (Berridge and Tan, 1993). 
Since for most cell populations the total mitochondrial activity is related to the number 
of viable cells, this assay is broadly used to measure the in-vitro cytotoxic effects of 
drugs on cell lines or primary patient cells (van Meerloo et al., 2011).  
MTT is a water soluble tetrazolium salt. Dissolved MTT is converted to an insoluble 
purple formazan by cleavage of the tetrazolium ring by dehydrogenase enzymes. This 
water insoluble formazan can be solubilized using solvents (e.g., dimethyl sulfoxide 
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(DMSO)) and the dissolved material is measured spectrophotometrically yielding 
absorbance as a function of concentration of converted dye.  The cleavage and 
conversion of the soluble yellow dye to the insoluble purple formazan has been used to 
develop a cell viability assay system as active mitochondrial dehydrogenases in living 
cells will cause this conversion whereas dead cells do not cause this change (Frei, 
2011). The reduction of MTT to coloured formazan compounds only occurs in 
metabolically active cells. The primary disadvantage of the MTT assay is that the living 
cells must be metabolically active in order to cause the cleavage, therefore the assay 
cannot distinguish between dead cells and living cells that are not metabolically active 
and therefore viable cells which are not metabolically active can be excluded from the 
cell number result. In light of this deficiency of the MTT assay, a second cell viability 
assay (apoptosis assay) was performed to support findings from the MTT assay. 
 
3.2.4 Cell viability and apoptosis (Flow cytometry assay) 
 
Flow cytometry can be defined as a technology to measure properties of cells as they 
flow in a liquid suspension. The majority of flow cytometers can measure two kinds of 
light from cells; a) light scatter and b) fluorescence. Light scatter is the interaction of 
light and matter. All materials, including cells, will scatter light. In the flow cytometer, 
light scatter detectors are located opposite the laser (relative to the cell), and to one side 
of the laser, in-line with the fluid-flow/laser beam intersection. The measurements made 
by these detectors are called forward light scatter and side light scatter, respectively. 
Forward light scatter provides information on the relative size of individual cells, whilst 
side light scatter provides information on the relative granularity of individual cells 
(Loughran, 2007). Fluorescence is the property of a molecule to absorb light of a 
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particular wavelength and re-emit light of a longer wavelength. The wavelength change 
relates to an energy loss that takes place in the process. By gathering fluorescence 
information, flow cytometry can be used to assess cell viability and more specifically 
apoptotic and necrotic processes in conjunction with commercially available molecular 
tools. Forward scatter and side scatter are used to focus on (referred to as gating) on a 
population of cells which are simultaneously analysed for fluorescence (Loughran, 
2007).  
Apoptosis, or programmed cell death is a normal physiologic process for the removal of 
unwanted cells. Necrosis is defined as unscheduled cell death, usually as a result of 
injury or disease. Apoptosis is a genetically programmed process that occurs during 
embryonic development, as well as in maintenance of tissue homeostasis, under 
pathological conditions, and in aging (Hingorani et al., 2011). The term apoptosis, from 
the Greek word for “falling off” of leaves from a tree, is used to describe a phenomenon 
in which a cell actively participates in its own destructive processes. The process is 
characterized by specific morphologic features, including loss of plasma membrane 
asymmetry and attachment, plasma membrane blebbing, condensation of the cytoplasm 
and nucleus, and internucleosomal cleavage of DNA. Loss of plasma membrane 
asymmetry is one of the earliest features of apoptosis (Hingorani et al., 2011). In normal 
healthy live cells (viable cells), phosphatidyl serine (PS) is located on the cytoplasmic 
surface of the cell membrane (Figure 3.1 A). However, in apoptotic cells, PS is 
translocated from the inner to the outer leaflet of the plasma membrane, thus exposing 
PS to the external cellular environment. The human anticoagulant, Annexin V, is a 35–
36 kDa Ca2+ -dependent phospholipid-binding protein that has a high affinity for PS and 
can be used to identify apoptotic cells by binding to PS. Annexin V can be conjugated 
to fluorochromes (e.g., fluorescein isothiocyanate (FITC)) whilst maintaining its high 
affinity for PS and therefore can serve as a sensitive probe for flow cytometric analysis 
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of cells undergoing apoptosis (Figure 3.1 B). PS translocation precedes the loss of 
membrane integrity, which accompanies the later stages of cell death resulting from 
either apoptotic or necrotic processes, hence, staining with Annexin V is usually used in 
conjunction with a fluorescent dye (referred to as a vital dye) such as propidium iodide 
(PI) that binds to nucleotides and which only penetrates damaged cellular membranes. 
Intercalation complexes are formed by PI with double-stranded DNA (deoxyribonucleic 
acid), which results in an amplification of the fluorescence. This vital dye is used in 
order to distinguish between early apoptosis (Figure 3.1 B), late apoptosis/necrosis 
(Figure 3.1 C) and necrosis (Figure 3.1 D). Since PS translocation and loss of 
membrane integrity are features of both apoptotic and necrotic processes, albeit at 
different stages, (Hingorani et al., 2011 and Kawamura and Ye., 2007) a combination of 
these dyes are required to distinguish between the four events (viable cells, early 
apoptosis, late apoptosis/necrosis and necrosis). 
In summary, when molecular tools such as Annexin V-FITC and PI are used in 
combination the following interactions occur; viable cells with intact membranes 
exclude Annexin V-FITC and PI (i.e., negative for both), whilst cells in the early stage 
of apoptosis stain positive for Annexin V-FITC and negative for PI. In the case of cells 
that stain positive for both Annexin V-FITC and PI, these cells are classified as late 
apoptotic or necrotic as it is possible that they may have died via necrosis or apoptosis. 
In the case of late apoptotic/necrotic events, it is possible to gain more information 
about the mechanism of cell death by measuring apoptosis over time, as it allows cells 
to be tracked from Annexin V-FITC and PI negative (viable, or no measurable 
apoptosis), to Annexin V-FITC positive and PI negative (early apoptosis with intact 
membranes), and finally to Annexin V-FITC and PI positive (end stage apoptosis and 
death). The presence of cells with these three phenotypes within a mixed cell 
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population, or the “movement” of a synchronized cell population through these three 
stages, suggests apoptosis (Hingorani et al., 2011).  
 
Finally, it is proposed by Kawamura and Ye that cells that are undergoing or have 
recently underwent necrosis stain negative for Annexin V-FITC but positive for PI. It is 
possible to distinguish these cells from apoptotic cells as a result of the fact that the cell 
membrane of cells undergoing necrosis being much more permeable to PI than 
apoptotic cells, resulting in PI staining prior to PS externalizing on the outer surface of 
the cell membrane (Kawamura and Ye., 2007).  In flow cytometry using Annexin V-
FITC and P), this necrotic event is not cited to same extent as the other three events 
(viable, early apoptotic and late apoptotic/necrotic), however the event warrants 
reporting under the following circumstances; a) where there is a specific Annexin V-
FITC negative/PI positive result for a particular treatment group in comparisons to other 
groups (i.e., the event is not attributable to a sample preparation artefact) and b) where 
the results are gated for size and granularity consistent with cells (i.e., unwanted 
particles such as debris from necrotic events is eliminated). 
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Figure 3.1 Diagram showing viable healthy cells (Annexin V-FITC- and PI-), early apoptotic cells 
(Annexin V-FITC+ and PI-) late apoptotic/necrotic cells, (Annexin V-FITC+ and PI+) (Hingorani et al., 
2011) and necrotic cells (Annexin V-FITC- and PI+) (Kawamura et al., 2007). The diagram includes the 
markers for the detection of apoptosis and necrosis. The diagram is presented in a quadrant which 
correlates to the position of these cells in flow ctyometry dot plots (see Figure 3.6). This figure has been 
adapted from Hingorani and colleagues (Hingorani et al 2011). 
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3.2.5 Cancer metastasis (scratch wound healing assay) 
 
Metastatic disease is the major cause of death in patients with colorectal cancer, and 
depending on the tumour stage, liver metastases occur in 20% to 70% of patients, while 
lung metastases occur in 10% to 20% of cases (Shibayama et al., 2011), therefore the 
metastatic potential of tumour cells (i.e., their ability to migrate and invade) is an 
extremely important factor for formation of solid tumours and necessary for their spread 
to distant organs. COX-2 expression is a hallmark of increased metastatic potential in 
colon cancer cells (Greenhough et al., 2009) and NSAIDs have been shown to abrogate 
this invasiveness (Tsujii et al., 1997). Cell migration is defined as the movement of 
individual cells, cell sheets and clusters from one location to another. It is central to a 
variety of different pathologic and physiologic processes across many disciplines of 
biology including wound healing, cancer, cell growth and differentiation. (Hulkower 
and Herber, 2011). There are many complex mechanisms underlying the processes of 
cell migration and invasion including angiogenesis (physiological process through 
which new blood vessels are formed from pre-existing vessels). Interestingly, COX-2 
inhibition has been suggested to block angiogenesis and CLX has been successfully 
used in combination with other compounds to block tumour cell migration and invasion 
in-vitro (Zengel et al., 2010).  
Scratch wound healing assays have been widely used to assess the effect of drugs, 
including CLX, on cell migration and proliferation (Erdog et al., 2013, Sade et al., 
2012). The basic principle of the assay is that a ‘scratch’ is inflicted on a monolayer of 
cells which creates a ‘wound’, followed by monitoring of the ‘healing’ of the wound as 
a result of cells migrating/growing towards the centre of the wound, thereby closing the 
wound (Figure 3.2). In the event that the addition of drug (treated cells) prevents cell 
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migration and proliferation, the % wound closure would be expected to be less than for 
untreated cells or control-treated cells. 
          
Figure 3.2 Scratch wound healing assay. A) a confluent monolayer of cells are grown in a well, B) a 
scratch wound is inflicted with a pipette tip, C) the width of the wound is measured prior to incubation 
with drug and D) the width of the wound is measured after incubation for a specified number of hours. 
Image adapted from Hulkower and Herber (Hulkower and Herber, 2011). 
 
3.2.6 Objectives 
 
As described in Chapter 1, CRC is the third most common cause of cancer mortality and 
significant research has been dedicated to identify novel drug targets for CRC 
prevention and treatment, including the use of COX-2 inhibitors such as CLX (Siegel, et 
al., 2014). In the context of the overall aim of this project to develop a CLX formulation 
(in which CLX was pre-solubilised) for the prevention and treatment of CRC, the work 
presented in this chapter focused on the in-vitro evaluation of the effect of liquid CLX 
formulations (i.e., pre-solubilised CLX) on the viability of the COX-2 expressing colon 
cancer cell line HT29, compared to the marketed product Celebrex®. The primary 
aims/objectives of this stage of the project were as follows: 
 
A. Firstly to assess and compare the effects of CLX liquid formulations and 
Celebrex® on the viability of HT29 using an MTT assay. 
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B. Secondly to use flow cytometry as a secondary assay to confirm the cell viability 
results of the MTT assay and also to assess the cell death pathway (i.e., 
apoptosis and necrosis). 
 
C.  The third objective was to assess and compare the effect CLX of liquid 
formulations and Celebrex® on the metastatic potential of HT29 via a scratch 
wound healing assay. 
 
D.  The fourth objective was to analyse the data obtained from A, B and C above in 
order to assess if there existed any correlation between the solubility of the 
formulations and the anti-carcer effect observed and to perform additional drug 
release studies where applicable to further investigate any possible correlation 
identified.  
 
E. The fifth and final objective of this stage of the project was to confirm that the 
liquid formulations tested were suitable precursors for the development of 
optimal microbead formulations (Chapter 4). 
3.3 Materials and methods 
3.3.1 Materials 
3.3.1.1 Formulation materials  
 
CLX liquid formulations were made using the following materials; Solutol HS-15® 
(BASF, Germany) and Miglyol® 810N (Sasol, South Africa). A sample of CLX active 
pharmaceutical ingredient (API) was kindly provided by Erregierre (Italy). The purity of 
the API was 99.6% based on the COA (certificate of analysis) provided by the supplier. 
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All chemicals used for the release experiments and HPLC testing were of laboratory 
grade. Celebrex® was manufactured by Pfizer (USA). 
 
3.3.1.2 In-vitro model materials  
 
McCoy’s 5A modified medium, L-glutamine, 10% FBS (fetal bovine serum), 1% 
penicillin/streptomycin, molecular grade DMSO, phosphate buffered saline (PBS) (all 
Sigma Aldrich, USA), VybrantMTT assay kit (Invitrogen, USA) and Annexin V-
FITC/PI Apoptosis Detection Kit (BD Biosciences, USA).  
 
3.3.2 Methods 
3.3.2.1 Preparation of liquid formulations 
 
CLX liquid formulations were prepared by dissolving measured quantities of CLX into 
measured quantities of liquids. Formulations were prepared as one or two component 
systems (i.e., containing a single liquid vehicle or mixtures of two liquid vehicles). 
 
3.3.2.2 In-vitro release testing 
 
Release testing of CLX formulations were performed (n=3) at 37°C in purified water 
(PW). All release experiments were carried out using either a Varian/Vankel VK7010 
dissolution apparatus (VanKel, USA) or a Distek Evolution 6300 (Distek, USA) 
equipped with standard glass vessels and USP type II paddles. Paddle rotating speed in 
all experiments was 75 rpm. Formulations containing 50 mg of CLX were weighed and 
added to 1000 ml of the relevant dissolution medium. At specified times 1.8 ml samples 
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were withdrawn, filtered through a 70 µm pore filter (QLA, USA) and analysed using a 
high performance liquid chromatography (HPLC) method. The % of drug released at 
particular time points was determined from peak areas which were calculated against a 
single point external reference standard.  
 
3.3.2.3 HPLC method 
 
The HPLC method for the analysis of the release and assay samples was adapted from 
Saha and colleagues (Saha et al., 2002). The HPLC column used was a reverse phase 
4.6 x 250 mm Inertsil® C8 column (Inertsil, The Netherlands) with 5 µm particles. The 
mobile phase was acetonitrile:water (65:35). The isocratic method used a flow rate of 
1.25 ml/min and ultraviolet (UV) detection at 230 nm. The injection volume was 20 µl 
and the retention time was 8 min. The HPLC apparatus that was used for the analysis 
were Thermo Finnigan (Thermo Electron Corporation, USA) and Waters (Waters, 
USA) HPLC systems (and associated Chromquest and Empower software). 
 
 
3.3.2.4 Cell culture 
 
The HT29 cell line was grown in McCoy’s 5A modified medium supplemented with 1.5 
mM L-glutamine, 10% FBS (fetal bovine serum) and 1% penicillin/streptomycin. The 
cells were grown in a humidified atmosphere containing 5% CO2.  
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3.3.2.5 Cell viability – MTT assay 
 
Cell viability was measured using the VybrantMTT assay kit according to the 
manufacturer’s guidelines. HT29 cells (10,000) were plated in 100 μl of complete 
McCoy’s 5A media in 96-well tissue culture dishes. After 24 h cells were treated with 
CLX (CLX liquid formulations, Celebrex® and CLX dissolved in DMSO) at 20, 30, 50 
and 100 μM (n=6 for each concentration). In the case of CLX dissolved in DMSO, the 
CLX was dissolved overnight in DMSO before treatment. The working concentration of 
DMSO in all treatments involving DMSO was <0.1%. Two control groups were 
employed, one which involved no treatment (referred to as media) and the other which 
involved treatment with DMSO and media (referred to as DMSO). After 72 h, the MTT 
labelling reagent (10 µl) was added and incubated for 3 h, followed by solubilisation 
with DMSO. The absorbance (A) was determined in a BioRad 680 microplate reader 
(BioRad, USA) at 550 nm. The effect of a placebo formulation (i.e., no CLX) on the 
viability of HT29 cells was also assessed (using the procedure described above) by 
treating cells with excipient mixtures equating to quantities of excipients that were 
present in the equivalent 20 and 50 μM CLX liquid formulations. The same passage 
number of cells was used for both the active and placebo experiments. In the case of 
both experiments treatments were compared to controls which were set to 100% to 
reveal relative viability.   
 
3.3.2.6 Cell viability and apoptosis assay (flow cytometry) 
 
HT29 cells were seeded at 5 x 105 cells/mL in 10% FBS-supplemented medium prior to 
treatment with CLX at 50 µM (CLX liquid formulations, Celebrex® and CLX dissolved 
in DMSO) for a period of 72 h. Two control groups were employed, one which involved 
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no treatment (referred to as media) and the other which involved treatment with DMSO 
dissolved in media (referred to as DMSO). Cell viability and the onset of apoptosis was 
monitored using an AnnexinV-FITC/PI Apoptosis Detection Kit which contains 
recombinant Annexin V-fluorochrome FITC conjugate and the vital dye (PI) followed 
by flow cytometry on a FACSCalibur system using CellQuest software (BD 
Biosciences, USA) . Data for at least 10,000 events were collected for each treatment 
made and two-dimensional plots of Annexin V-FITC versus PI were generated from 
gated populations consistent with size and granularity of HT29 cells (as determined 
using forward and side light scatter). 
 
3.3.2.7 In-vitro scratch wound healing assay 
 
Cellular motility was measured by an in-vitro scratch wound healing assay. HT29 cells 
were seeded in six-well plates and incubated until they were 90% confluent. The 
monolayer of cells was scratched vertically down the plate with a sterile pipette tip and 
debris was removed from the culture by washing twice with PBS. Images were captured 
immediately after wounding, with a Nikon Eclipse Ti optical inverted microscope with 
4X objective (Nikon, Japan). The cells were then incubated in complete medium with or 
without CLX at 50 μM (CLX liquid formulations, Celebrex® and CLX dissolved in 
DMSO). Two control groups were employed, one which involved no treatment (referred 
to as media) and the other which involved treatment with DMSO dissolved in media 
(referred to as DMSO). Wound closure was monitored microscopically after the wound 
persisted for 72 h. Scratch width before and after healing was measured (n=9) and 
compared to the controls. The percentage wound closure between the wound edges were 
analysed using Nikon NIS microscope imaging software. The experiments were 
performed with a minimum of three replicates. 
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3.3.2.8 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism (La Jolla, USA). Results are 
presented as mean ± SEM (n=3-9). Statistical significance was determined by ANOVA 
using the Dunnett’s test for multiple comparisons to the relevant control (*** p ≤ 0.001, 
** p ≤ 0.01, * p ≤ 0.05). 
 
3.4 Results and discussion 
3.4.1 CLX liquid formulations 
 
Based on the findings detailed in Chapter 2, two liquid formulations (CLX 016/L and 
CLX 021/L) were selected for progression to the in-vitro cell culture study described 
here. The composition of formulations CLX 016/L and CLX 021/L are detailed in Table 
3.1 below. 
 
             Table 3.1 Comparison of the composition of formulations CLX 016/L and CLX 021/L 
Formulations CLX 016/L CLX 021/L 
 
 
Component 
Concentration 
(mg/g) 
Celecoxib 100.00 66.67 
Solutol HS-15 900.00 600.00 
Miglyol 810N - 333.33 
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3.4.2 Effects of CLX formulations on the viability of HT29 cells 
 
The effect of CLX liquid formulations, CLX 016/L and CLX 021/L, on the viability of 
HT29 colorectal cancer cells was assessed and compared to that of the marketed CLX 
product Celebrex®.  In addition to the two control groups (media and DMSO), cells 
were treated with CLX formulations CLX 016/L and CLX 021/L, Celebrex® and CLX 
API (dissolved in DMSO) at 20, 30, 50 and 100 μM for a period of 72 h. The results for 
the two control groups were comparable. It was observed that formulations CLX 016/L 
and CLX 021/L resulted in a reduction in cell viability by approximately 60–70% 
(compared to media) in the concentration range of 20–100 μM whereas in contrast CLX 
API (compared to DMSO) and Celebrex® (compared to media) reduced cell viability by 
only 30–40 % across the same concentration range (Figure 3.3).  
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Figure 3.3 The effect of CLX on the viability of HT29 cells. (A) HT29 cells were plated in 96-well plates 
and after 24 h the cells were treated with CLX (CLX liquid formulations, Celebrex® and CLX dissolved 
in molecular grade DMSO) at 20, 30, 50 and 100 μM (n=6 for each concentration) for 72h. Cellular 
viability was determined by MTT assay.  
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As outlined in the objectives, the first aim of this phase of the project was to compare 
the effects of treatment with liquid CLX formulations to that of Celebrex® on the 
viability of a COX-2 expressing CRC cell line, HT29. CLX liquid formulations were 
used as they represented a precursor to microbead formulations and were also amenable 
for direct application to the cells (in contrast to testing with microbeads which was 
unviable due to the quantity of media required to hydrate and dissolve the microbeads). 
The primary hypothesis of this phase of the project was that presenting CLX to the cells 
in a stable soluble form would allow for maximum distribution of CLX to the cells (and 
hence interaction) and consequently would allow for a greater inhibition of cellular 
viability. The results observed from the MTT assay (Figure 3.3) agree with this 
hypothesis, wherein both CLX liquid formulations (CLX 021/L and CLX 016/L) 
inhibited HT29 viability (approximately 60–70% across the range from 20 µM to 100 
µM) to a much greater extent than the current marketed product Celebrex® (reduction of 
cell viability in the region of 30–40% across the same concentration range). It has been 
reported that maximum anti-cancer effects of Celebrex® are enhanced at higher doses 
such as 800 mg/day (Steinbach et al., 2000) whereas the recommended dosage of 
Celebrex® for its anti-inflammatory indication is 200–400 mg/day (Celebrex® Rxlist, 
2014) and that the risk of GI and CV side effects are greater at higher doses (discussed 
at length in Chapter 1). The MTT assay results presented here reveal the possibility for 
using a reduced dose of CLX to exert an anti-cancer effect with a consequent reduction 
or elimination of these unwanted side effects. The study also revealed that CLX 
dissolved in DMSOhad an enhanced inhibitory effect compared to Celebrex®. IC50 
concentrations were not established for the formulations across the concentration range 
tested, however the primary objective was to observe differences in the inhibitory effect 
of the various formulations rather than establishing the IC50 (which based on the results 
would require a broader range of drug concentrations). 
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In order to confirm that the inhibitory effect of the CLX liquid formulations were 
related to the activity of the drug (CLX) as opposed to the excipients, a placebo 
formulation (excipient mixture of Solutol® HS-15 and Miglyol 810N®) was prepared 
and cells were treated with an excipient mixture equating to quantities of excipients that 
were present in the equivalent 20 and 50 μM formulation of CLX 021/L (see Table 3.1 
for concentration of excipients employed). Formulation CLX 021/L was selected for 
comparison on the basis that it contained both Solutol® HS-15 and Miglyol 810N®.  
Although there was some inhibitory effect observed for the placebo formulation, it is 
shown in Figure 3.4 that the placebo formulation did not have the same inhibitory effect 
as the formulations containing CLX, with the placebo formulation resulting in 
approximately a 1.25 fold decrease in the number of viable cells whereas formulation 
CLX 021/L resulted in approximately a 2.5 fold decrease. 
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Figure 3.4 A comparison of the effect of placebo and CLX formulations on the viability of HT29 cells 
(the same cell passage number was used for both placebo and active experiments). HT29 cells were plated 
in 96-well plates and after 24 h the cells were treated with (A) CLX liquid formulation CLX 021/L at 20 
and 50 μM (n=6 for each concentration) for 72h and (B) a placebo excipient mixture at equivalent 20 and 
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50 μM concentrations (n=6 for each concentration) for 72h.  Cellular viability was determined by MTT 
assay. The placebo formulation resulted in a 1.25 fold decrease in the number of viable cells, whereas 
formuation CLX 021/L resulted in a 2.5 fold decrease. 
3.4.3 Effects of CLX formulations on cell viability and apoptosis 
 
Cell viability and the onset of apoptosis were assessed via flow cytometry. In addition 
to the two control groups (media and DMSO), cells were treated with CLX 
formulations, CLX 016/L and CLX 021/L, Celebrex® and CLX API (dissolved in 
DMSO) at 50 μM for a period of 72 h (n=6). Relative to the controls (media in the case 
of CLX 016/L, CLX 021/L and Celebrex® and DMSO in the case of CLX API), it was 
observed that the % of viable cells for formulations CLX 021/L and CLX 016/L were 
significantly reduced whereas in the case of Celebrex® there was no significant 
reduction in the % of viable cells (Figure 3.5).  The % viable cells in the case of 
formulation CLX 021/L (59.6 ± 2.59%) was lower than that for formulation CLX 016/L 
(70.51% ± 3.99%).  The % viable cells for CLX API (69.02 ± 2.71%) was higher than 
that for formulation CLX 021/L but was comparable to formulation CLX 016/L, 
however the % of necrotic death for CLX API (13.96 ± 2.48%) was significantly higher 
than for any of the other formulations tested. The % of cells undergoing early apoptosis 
for formulation CLX 021/L and formulation CLX 016/L were 22.08 ± 0.92% and 10.77 
± 1.84% respectively, which was higher than for CLX API (6.30 ± 1.42%) and notably 
higher than that achieved for Celebrex® (3.91 ± 0.83%). An example of one of the dot 
plots from which this data was obtained is shown in Figure 3.6. It was noted that in the 
case of formulations CLX 021/L and CLX 016/L, that the cell culture media remained 
transparent following treatment with the drug but that the media was or became cloudy 
in the case of treatments with Celebrex® and CLX API (dissolved in DMSO). In the 
case of CLX API, the media was not initially cloudy on application of the drug but 
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appeared cloudy when observed at 72 h as result of drug precipitating out of solution 
(the onset time for precipitation is unknown) whereas in the case of Celebrex®, the 
media became cloudy immediately on application of the treatment as Celebrex® did not 
dissolve in the media. 
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Figure 3.5 HT29 cells were plated in 24-well plates 24 h prior to treatment with CLX at 50µM (CLX 
liquid formulations, Celebrex® and CLX dissolved in DMSO). Seventy two hours later, cells were double 
stained with recombinant Annexin V-FITC conjugate and PI and survival profiles monitored by flow 
cytometry. Viable cells (Annexin V-FITC- and PI-), early apoptotic cells (Annexin V-FITC+ and PI-), late 
apoptotic/necrotic cells (Annexin V-FITC+ and PI+) (Hingorani et al., 2011) and necrotic cells (Annexin 
V-FITC- and PI+) (Kawamura et al., 2007), were plotted as a percentage of the total population for each 
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treatment (n = 6). Data for 10,000 events was collected for each replicate. Statistics were performed 
relative to media for formulations CLX 021/L, CLX 016/L and Celebrex® and relative to DMSO in the 
case of CLX API. 
 
Figure 3.6 2-D dot plots of Annexin V FITC-PI flow cytometry of HT29 cells following treatment with 
CLX at 50µM (Celebrex, CLX 021/L, CLX 016/L and CLX API (dissolved in DMSO)). There were two 
controls (media alone and DMSO). Seventy two hours after treatment, cells were double stained with 
recombinant Annexin V-FITC conjugate and PI. The lower left quadrant represents viable cells cytometry 
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(Annexin V-FITC- and PI-), the lower right hand quadrant represents early apoptotic cells (Annexin V-
FITC+ and PI-), the upper right quadrant represents late apoptotic/necrotic cells (Annexin V -FITC+ and 
PI+) and the upper left hand quadrant represents necrotic cells (Annexin V-FITC- and PI+). One 
representative experiment is shown. 
 
One of the aims of the cell viability and apoptosis assay was to verify the MTT assay 
results described in Section 3.4.2. CLX formulations CLX 016/L and CLX 021/L were 
again demonstrated to exert a greater effect than  Celebrex® with respect to their 
inhibitory effect on HT29 cells relative to a control (Figures 3.5 and 3.6). The data also 
revealed interesting findings with respect to the mechanisms of inhibition. In the case of 
Celebrex®, in addition to the observation that there was no significant impact on cell 
viability, there was no significant necrotic (passive cell death) or apoptotic (controlled 
cell death) effect observed. There exists a theory that the cancer killing effect of CLX 
on CRC cell lines may be related to direct cytotoxicty (resulting from irreversible 
binding and damage to the plasma membrane by CLX precipitates) as opposed to 
molecular toxicity (Sacchetti, 2013). Based on this theory, it could be argued that the 
concentration of Celebrex® used (50 µM) was not sufficient to result in direct 
cytotoxicty. In contrast, in the case of CLX API dissolved in DMSO, a significant 
necrotic effect was observed which is consistent with the direct cytotoxicity theory. It is 
postulated that by pre-dissolving CLX in DMSO that the drug was allowed to seed onto 
the cells prior to exerting a cytotoxic effect for example via direct damage to the plasma 
membrane. The capacity of precipitates of CLX to damage cellular membranes has 
previously been shown by Sacchetti [14]. Given that the CLX API formulation (pre 
dissolved in DMSO) was observed to precipitate in the cell culture media, it is proposed 
that the precipitation of the drug allowed it to exert a strong necrotic effect in contrast to 
formulations A and B (neither of which were observed to precipitate in the media) and 
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also Celebrex® which was never in solution and therefore did not get an opportunity to 
seed onto the monolayer of cells  In strong contrast to the results obtained for Celebrex® 
and CLX API there was a significant inhibitory effect observed for both formulations 
CLX 021/L and CLX 016/L without exerting a significant necrotic effect. The strong 
apoptotic effect for formulations CLX 021/L and CLX 016/L is very important as it 
suggests that these formulations caused HT29 cell death via molecular mechanisms and 
thereby is a new development on the data presented by Sacchetti in which it was found 
that in-vitro cell death for CRC cell lines only occurred at insoluble concentrations of 
CLX. The data presented here suggests that a molecular toxicity effect is possible for 
CLX if the drug is optimally presented to the cells (i.e., in a stable solubilised state). In 
the case of the CLX API dissolved in DMSO, an early apoptotic effect was also 
observed (albeit less pronounced than for formulations CLX 021/L and CLX 016/L – 
see Figure 3.5) which suggests some of the API which remained in solution may have 
been able to exert a toxic effect by molecular mechanisms. The finding that 
formulations CLX 016/L and CLX 021/L did not exhibit a significant necrotic effect is 
an important finding given that previous research by Tomisato and colleagues 
(Tomisato et al., 2004) has shown that NSAIDs including CLX kill cells by both 
necrosis and apoptosis and that necrosis is linked to unwanted GI side effects.  
As the assay performed cannot distinguish between late apoptotic and necrotic cells in 
the case of cells staining positive for both Annexin V-FITC and PI (see Section 3.2.4), 
these results are not discussed as it would be necessary to perform a time course 
experiment to track the movement of cells through the stages of viable cells, early 
apoptotic cells and late apoptotic cells in order to fully distinguish late apoptotic cells 
from necrotic cells. Also while the necrotic effect of the various formulations are 
discussed here, it is acknowledged that further studies involving a time course annexin 
V/PI apoptosis assay, microscopic analysis or an alternative apoptotic assay (e.g., 
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TUNEL - terminal deoxynucleotidyl transferase dUTP nick end labelling) could be 
performed to support the proposed necrotic effect observations for CLX API. 
3.4.4 Effects of CLX formulations on the motility of HT29 cells 
 
In order to examine the effects of CLX liquid formulations CLX 016/L and CLX 021/L 
on the motility of HT29 cells in comparison to Celebrex®, an in-vitro scratch wound 
healing assay was performed. In addition to the two control groups (media and DMSO), 
cells were treated with CLX formulations, CLX 016/L and CLX 021/L, Celebrex® and 
CLX API (dissolved in DMSO) at 50 μM for a period of 72 h after the scratch wound 
was inflicted. Figure 3.7 displays a sample of images of the wound on the day of 
application and after 72 h of incubation for illustrative purposes. As seen in the 
histogram in Figure 3.8, treatment with formulations CLX 021/L and CLX 016/L 
significantly reduced the % wound closure relative to the control (media in the case of 
CLX 016/L, CLX 021/L and Celebrex®); which indicated a loss in the motility of the 
HT29 cells after 72 h. In contrast the % wound closure for Celebrex® and CLX API was 
not significant. The data also revealed a difference in the effect observed for 
formulations CLX 021/L and CLX 016/L. As previously stated in Section 3.2.5, the 
high mortality associated with CRC is related to its ability to spread beyond the large 
intestine and invade distant sites. Therefore the metastatic potential of tumour cells (i.e., 
their ability to spread) is an extremely important factor for formation of solid tumours 
and necessary for their spread to distant organs. As described in the present study, the 
motility of HT29 cells were examined as a measure of their metastatic potential via the 
scratch wound healing assay. As with the other assays performed, in contrast to 
Celebrex®, relative to the control, the CLX liquid formulations CLX 021/L and CLX 
016/L had a significant effect, whereby the % wound closure was markedly reduced for 
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formulations CLX 021/L and CLX 016/L (Figure 3.8), illustrating that these 
formulations had the potential to reduce the likelihood of CRC cells to metastazize. 
 
 
Figure 3.7 The effect of CLX on the motility of HT29 cells. Scratch wound healing assay was conducted 
and inverted microscope images were captured and analysed (including measurements) immediately after 
the wound (0 h) and after treatment with CLX at 50 µM (CLX liquid formulations CLX 016/L and CLX 
021/L, Celebrex® and CLX dissolved in molecular grade DMSO) (n=9 for each group) for 72 h. Images 
for the control group are also shown.   
Media 
CLX 021/L 
CLX 016/L 
Celebrex® 
Celecoxib 
0 h 72 h 
DMSO 
 105 
 
 
                  
Me
dia
DM
SO
CL
X 0
21
/L
CL
X 0
16
/L 
Ce
leb
re
x
Ce
lec
ox
ib 
AP
I
0
20
40
60
80
  **
**
%
 
W
o
u
n
d 
Cl
o
s
u
re
 
 
Figure 3.8 The effect of CLX on the motility of HT29 cells. The histogram shows the percentage wound 
closure for the controls and for the CLX treatments 72 h after the wound persisted. Statistics were 
performed relative to media for formulations CLX 021/L, CLX 016/L and Celebrex® and relative to 
DMSO in the case of CLX API. 
 
 
 
3.4.5 In-vitro drug release studies on CLX liquid formulations 
 
Given the differences in the effects observed for the CLX formulations compared to 
Celebrex® with respect to the in-vitro cell model parameters examined and also the 
enhanced effect for formulation CLX 021/L compared to formulation CLX 016/L, an 
in-vitro drug release study was performed over a period of 12 h to study the release of 
CLX and to assess whether a correlation existed between drug release performance and 
the performance of the various formulations in the in-vitro cell model (previous to this, 
release analysis had only been performed over a period of 6 h). Figure 3.9 shows the in-
vitro CLX release profiles of formulation CLX 016/L, formulation CLX 021/L, 
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Celebrex® and CLX API (pre dissolved in DMSO). Consistent with the in-vitro cell 
model data, formulations CLX 016/L and CLX 021/L markedly outperformed both 
Celebrex® and CLX API. Interestingly the % release for formulation CLX 021/L 
remained steady over the 12 h period at 98.83 ± 0.75%, whereas in the case of 
formulation CLX 016/L, CLX was observed to have started to precipitate by 6 h and at 
12 h the % of drug which remained dispersed in the mediahad reduced to 59.23 ± 
9.90%. CLX API (pre dissolved in DMSO) was also observed to precipitate almost 
immediately upon contact with the dissolution media. 
 
 
 
Figure 3.9 Percentage of drug released from release testing of formulation CLX 016/L, formulation CLX 
021/L, Celebrex and CLX API (all tested in PW over a period of 12 h). The data presented are mean 
values ± STDEV (n=3). 
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In the case of both the cell viability/apoptosis assay and the scratch wound healing 
assay, formulation CLX 021/L was observed to have had a greater effect compared to 
formulation CLX 016/L. The in-vitro drug release test performed in PW therefore 
revealed a correlation between % of drug released (and which remained in solution) 
(Figure 3.9) and the performance of the formulation with respect to the in-vitro cell 
culture model. This is an important finding as it identifies the use of release testing in 
PW as a simple and effective tool for screening and selecting stable CLX formulations. 
It was also notable that CLX API, dissolved in DMSO, performed marginally better 
than Celebrex® with respect to its drug release performance which was also the case for 
the in-vitro cell culture experiments. 
 
3.5 Conclusions 
 
In this phase of the project it was shown that CLX liquid formulations performed 
significantly better than the marketed CLX product Celebrex® with respect to their 
ability to inhibit the viability and motility of a HT29 CRC cell line in-vitro. Whilst 
focusing on only one cell line (HT29), it was also demonstrated that liquid CLX 
formulations had an apoptotic effect on HT29 cells, whereas CLX API alone had both a 
necrotic and apoptotic effect, which was an important finding as it presented the 
opportunity for targeted CLX therapy with reduced GI side effects for which there is an 
obvious unmet clinical need. Although the exact mechanisms for the anticancer activity 
of CLX are unclear, a wide array of tumour-associated moleculat events have been 
shown to be modulated by CLX in in-vitro assays. It has been proposed that the 
mechanisms of action include the induction of apopt
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angiogenesis and the induction of endoplasmic reticulum stress. This study 
demonstrated that the liquid CLX formulations developed had a greater cytotoxic effect 
on HT29 CRC cells in comparison to Celebrex® and that the mechanism of cell death 
was predominatly via apoptosis. It is proposed here that the administration of CLX to 
these cancer cells targets proteins (e.g., peroxisome proliferator-activated receptor 
(PPAR) involved in the apoptosis pathway and has the ability to to switch off the 
survival signals that these cells depend on (Yang and Frucht, 20001 and Gong et al., 
2012). 
 
A correlation between the drug release performance of CLX formulations in PW and 
their ability to affect HT29 cells was also observed, thereby presenting an effective tool 
for formulation screening. CLX liquid formulations were used for this in-vitro cell study 
as they represented a precursor to microbead formulations and were also amenable for 
direct application to the cells. In Chapter 2, a feasibility study was performed to assess 
the potential of the liquid formulations produced to be converted into microbeads. The 
feasibility study described in Chapter 2 revealed that it was possible to make 
microbeads from a formulation consisting of CLX dissolved in Solutol® HS-15 and 
Miglyol® 810N. Given the performance of formulations CLX 016/L (formulation 
containing Solutol® HS-15) and CLX 021/L (formulation containing a mixture of 
Solutol® HS-15 and Miglyol® 810N) in the in-vitro cell culture study, their suitability 
with respect to excipient selection was confirmed. The next phase of the project 
(Chapter 4) focused on the translation of these formulations into optimal microbead 
formulations.  
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3.6 Nomenclature  
            Table 3.2 List of abbreviations which are listed according to their appearance in the text. 
Abbreviation Definition 
CLX  Celecoxib  
COX-2 Cycloxygenase 2 
CRC Colorectal cancer 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
NADPH Nicotinamide adenine dinucleotide phosphate-oxidase 
NADP Nicotinamide adenine dinucleotide phosphate 
DMSO Dimethyl sulfoxide 
PS Phosphatidyl serine 
FITC Fluorescein isothiocyanate 
PI Propidium iodide 
DNA Deoxyribonucleic acid 
API Active pharmaceutical ingredient 
COA Certificate of analysis 
PBS Phosphate buffered saline 
HPLC High performance liquid chromatography 
FBS Fetal bovine serum 
PW Purified water 
UV Ultraviolet 
SEM Standard error of the mean 
STDEV Standard deviation 
TUNEL Terminal deoxynucleotidyl transferase dUTP nick end labelling 
CLX xxx/L 
Celecoxib liquid formulation numbering system where xxx is a 
sequential number and L is liquid 
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4.1 Abstract 
The purpose of this phase of the project was to develop, optimise and characterise a 
lipid-based spherical multiparticulate celecoxib (CLX) formulation in which CLX was 
retained in a fully solubilised form.  One of the primary objectives of the project to meet 
the stated purpose involved developing a robust spherical microbead with sufficient 
drug loading in which precipitation was absent both during processing and also in the 
final product. This objective was achieved through a combination of formulation 
approaches including; excipient substitution, inclusion of precipitation inhibitors and 
ratio alterations. In-vitro drug release and content assay (entrapment efficiency) analysis 
were the primary tools used to assess and compare formulations. An optimised 
microbead with a CLX loading of 6% w/w was produced, with an entrapment efficiency 
of 97% and an in-vitro drug release result of 80% over 6 h. The structure of these 
microbead formulations were characterised and compared using light microscopy which 
revealed a correlation between droplet size and drug release performance. 
 
4.2 Introduction 
4.2.1 Background 
 
At the conclusion of Chapter 3, two CLX lipid-based liquid formulations (formulations 
consisting of CLX dissolved in Solutol® HS-15 and Miglyol® 810N) were identified as 
being better than the marketed CLX formulation Celebrex® with respect to both their in-
vitro physicochemical performance (i.e., release) and in-vitro cell culture performance 
(i.e., inhibitory effect on colorectal cancer (CRC) HT29 cell line). The next phase of the 
project focused on the translation of these liquid formulations into optimal microbead 
formulations that would be amenable to colon targeting.  
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In Chapters 1 and 2, the advantages of oral drug delivery and lipid-based drug delivery 
systems were outlined respectively. The limitations of the use of conventional dosage 
forms such as soft gelatine capsules with respect to the delivery of lipid-based 
formulations were also described in Chapter 2. At the conclusion of Chapter 2, a 
feasibility study was described in which liquid lipid-based formulations were converted 
into microbeads via a manual ‘dripping’ microencapsulation process. 
Microencapsulation is defined as a process, which involves the complete envelopment 
of pre-selected core material(s) within a defined porous or impermeable membrane 
(shell) using various techniques, to give miniature sized particles (Whelehan, 2010). 
Depending on the size of the resultant particles, various terminologies can be applied 
(microcapsules, macrocapsules etc.) which can lead to confusion, however, the term 
“microcapsule” is often defined as a spherical particle containing a core substance with 
the size of the microcapsule varying between 2-2000 µm (Singh et al., 2010). This 
definition distinguishes microcapsules from smaller nanoparticles or nanocapsules 
(Singh et al., 2010). There are many different examples of microencapsulation 
processes which include but are not limited to the following; spray drying, spray 
congealing, hot melt extrusion (HME), coacervation, supercritical CO2 – assisted 
microencapsulation, concentric nozzle extrusion and prilling (Particle Sciences 
Technical Brief, 2010, Umer et al., 2011, Ghosh, 2006). A review of 
microencapsulation techniques specifically relating to lipid-based drug delivery systems 
is included below. The critical quality attributes (CQAs) of the desired CLX 
formulation/technology which formed the basis for the selection of the manual 
‘dripping’ microencapsulation process employed in this study for the production of 
CLX microbeads is also described. Finally the objectives for this phase of the project 
are detailed.   
 117 
 
4.2.2 Microencapsulation 
 
As described in section 4.2.1, microencapsulation processes yield miniature sized 
particles ranging in size from 2-2000 μm. These miniature-sized particles are usually 
referred to as microcapsules or microbeads/microspheres depending on their 
morphology. Microcapsules or microbeads may have regular or irregular shapes and on 
the basis of their morphology, they can be classified as mononuclear, polynuclear or 
matrix types (Figure 4.1). 
 
 
 
 
 
                  
Figure 4.1 Morphology of microcapsules/microbeads. (Diagram adapted from Ghosh, 2006). 
 
The term microcapsule is most commonly used for particles with mononuclear and 
polynuclear morphologies shown in Figure 4.1. Mononuclear microcapsules are also 
referred to as core-shell microcapsules as they contain a shell surrounding a single core. 
In contrast, in the case of matrix encapsulation, the core material is distributed 
homogenously in the shell material. Particles possessing the matrix morphology shown 
in Figure 4.1 are commonly referred to as microbeads or microspheres. 
Microencapsulation has the potential to pose a number of advantages as a drug delivery 
technology including the following; enhanced shelf life stability (protection of API from 
Polynuclear 
Microcapsule/Microbead 
Mononuclear Matrix 
 118 
 
the storage environment (oxygen, humidity etc.)), presentation of a multiparticulate 
amenable to further processing, potential for inherent controlled and/or targeted drug 
delivery, safe handling of potent materials (API entrapped from outer surface), taste 
masking and crucially the ability to handle liquids as solids (Ghosh, 2006, Singh et al., 
2010, Umer et al., 2011, Particle Sciences Technical Brief, 2010). The advantages of 
microencapsulation described above met the desired CQAs for a colon targeted CLX 
formulation as outlined in Chapter 1 (i.e., lipid-based multiparticulate), therefore the 
next step of the process focused on the selection of the most appropriate 
microencapsulation technique. 
 
4.2.3 Microencapsulation techniques 
 
There are many techniques available in which core materials can be encapsulated within 
a shell or matrix. These techniques are typically divided into chemical, physicochemical 
and mechanical processes although there is considerable overlap between the 
techniques. Chemical processes include interfacial and in situ polymerization methods. 
Physicochemical processes include coacervation, layer-by layer assembly, sol-gel 
encapsulation, supercritical fluid-assisted and solvent evaporation. Mechanical 
processes include spray drying, spray congealing, HME, concentric nozzle extrusion, 
and finally mechanically aided dripping techniques such as prilling (Ghosh, 2006, Singh 
et al., 2010, Umer et al., 2011, Particle Sciences Technical Brief, 2010). Given that the 
aim of this project was to encapsulate a liquid lipid core containing CLX and ultimately 
to develop an acceptable pharmaceutical product and process (i.e., a low cost, high 
efficiency, reproducible and environmentally acceptable process) the focus of the 
review below was restricted to the mechanical technologies described as they were 
considered to have the greatest potential to meet these requirements. Most of the 
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technologies described are based on the principle of generating droplets from a polymer 
(liquid form) extruded through a nozzle (orifice) and they work on the basis that a 
mechanical force (cutting/vibration/atomisation) is applied at the nozzle to break-up the 
extruded polymer. In all cases with the exception of concentric nozzle extrusion 
(Section 4.2.3.4), the active drug is dispersed homogenously in the extruded polymer. It 
should be noted that spray drying, spray congealing and HME can also be used to 
produce particles consisting of only matrix material and active drug (i.e., no 
encapsulate), therefore the resultant products are collectively often referred to in terms 
of solid dispersions rather than using microcapsule terminology. 
4.2.3.1 Spray congealing 
 
Spray congealing or spray cooling involves a method in which molten material (e.g., 
lipid) is sprayed (via atomisation at the nozzle) into a cooling chamber and on contact 
with cool air, congeals into spherical solid particles (Kalepu et al., 2013). In terms of 
microencapsulation, the molten material is usually the core, whereas the matrix consists 
of inert fillers such as lactose.  Among the advantages of spray congealing are; a) it does 
not require the input of aqueous or organic solvents , b) it yields solid particles (often 
referred to as solid dispersions) that are directly amenable to coating and c) the solid 
dispersions produced presents an opportunity for presenting drug in an amorphous state 
thereby potentially increasing its solubility. Despite these advantages, the technology is 
limited with respect to the choice of acceptable excipients on two levels; a) a 
requirement for the molten excipients to instanteously solidify in the cooling chamber at 
the set temperature and b) a requirement for the core excipients to be solid at room 
temperature (i.e., the preclusion of liquid excipients). A review of the literature revealed 
that spray congealing is usually limited to waxy materials such as polyethylene glycol 
(PEG) 4000, PEG 1500, Poloxamer® 188, and Gelucire® 50/13 (Passerini et al., 2006, 
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Mackaplow et al., 2006, Cavallari et al., 2005, Passerini et al., 2002 and Martinsa et al., 
2012). 
4.2.3.2 Spray drying 
 
Spray drying is a unit operation in which a drug solution (containing the drug, the core 
material (lipids) and the shell/matrix (solid carrier) dissolved in an organic 
solvent/water) is sprayed (atomised at the nozzle) into a hot chamber in which the 
organic solvent or water evaporates thereby giving rise to solid microparticles of the 
remaining materials. Although spray drying is a low cost, readily scalable and efficient 
process, there are a number of disadvantages of the technology; a) the solid particles 
produced are powder particles which have an irregular shape and have large size 
distribution which are directly not amenable to coating (i.e., an intermediate 
agglomeration stage is required) and b) organic solvents are routinely employed as 
solvents due to the limited selection of suitable water soluble shell/matrix materials 
(Gharsallaoui et al., 2007). 
4.2.3.3 Hot melt extrusion (HME) 
 
HME involves pumping a mixture of raw materials at an elevated controlled 
temperature (temperature at which the mixture becomes molten) and pressure through a 
heated barrel into a product of uniform shape and density which is subsequently 
extruded through a nozzle and cut into rods of defined length (Maniruzzaman et al., 
2012, Andrews et al., 2009).  Whilst HME is predominantly used to disperse APIs 
(active pharmaceutical ingredients) in a matrix at the molecular level, thus forming solid 
dispersions, it can also be used as a microencapsulation technology where the drug is 
dissolved/suspended in a lipid which is homogenously dispersed in the matrix. HME 
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offers many advantages compared with traditional solid oral dosage processing 
techniques namely; solvents are not required and it is amenable to continuous 
processing resulting in an environmentally friendly and cost effective process (Andrews 
et al., 2009). There are however also a number of disadvantages of HME; a) its use is 
limited to a narrow range of polymers/excipients due the high flow properties required 
and b) the technology is not suitable for all actives and excipients due to the prolonged 
thermal residence time involved which can cause degradation (Maniruzzaman et al., 
2012). Another disadvantage of the technology is that the extrudate from HME 
processes is in the form of a rod and therefore requires an extra spheronisation step prior 
to being amenable the application of a polymer coat.  
4.2.3.4 Concentric nozzle extrusion  
 
Concentric nozzle extrusion or co-extrusion is a process that was developed by the 
Southwest Research Institute in the USA (Ghosh, 2006). It involves the dual pumping 
of two liquids (core and shell) through a concentric vibrating nozzle which results in the 
shell material (generally hydrophilic) enveloping the core material (generally 
hydrophobic) in the form of a droplet. The droplet maintains its structure due to 
viscosity and crucially surface tension differences between the core and shell materials 
(Brandau, 2014). The shell of the droplet is then hardened in a hardening bath by one of 
a number of processes depending on the nature of the shell material (chemical 
crosslinking, cooling or solvent evaporation). A diagram depicting concentric nozzle 
extrusion is shown in Figure 4.2 below. It should be noted that in some instances the 
nozzle may be submerged in the hardening solution, in which case the surface tension 
difference between the shell material and the hardening liquid also plays a key role with 
respect to microcapsule formation. 
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Figure 4.2 Diagram depicting concentric nozzle extrusion (Diagram adapted from Ghosh, 2006). 
 
Although in theory co-extrusion technology has the potential to achieve all the benefits 
associated with encapsulation technology as outlined in Section 4.2.2, in practice co-
extrusion poses a number of limitations in terms of a technology that is suitable for the 
colon delivery of pre-solubilised poorly soluble API. These limitations revolve around 
the limited choice and concentration of surfactant that can be encapsulated in the core. 
Because of the key role that surface tension plays in maintaining the concentric droplet 
following extrusion from the nozzle, the incorporation of a surface active agent (i.e., a 
surfactant) with a high HLB (hydrophilic-lipophilic balance – refer to Chapter 2 for 
further details) disrupts this surface tension thereby causing the droplet to collapse or 
the formation of ‘leaky’ microcapsules (Refer to Section 4.4.5 for further details on 
‘leaky’ microcapsules) which are not amenable to further processing because of a lack 
Vibration Applied to Nozzle 
Hardening Bath 
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of robustness. The scalability of concentric nozzle extrusion also poses challenges due 
to mechanical/tooling difficulties of producing multiple concentric nozzles (both raised 
and submerged nozzle processes) and of applying an even flow of the hardening 
solution around each nozzle in the case of submerged nozzle process (Brandau, 2014). 
4.2.3.5 Mechanically aided dripping extrusion techniques  
 
Dripping involves a technique similar to the co-extrusion technique described in Section 
4.2.3.4, whereby instead of extruding two liquids (core and shell) through a concentric 
nozzle, a single liquid (mixture of core and shell/matrix materials) is extruded through a 
single nozzle resulting in a matrix droplet in which the core material is homogenously 
dispersed within the matrix. Similar to co-extrusion, the matrix of the droplet is then 
hardened in a hardening bath to form a microsphere by one of a number of processes 
depending on the nature of the matrix material (chemical crosslinking, cooling or 
solvent evaporation). The principle of this process is based on natural gravity whereby 
when the liquid passes through the tip of the nozzle, a droplet grows and separates from 
the stream before falling into the hardening solution. A diagram depicting gravity 
dripping is depicted in Figure 4.3 below (Chavarri et al., 2012 and Nisco gravity 
dripping, 2014).  
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Figure 4.3 Diagram depicting gravity dripping extrusion (Diagram adapted from Nisco gravity dripping 
2014). 
 
Dripping techniques offer the advantage over co-extrusion in that surfactants can be 
easily incorporated into these formulations as long as the ratio of the matrix to core 
phase is appropriate. Gravity dripping represents the simplest method of making 
individual droplets and hence microspheres, however the size of the droplet is not easily 
controlled as it is determined by the weight and surface tension of the droplet (i.e., the 
formulation) and by the diameter of the nozzle. The flow rates for gravity dripping 
processes are also very slow thereby rendering them unsuitable for industrial 
applications (Chavarri et al., 2012). The disadvantages associated with gravity dripping 
can be overcome by increasing the flow rate to the nozzle and via the application of a 
mechanical force to break up the stream of liquid as it flows from the nozzle (i.e., 
droplet formation is no longer reliant on the force of gravity). These mechanical forces 
give rise to the following techniques based on the principle of dripping; jet cutting 
technology, rotating (spinning) disc atomisation, electrostatic extrusion, coaxial air flow 
and prilling. A review of these mechanically aided dripping techniques is described in 
Chapter 6. A primary advantage of all of these dripping technologies is that they 
Hardening solution 
Matrix/core mix extruded through 
a nozzle 
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represent a single step process (with the exception of a simple drying step) in which the 
end product is amenable to direct further processing (i.e., coating). 
 
4.2.4 Desired CQAs of CLX formulation/technology 
 
As outlined in Chapter 1, the overall objective of this project was to develop a spherical 
multiparticulate lipid-based oral drug delivery formulation/technology for the delivery 
of pre-solubilised CLX to the colon for the treatment and prevention of CRC. The 
desired CQAs of the final CLX formulation have been discussed in the previous 
chapters, however a summary of these CQAs and the rationale for them is included in 
Table 4.1 below. Three critical process requirements (CPRs) are also included.  
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Table 4.1 Summary of desired CQAs and CPRs for colonic delivery of CLX CRC 
formulation/technology  
CQA Rationale 
Formulation that can incorporate a 
wide range and concentration of 
surfactants 
As outlined in Chapter 2, the use of surfactants is required for 
an optimal formulation in which the drug is dissolved and 
which remains in solution on contact with dissolution media 
and gastrointestinal (GI) contents. Surfactants also have the 
potential to stabilise the formulation (e.g., prevention of 
recrystallization). 
Formulation in which liquids can be 
encapsulated 
One of the key objectives of the final formulation is the 
delivery of pre-solubilised CLX to the colon so that it is 
available to tissue in a free molecular form. Many of the 
excipients described in Chapter 2 required to dissolve CLX are 
liquid at room temperature hence it is a requirement of the final 
formulation to be amenable to liquid encapsulation. 
Multiparticulate formulation The benefits of presenting CLX in a multiparticulate format are 
described in Chapters 1 and 5. The key benefits include; 
 Enhanced safety regarding GI irritation 
 Reduced stomach residence time 
 Even distribution of drug to the colon (including 
polyps and CRC tumours) 
 Suitable for the application of controlled release 
polymers 
 Application of consistent/uniform film coatings 
(particularly for spherical multiparticulates) 
Formulation that is amenable to 
coating 
Delivery to the colon requires the application of controlled 
release polymers hence in addition to being a multiparticulate 
the formulation/technology must be amenable to robust coating 
processes (high temperatures and high attrition). 
CPRs Rationale 
Single step process In order to have an efficient cost effective process, a single step 
process that yields a multiparticulate is desirable. 
Readily scalable process The formulation/technology must be readily scalable in order to 
be commercially viable. 
Process that can be manually simulated 
at the bench 
Based on the resources available at this stage of the project, it 
was necessary that the type of technology applied could be 
manually simulated at the bench without the requirement for 
complex process equipment. 
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4.2.4.1 Assessment of microencapsulation technologies against CQAs and CPRs 
 
On the basis of the CQAs and CPRs described in Section 4.2.4, a review of all the 
technologies described in Section 4.2.3 was performed to assess and identify the 
technology which was most amenable to the needs of the desired CLX formulation. A 
summary of this assessment is outlined in Table 4.2 below. 
 
Table 4.2 Summary assessment of microencapsulation technologies against CQAs and CPRs for desired 
CLX formulation/technology 
 
CQAs/CPRs 
Technology 
Spray Congealing Spray Drying HME Co-extrusion 
Dripping 
Techniques 
Amenable to 
surfactants 
     
Amenable to 
liquids 
  [1] [1]   
Multiparticulate   [2]  [2]   
Directly 
amenable to 
coating 
     
Single step 
process [1] 
   [3] [3] 
Scalable 
Process 
     
Manually 
simulated 
process 
     
 
[1] These technologies have been determined to meet this requirement on the basis that a literature review 
identified some examples of liquids being encapsulated using these technologies, however this application 
appears limited. 
[2] These technologies have been determined to meet this requirement on the basis that their end products 
in theory meet the definition of a multiparticulate (Porter, 2013) or can be translated into 
multiparticulates. It is noted that a technology that directly yields a multiparticulate is preferable. 
[3] Although these technologies usually require a drying step after the formation of the 
microcapsule/microbead, they are considered here to be a single step process given the simple nature of 
the drying step in comparison to secondary steps required for some of the other technologies to yield a 
suitable multiparticulate (e.g., spheronisation in the case of HME). 
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Following a review of Table 4.2, dripping techniques were identified as the technology 
of choice. Although the eventual aim of the project was to employ one of the 
mechanically aided dripping techniques described in Section 4.2.3.5, for this phase of 
the project a manual dripping technique (gravity dripping) was employed. Details of this 
technique are described in Section 4.3.2.1. 
4.2.5 Objectives 
 
As outlined in Section 4.2.1, this phase of the project focused on the translation of 
liquid formulations developed in Chapters 2 and 3 into optimal CLX microbead 
formulations that would be amenable to colon targeting using the aforementioned 
manual dripping technique. The primary objectives in producing an optimal CLX 
microbead formulation were as follows; 
 
A. The first objective was to produce ‘fit for purpose’ microbeads to meet the 
following pharmaceutical requirements; 
 High entrapment efficiency  
 Consistent drug content 
 Spherical beads amenable to coating 
 A robust process in which CLX was maintained in a soluble state (i.e., 
precipitation was avoided) 
 Sufficient drug loading to allow for intended dose to be filled into a 
reasonable sized capsule (maximum of size 00 capsule) 
 High % drug release in simple media including a greater performance to 
the marketed CLX product Celebrex® 
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B. The second objective for this phase of the project was to perform some initial 
physical characterisation of the optimised microbeads to develop an 
understanding of their internal structure and to predict how this internal structure 
might impact on their in-vitro (and consequently in-vivo) performance.  
 
In the subsequent sections the terms ‘suitable’ and ‘unsuitable’ are used with respect to 
the manufacture of microbeads, where ‘suitable’ refers to robust spherical microbeads in 
which precipitation was absent during processing. 
4.3 Materials and Methods 
4.3.1 Materials 
 
The vehicles used here were as follows; Solutol HS-15® and Cremophor EL® (both 
BASF, Germany), Transcutol® P (Gattefosse, France), Miglyol® 810N (Sasol, South 
Africa). Microbeads were prepared using these vehicles in combination with porcine 
gelatin (Nitta Gelatin, Japan) and sorbitol (Neosorb® - Roquette, France). An array of 
precipitation inhibitors were also investigated including Sodium Dodecyl Sulphate 
(SDS), Vitamin E acetate (both Merck, Germany), Vitamin E TPGS (Eastman, USA), 
Hydroxypropyl Methylcellulose (HPMC), Hydroxypropyl cellulose (HPC), polyvinyl 
alcohol (PVA), Pluronic® F127, hypromellose (all Sigma Aldrich, USA), Opadry® II 
and Opadry® White (both Colorcon, USA). A range of fluorescent dyes were sourced 
from Invitrogen. A sample of CLX API was kindly provided by Erregierre (Italy). The 
purity of the API was 99.6% based on the COA (certificate of analysis) provided by the 
supplier. All chemicals used for the release experiments, HPLC (high performance 
liquid chromatography) and UV (ultraviolet) testing were of laboratory grade. 
 130 
 
 
4.3.2 Methods 
4.3.2.1 Preparation of microbeads 
 
Microbeads containing CLX were prepared via a manual gravity dripping method. The 
microbeads were manufactured by combining a ‘surfactant phase premix’ (drug 
dissolved in various combinations of oils, surfactants and co-solvents) with a ‘gelatin 
phase premix’ (mixture of gelatin, water and sorbitol) and mixing at approximately 
60°C on a magnetic stirrer. Aliquots of the mixture were removed using a pipette for 
ejection of droplets of the mixture into a bath of cooling/hardening oil (Miglyol® 810N 
at 10°C). As the mixture droplets fall in air, coacervation occurs to form a coacervate 
suspension in which droplets of the surfactant/oil phase are surrounded by a layer of 
gelatine (multiple coacervates exist homogenously within the bead matrix). The 
dropping of the bead into a cooling/hardening bath allows the beads to harden before 
being recovered for drying. The bead formation occurs in air prior to impaction with the 
cooling oil, thereby preventing interaction of the cooling oil with the internal 
surfactant/oil phase droplets due to the presence of the layer of gelatine at the surface of 
the coacervates and hence the bead. A range oils were investigated (olive oil, mineral oil 
and other medium chain triglycerdies) for use as the cooling/hardening oil in the 
production of microbeads. Miglyol® 810N was selected as it was observed to perform 
optimally in the production of spherical beads, it has been shown to be stable against 
oxidation and is listed on the FDA’s inactive ingredient (IIG) database (FDA IIG 
database, 2014). The beads were then air dried for 24 h (over this time the water in the 
formulation evaporated). In some of the formulations other components were added to 
the gelatine phase to prevent precipitation of drug during manufacturing and also to help 
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maintain the bead structure. Gelatine was selected as shell encapsulation material as it 
fulfilled a number of criteria namely; it is predominantly hydrophilic and therefore 
suitable for encapsulation of hydrophobic materials (e.g., oils), it forms a thermal 
hydrogel which melts when heated but solidifies when cooled again (i.e., suitable for 
extrusion process described), it is water soluble and generally melts in the region of 
35°C (i.e., melts at body temperature in GI fluids) and it is also a well-known and 
acceptable pharmaceutical polymer (Rowe et al., 2006) 
 
 
Figure 4.4 A schematic of the manual microbead gravity dripping process. The emulsion/micelle 
formulation contains the drug (CLX) dissolved in a mixture of the gelatine phase (gelatine, sorbitol water 
and other components) and the surfactant phase (drug dissolved in mixtures of surfactants, oils and co-
solvents). The mixture was maintained at 60°C on a magnetic stirrer and aliquots were removed using a 
pipette for ejection of droplets of the mixture into the cooling oil bath (Miglyol® 810N at 10°C). The 
pipette was moved in a circular motion above the cooling oil bath to prevent the droplets from coalescing. 
The resultant beads were maintained in the cooling oil for 20 min before being separated and dried (at 
ambient conditions) to remove water from the beads.  
Microbeads harden upon impact with 
cooling oil (10°C) 
Pipette containing mixture of 
‘surfactant phase premix’ and 
‘gelatine phase premix’ at 60°C 
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4.3.2.2 In-vitro Release Testing 
 
Release of CLX formulations (CLX microbeads and Celebrex®) were performed (n=3) 
at 37°C in purified water (PW). Release experiments were carried out using either a 
Varian/Vankel VK7010 dissolution apparatus (VanKel, USA) or a Distek Evolution 
6300 (Distek, USA) equipped with standard glass vessels and USP type II paddles. 
Paddle rotating speed in all experiments was 75 rpm. Formulations containing 50 mg of 
CLX were weighed and added to 1000 mL of PW. At specified times 1.8 mL samples 
were withdrawn, filtered through a 70 µm pore filter (QLA, USA) and analysed using 
either a HPLC method or an UV spectrophotometric method. The % of drug released at 
particular time points was determined from peak areas which were calculated against a 
single point external reference standard in the case of the HPLC method, whereas a 
standard curve was used for the UV method. 
4.3.2.3 HPLC and UV Analysis 
 
The HPLC method for the analysis of the release and assay samples was adapted from 
Saha and colleagues (Saha et al. 2002). The HPLC column used was a reverse phase 4.6 
x 250 mm Inertsil® C8 column (Inertsil, The Netherlands) with 5 µm particles. The 
mobile phase was acetonitrile:water (65:35). The isocratic method used a flow rate of 
1.25 ml/min and ultraviolet (UV) detection at 230 nm. The injection volume was 20 µl 
and the retention time was 8 min. The HPLC apparatus that was used for the analysis 
were Thermo Finnigan (Thermo Electron Corporation, USA) and Waters (Waters, 
USA) HPLC systems (and associated Chromquest and Empower software). The UV 
method for the analysis of the release samples was also adapted from Saha and 
colleagues (Saha et al. 2002). The spectrophotometer used was a Genesys 10 series UV-
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visible spectrophotometer (Thermo Electron Corporation, USA). Absorbance was read 
at a wavelength of 251 nm. 
4.3.2.4 Evaluation of Entrapment Efficiency 
 
The amount of incorporated CLX was determined in the optimised microbead 
formulations produced. A quantity of beads (n=2) with a theoretical potency between 5 
mg and 50 mg (depending on the quantity of sample available) were sonicated for 2 h in 
a mixture of acetonitrile:water 65:35 (HPLC method) or acetonitrile:phosphate buffer 
50:50 (UV method) to extract the drug from the microbeads. The resultant solution was 
passed through a 0.45 µm filter prior to absorbance analysis. Where required the 
samples were diluted prior to analysis. The concentration of CLX was determined by 
absorbance measurements at 230 or 251 nm via the HPLC or UV analysis methods 
described above. CLX content (%) was calculated as the amount of determined CLX 
with respect to the total mass of dried microbeads.  The entrapment efficiency (%) of 
CLX was expressed as a percentage of the determined CLX with respect to the total 
amount of CLX used in the preparation of the microbeads. 
4.3.2.5 Microbead Characterization using Light Microscopy 
 
Shape and surface morphology of freshly prepared and dried microbeads were observed 
under a Nikon (Nikon, Japan) Eclipse Ti optical microscope mounted with a digital 
camera. Pictures were taken of sliced sections of dried microbeads. Thin films of 
selected formulations were also prepared and viewed under the microscope in an effort 
to understand the internal structure of the beads. A number of fluorescent dyes (Nile 
red, Bodipy 505/ 515, Sudan orange, Dextran Alexa Fluor 546, Dextran Rhodamine 
Green and Dextran Cascade Blue – all Invitrogen, USA) were incorporated into some of 
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these formulations in an attempt to distinguish between the surfactant/lipid and gelatine 
phases of the formulations. 
4.4 Results and discussion 
 
4.4.1 Development and optimisation of CLX microbeads 
 
In Chapter 2, the details of a microbead production feasibility study were outlined in 
which one formulation (CLX 030/B) was found to be amenable to manufacture. The 
composition of CLX 030/B is detailed in Table 4.3 below. 
                                    Table 4.3 Composition of formulation CLX 030/B 
Components (mg/g) 
Celecoxib 23.03 
Gelatine 554.40 
D-Sorbitol 61.70 
Miglyol® 810N 130.53 
Solutol® HS-15 230.34 
 
 
A review of formulations CLX 027/B to CLX 032/B from the feasibility study, revealed 
that five of the formulations were unsuitable due to precipitation. It also revealed that 
the only suitable formulation (CLX 030/B) had a much lower drug loading (2.3% w/w) 
than the five unsuitable formulations (drug loadings of 9.8–10.4% w/w). Based on these 
observations,the first aim of the microbead development and optimisation study 
presented here was to overcome precipitation whilst increasing the drug loading to 
commercially viable levels.  
Whilst formulation development focused primarily on formulations containing 
Miglyol® 810N and/or Solutol HS-15® in the ‘surfactant phase’ due to the promising in-
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vitro cell culture results described in Chapter 3, based on the observation above 
regarding the drug loading, the scope of the formulation development was also widened 
to look at other ‘surfactant phase’ components including Transcutol® and Cremophor® 
EL. 
4.4.1.1 Overcoming precipitation during manufacture and optimising loading of 
CLX 
 
A number of formulation aspects were investigated with the aim of overcoming 
precipitation and optimising the loading, including an assessment of the impact of the 
following; a) increasing the CLX concentration and changing excipient composition, b) 
modifying the ‘gelatine phase’ and c) incorporation of precipitation inhibitors. 
4.4.1.1.1 Increasing CLX concentration and changing excipient composition 
 
Two formulations (CLX 033/B and CLX 034/B – Table 4.4) were produced on the basis 
of formulation CLX 030/B. CLX 033/B and CLX 034/B contained increasing 
concentrations of 10% and 15% w/w CLX in their respective ‘surfactant phases’, 
equating to corresponding final loadings of 3.8% and 5.8%. In the case of CLX 033/B, 
there was no precipitation evident and bead manufacture was successful (i.e., suitable 
beads were manufactured). In the case of CLX 034/B there was slight evidence of 
precipitation and whilst bead manufacture was still possible there was tailing evident 
(see Figure 4.5 below).  
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Figure 4.5 Photographs (using Inverted Microscope (Nikon Eclipe Ti) of representative microbeads from 
CLX 034/B demonstrating the ‘tailing effect’ 
It was concluded from these formulations that the loading of CLX played a crucial role 
with respect to precipitation. Dissipation of the emulsion into the cooling oil was 
evident for both of these formulations. It was proposed that the inclusion of Miglyol® 
810N in the formulations could be contributing to the dissipation. Given that Miglyol® 
810N was also employed as the cooling oil, it was proposed that the Miglyol® 810N in 
the formulation could have a high affinity for the cooling oil resulting in dissipation of 
the formulation. Three further formulations were produced to assess the impact of 
removing Miglyol® 810N from the formulation. The three formulations contained 
increasing concentrations of CLX in their respective ‘surfactant phases’. The 
concentration of CLX was 15%, 20% and 25% w/w in the ‘surfactant phases’ of 
formulations CLX 036/B, CLX 037/B and CLX 038/B respectively (Table 4.4). 
Dissipation of the emulsion into the oil component was not observed for any of these 
formulations which confirmed that Miglyol® 810N was the cause of the dissipation. An 
increasing level of precipitation was observed for the three formulations relative to their 
increased loading of CLX which also reaffirmed the conclusion regarding precipitation 
(i.e., precipitation was related to the concentration of the drug). 
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Table 4.4 Composition of CLX microbead formulations CLX 033/B, CLX 034/B, CLX 036/B, CLX 
037B and CLX 038/B 
 
Formulations CLX 033/B 
CLX 
034/B 
CLX 
036/B 
CLX 
037/B 
CLX 
038/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 38.46 57.69 57.25 73.86 96.01 
Gelatine 553.85 553.85 552.55 567.63 555.32 
D-Sorbitol 61.54 61.54 61.39 63.07 60.63 
Miglyol® 810N 115.38 107.69 - - - 
Solutol® HS-15 230.77 219.23 328.81 295.44 288.04 
 
 
The entrapment efficiency for formulations CLX 036/B and CLX 037/B was 
determined by analysing quantities of microbeads equating to 5 mg doses of CLX. The 
% entrapment was 94.95 % ± 0.04% and 95.73% ± 0.21% for formulations CLX 036/B 
and CLX 037/B respectively.  
Two further microbead formulations (CLX 039/B and CLX 040/B – Table 4.5) were 
prepared to investigate whether the type of excipients employed impacted on the 
occurrence or levels of precipitation when drug loadings were high. The Solutol® HS-15 
employed in formulations CLX 036/B and CLX 037/B was replaced with a combination 
of Transcutol® P, Cremophor® EL and Miglyol® 810N. In the case of both CLX 039/B 
and CLX 040/B precipitation was evident in the respective emulsions overtime. The 
level of precipitation for both formulations was greater than that observed for the 
corresponding formulations containing Solutol® HS-15 indicating that excipient choice 
employed played a role with respect to the precipitation of the drug. As Transcutol® P 
was present in the highest concentration; it is likely that it had the largest impact. 
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      Table 4.5 Composition of CLX microbead formulations CLX 039/B and CLX 040/B 
 
Formulations CLX 039/B 
CLX 
040/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 78.24 56.98 
Gelatine 548.80 552.89 
D-Sorbitol 59.99 61.67 
Transcutol P 163.60 171.05 
Miglyol 810N 49.79 103.05 
Cremophor EL 99.58 54.36 
 
 
 
4.4.1.1.2 Modifying the ‘gelatine phase’ – Stage 1 
 
In the formulations described in Table 4.4, the % of gelatine was in the region of 55% 
w/w. Formulations CLX 041/B and CLX 042/B (Table 4.6) were produced to assess the 
impact of reducing the concentration of gelatine from 55% to 52% w/w. It was evident 
from these formulations that the level of precipitation was slightly greater for the 
formulation containing 55% gelatine (CLX 041/B) than for that containing 52% gelatine 
(CLX 042/B). This was the first indication that the level of water and/or gelatine in the 
formulation impacted on the level of precipitation. 
 
Table 4.6 Composition of formulations CLX 041/B and CLX 042/B (including wet bead compositions) 
 
Formulation 
Components 
CLX 041/B CLX 042/B 
Dry Bead 
Composition 
mg/g 
Wet Bead 
Composition 
mg/g 
Dry Bead 
Composition 
mg/g 
Wet Bead 
Composition 
mg/g 
Celecoxib 77.85 22.46 84.67 25.42 
Solutol® HS 15 307.04 88.57 330.55 99.25 
Gelatine 554.05 159.83 521.20 156.50 
D-Sorbitol 61.05 17.61 63.58 19.09 
Purified Water - 711.53 - 699.73 
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4.4.1.1.3 Inclusion of Precipitation Inhibitors 
 
It was shown in the previous section that it was possible to affect the level of 
precipitation of CLX in the formulations by using different excipients and that it was 
possible to eliminate precipitation by employing very low concentrations of the drug. 
These formulations were however not viable for further progression as the concentration 
of drug was insufficient. It was required to produce a formulation in which precipitation 
of the drug was eliminated and also in which the drug loading was at a viable level. A 
number of known precipitation inhibitors for CLX (Guzman et al., 2007) and some 
other recognised pharma excipients that were known to act as precipitation inhibitors 
were selected and investigated with respect to their ability to inhibit precipitation in the 
CLX formulations described here.  
 
A. Hydroxypropyl methylcellulose (HPMC) 
 
HPMC is widely used in the pharmaceutical industry as an excipient in oral 
formulations. It is primarily used as a binder, in film-coatings and also as a matrix for 
extended release formulations. HPMC has also been widely shown to prevent the 
precipitation of poorly soluble drugs in-vitro and in-vivo (Brouwers et al., 2009, Rowe 
et al., 2006). In the formulations presented in Table 4.7 below, the HPMC that was used 
was Methocel® E15 LV (referred to as HPMC E-15) from Colorcon®. In all 
formulations the HPMC was added to the ‘gelatine phase’ during the processing of the 
microbeads. Concentrations of 3% (CLX 050/B), 6% (CLX 051/B) and 8% (CLX 
052/B) w/w of HPMC were attempted and although the increasing concentration of 
HPMC did reduce the level of precipitation it was not sufficient to eliminate it. It was 
also observed that the processing of the microbeads became increasingly difficult as the 
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concentration of HPMC increased due to an increase in the viscosity of the emulsions. 
Formulations containing Trancutol® P, Miglyol® 810N and Cremophor® EL were 
assessed as they represented a worst case in terms of levels of precipitation observed up 
to this point. 
 
 Table 4.7 Composition of formulations CLX 050/B, CLX 051/B and CLX 052/B 
 
Formulations CLX 050/B CLX 051/B CLX 052/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 74.44 72.32 71.42 
Gelatine 537.20 521.90 503.29 
D-Sorbitol 60.12 58.41 55.92 
HPMC E-15 30.65 58.26 83.88 
Transcutol® P 156.18 151.74 149.84 
Miglyol® 810N 48.44 47.06 46.48 
Cremophor® EL 92.96 90.31 89.18 
 
 
B. Vitamin E (alpha tocopherol) 
 
Alpha tocopherol is primarily recognised as a source of Vitamin E. Alpha tocopherol 
has three chiral centres, giving rise to eight isomeric forms. The naturally occurring 
form is known as d-alpha tocopherol. The synthetic form is known as dl-alpha 
tocopherol or simply alpha tocopherol and it occurs a racemic mixture containing 
eqimolar quantities of all the isomers. It is a highly lipophilc compound and is an 
excellent solvent for many poorly soluble drugs (Rowe et al., 2006). There are many 
related substances to alpha tocopherol which include d-alpha tocopherol polyethylene 
glycol succinate (vitamin E TPGS) and dl-alpha tocopherol acetate (vitamin E acetate). 
The appearance of vitamin E TPGS is a white waxy solid, while vitamin E acetate is a 
yellow viscous oil. Vitamin E is widely used in the pharmaceutical industry as an 
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excipient in oral formulations. It has been used as a solvent for many poorly soluble 
drugs and also as a surfactant. It has also been shown that vitamin E TPGS can prevent 
the precipitation of celecoxib in-vivo (Guzman et al., 2007). For the purposes of this 
work, the two forms of vitamin E described above (Vitamin E TPGS and Vitamin E 
acetate) were investigated (the formulations are presented in Table 4.8 below). 
Although the literature pointed towards vitamin E TPGS being effective as a 
precipitation inhibitor, it was decided to also investigate vitamin E acetate to assess any 
differences in the liquid (acetate) and solid (TPGS) form of vitamin E. Initial 
concentrations of 6% w/w of vitamin E acetate and vitamin E TPGS were included in 
formulations CLX 053/B and CLX 054/B respectively. The formulation containing the 
vitamin E TPGS (CLX 054/B) was very viscous and was difficult to process into 
microbeads and any microbeads that were produced showed evidence of ‘tailing’. The 
viscosity of CLX 053/B (vitamin E acetate) did not pose any processing difficulties, 
however ‘tailing’ was again observed during the microbead manufacturing process. 
There was no precipitation evident with this formulation over a period of 3 h stirring at 
60 °C, however the drug did precipitate overnight. In an effort to combat the ‘tailing’ 
issues observed in the case of CLX 053/B, another formulation (CLX 055/B) was 
produced in which the concentration of vitamin E acetate was reduced to 1.6% w/w. It 
was observed that the reduction in the concentration of the vitamin E acetate resulted in 
more precipitation but also a reduction in the ‘tailing’ phenomenon. A further 
formulation (CLX 056/B) was produced consisting of a vitamin E acetate concentration 
of 3.3% w/w. This formulation exhibited properties that were a median of those 
observed for CLX 053/B and CLX 055/B. An attempt was also made to make Solutol® 
HS-15 based microbeads incorporating vitamin E acetate (CLX 059/B and CLX 061/B) 
in the formulation (the previous formulations described in this section all contained a 
combination of Miglyol® 810N, Cremophor® EL and Transcutol® P in the surfactant 
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phase). Precipitation was observed to be reduced for formulations CLX 059/B and CLX 
061/B compared to formulations CLX 053/B – CLX 057/B with no precipitation 
evident in the case of CLX 061/B.  Manufacturing however again posed some 
difficulties with ‘tailing’ evident. These results confirmed that vitamin E acetate had the 
potential to be a precipitation inhibitor in the formulation but that its high viscosity 
impacted on the ability to produce spherical microbeads. 
 
               Table 4.8 Composition of formulations CLX 053/B, CLX 054, CLX 055/B, CLX 056/B,    
                  CLX 057/B and CLX 059/B 
 
Formulations CLX 053/B 
CLX 
054/B 
CLX 
055/B 
CLX 
056/B 
CLX 
057/B 
CLX 
059/B 
CLX 
061/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 71.84 72.40 76.01 74.17 75.34 75.90 73.64 
Gelatine 518.80 515.55 542.13 534.84 542.77 543.43 526.28 
D-Sorbitol 58.59 59.22 61.58 61.30 62.20 63.01 58.85 
Vitamin E 
Acetate 63.61 - 16.45 33.21 - 15.28 47.53 
Vitamin E 
TPGS - 63.42  - 18.52 - - 
Transcutol® P 150.72 151.89 159.47 155.61 158.07 - - 
Miglyol® 810N 46.75 47.11 49.46 48.26 49.03 - - 
Solutol® HS-15 - - - - - 302.38 293.40 
Cremophor® 
EL 89.70 90.40 94.91 92.61 94.08 - - 
 
 
When lower concentrations of vitamin E acetate were employed, it was observed that 
the bead manufacture process posed fewer difficulties. On this basis, an attempt at 
producing a microbead formulation using vitamin E TPGS using a lower concentration 
to that previously employed for CLX 054/B (6% w/w) was performed. Formulation 
CLX 057/B which contained 1.8% w/w of vitamin E TPGS was produced. In this 
instance, the microbead manufacturing process was feasible (although the beads had a 
tendency to float on the top of the oil bath) and the level of precipitation was reduced.  
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The formulations described in this section highlighted the potential of vitamin E (both 
forms) to act as a precipitation inhibitor of CLX, however its incorporation into 
microbeads was shown to pose difficulties form a manufacturing perspective. The CLX 
content of formulations CLX 055/B and CLX 056/B were determined via the 
entrapment efficiency assay. Quantities of microbeads equating to 5 mg doses of CLX 
were weighed and analysed. The % entrapment was 78.85 % ± 0.30% and 99.48 % ± 
0.18% for formulations CLX 055/B and CLX 056/B respectively. These assay results 
reaffirmed the observation that the level of precipitation was related to the concentration 
of vitamin E acetate employed. The level of vitamin E acetate in formulation CLX 
055/B was approximately half of that employed in formulation CLX 056/B and there 
was approximately a 20% difference in the amount of CLX entrapped in the resultant 
microbeads. It is proposed that the % of entrapment for formulation CLX 055/B was 
low because some of the drug had precipitated prior to bead manufacture and therefore 
was not available during microbead manufacture (precipitated drug tended to 
accumulate on the sides of the mixing vessel). 
C. Opadry® II 
 
Opadry® II is an excipient manufactured by Colorcon® and is widely used in the 
pharmaceutical industry in oral formulations. It is primarily used for film coating (Rowe 
et al., 2006). Opadry® II contains polyvinyl alcohol (PVA), PEG 3000, titanium dioxide 
and talc (Colorcon Opadry® II product specification, 2010). Opadry® II was selected on 
the basis that PVA had been shown to prevent the precipitation of CLX in-vivo 
(Brouwers et al., 2009). The first formulation produced that contained Opadry® II was 
CLX 062/B (Table 4.9). It was observed that Opadry® II greatly facilitated the 
microbead manufacturing process. It was difficult to assess its impact on precipitation 
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as Opadry® II did not dissolve in the formulation, but instead formed a suspension. The 
next formulation produced containing Opadry II® was CLX 063/B (Table 4.9). The 
primary difference between formulations CLX 062/B and CLX 063/B was the inclusion 
of Solutol® HS-15 alone and a combination of Miglyol®/ 810N Transcutol® P/ 
Cremophor® EL in their respective ‘surfactant phases’. Precipitation was evident in the 
case of CLX 063/B which again pointed towards the role different excipients play with 
respect to the onset of precipitation. A further formulation was then produced (CLX 
067/B) which involved increasing the CLX concentration employed for formulation 
CLX 062/B from 7% w/w to 9% w/w. Again microbead manufacture was without 
difficulty; however some precipitation was evident after stirring overnight. This 
experiment  reaffirmed the criticality of the drug concentration employed with respect to 
precipitation (regardless of whether or not precipitation inhibitors were included). In the 
case of Opadry® II, it was not possible to increase its concentration above the levels 
employed here as the formulations became too difficult to process (i.e., too viscous). 
 
                  Table 4.9 Composition of formulations CLX 062/B, CLX 063/B and CLX 067/B 
 
Formulations CLX 062/B 
CLX 
063/B 
CLX 
067/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 72.87 74.55 92.35 
Gelatine 518.98 521.29 524.25 
D-Sorbitol 60.35 60.35 61.18 
Opadry® II 57.47 45.80 45.16 
Transcutol® P - 156.41 - 
Miglyol® 810N - 48.51 - 
Solutol® HS-15 290.33 - 277.06 
Cremophor® EL - 93.09 - 
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D. Opadry® White 20A28380  
 
Opadry® White 20A28380 is an excipient manufactured by Colorcon and widely used 
in the pharmaceutical industry in oral formulations. It is primarily used for film coating 
(Rowe et al., 2006). It contains talc, hydroxypropyl cellulose (HPC), hypromellose and 
titanium dioxide (Colorcon Opadry® White 20A28380 product specification, 2010) and 
was selected for screening as it contained HPC which has been shown to prevent the 
precipitation of CLX in-vivo (Guzman et al., 2007). CLX 066/B (Table 4.10) was 
produced with a concentration of 4.5% w/w of Opadry® White and a high loading of 
CLX (9.4% w/w). As was the case for the formulations containing Opadry® II, the 
inclusion of Opadry® White greatly assisted the microbead manufacturing process. 
Opadry® White also produced a fine suspension which made the detection of 
precipitation difficult. For formulation CLX 066/B, there was only slight evidence of 
precipitation which was encouraging given the high loading of CLX. CLX 068/B (Table 
4.10) was produced to assess the impact of Opadry® White on a formulation containing 
Miglyol® 810N/ Transcutol® P/ Cremophor® EL. In this case, precipitation was evident 
but to a lesser extent than with formulation CLX 063/B (similar formulation containing 
Opadry II) which suggested that Opadry® White was a greater precipitation inhibitor for 
CLX formulations in comparison to Opadry® II.  
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                              Table 4.10 Composition of formulations CLX 066/B and CLX 068/B 
 
Formulations CLX 066/B CLX 068/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 94.25 74.22 
Gelatine 520.03 523.82 
D-Sorbitol 57.43 59.25 
Opadry® White  45.56 45.99 
Transcutol® P - 155.73 
Miglyol® 810N - 48.30 
Solutol® HS-15 282.74 - 
Cremophor® EL - 92.68 
 
 
 
E. Hydroxypropyl cellulose (HPC) 
 
Although the exact composition of Opadry® White 20A28380 is unknown, it is known 
to include HPC and it is believed that HPC is a predominant component as HPC is 
widely used as a film coating agent in tablet formulations. HPC has been shown to 
prevent the precipitation of CLX in-vivo (Guzman et al., 2007). It was found that it was 
very difficult to make microbeads which incorporated HPC, as it was hard to disperse 
the HPC in the ‘gelatine phase’ which consequently made the formulations very 
viscous. Two formulations containing HPC were attempted (CLX 070/B and CLX 
072/B – Table 4.11), however neither of these were viable options for further 
consideration due to processing difficulties. If HPC is indeed the primary component of 
Opadry® White, then it is proposed that Colorcon® (the manufacturer) includes a 
processing step (e.g., milling) in their material manufacture that makes it more 
amenable for inclusion in this type of formulation. 
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Table 4.11 Composition of Formulations CLX 070/B and CLX 072/B 
Formulations CLX 070/B 
CLX 
072/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 74.63 94.09 
Gelatine 523.21 519.68 
D-Sorbitol 58.49 57.57 
HPC  46.34 46.41 
Solutol® HS-15 297.33 282.26 
 
 
F. Pluroinc® F127 and other precipitation inhibitors 
 
Pluronic® F127 was also assessed with respect to its effectiveness at preventing 
precipitation. Pluronic® F127 is a poloxamer polyol (a block copolymer of ethylene 
oxide and propylene oxide) and is typically used in pharmaceutical industry as an 
emulsifying and solubilizing agent.   Pluronic® F127 has also been shown to prevent the 
precipitation of CLX in-vivo (Guzman et al., 2007). In the case of formulation CLX 
075/B (Table 4.12), it was found to have no effect on the onset of precipitation and 
therefore was not pursued further. Other potential precipitation inhibitors that were 
investigated (CLX 111/B and CLX 112/B – Table 4.12) but which were ultimately 
unsuitable were hypromellose and PVA.  
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Table 4.12 Composition of formulation CLX 075/B, CLX 111/B and CLX 112/B 
 
Formulations CLX 075/B 
CLX 
111/B 
CLX 
112/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 92.08 54.35 54.35 
Gelatine 276.23 521.74 521.74 
D-Sorbitol 58.54 57.97 57.97 
Pluronic® F127 43.98 - - 
Hypromellose - 57.97 - 
PVA - - 57.97 
Solutol® HS-15 276.23 307.97 307.97 
 
 
4.4.1.1.4 Modifying the ‘gelatine phase’ – Stage 2  
 
A number of approaches were made to modify the gelatine phase of the CLX microbead 
formulations with the dual intention of increasing the loading and eliminating 
precipitation. These approaches involved a) addition of talc to the ‘gelatine phase’ and 
b) reduction of the ‘gelatine phase’ component (i.e., changing the ratio between the 
gelatine phase and surfactant phase components). 
 
A. Formulations containing Talc  
 
During the course of some of the experiments described above (Sections 4.4.1.1.3 C and 
D), it was observed that two of the potential precipitation inhibitors investigated 
(Opadry® II and Opadry® White) offered the potential benefit of modifying the 
formulation to the extent that microbead manufacture posed few difficulties. It was 
proposed that the incorporation of these components helped to maintain the structure of 
the emulsion droplet on impact with the cooling oil. The components of Opadry® II and 
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Opadry® White were examined to identify similarities. The one excipient common to 
both materials was talc. The impact of including talc in formulations similar to those in 
Section 4.4.1.1.3 B (i.e., formulations containing vitamin E) was investigated as these 
formulations containing vitamin E had previously exhibited difficulties with respect to 
microbead manufacture. Formulation CLX 081/B (Table 4.13) was produced, which 
was a similar formulation to CLX 055/B and CLX 056/B with the addition of talc (7.3% 
w/w). It was observed that the bead manufacture process was without difficulty which 
added to the hypothesis that the incorporation of talc helped to maintain the structure of 
the emulsion droplet on impact with the cooling oil.   
 
                       Table 4.13 Composition of Formulation CLX 081/B 
 
CLX 081/B 
Formulation Components mg/g 
Celecoxib 68.53 
Transcutol® P 143.78 
Cremophor® EL 85.57 
Miglyol® 810 44.60 
Gelatine 499.07 
Vit E Acetate 28.14 
Talc 73.67 
D-Sorbitol 56.66 
 
 
 
B. Reduction of the ‘gelatine phase’ component  
 
In all of the formulations presented to this point, the concentration of gelatine 
contributed in the region of 55% w/w of the entire dried formulation. Given the 
observation that increasing the concentration of CLX in the ‘surfactant phase’ 
generally led to increased precipitation, the possibility of reducing the ‘gelatine 
phase’ component in the formulation was investigated as an alternative method of 
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increasing the loading of CLX. An initial attempt (CLX 090/B – Table 4.14) was 
made in which the final gelatine concentration was reduced to approximately 40% 
w/w, which resulted in an increase in the CLX concentration up to 11% w/w. The 
formulation preparation was identical to that of formulations CLX 037/B, CLX 
041/B and CLX 042/B with the exception that the ‘surfactant phase’: ‘gelatine phase’ 
ratio was 1:4 for CLX 090/B whereas it was 1:9, 1:8 and 1:7 for CLX 037/B, CLX 
041/B and CLX 042/B respectively. The concentration of CLX in the ‘surfactant 
phase’ (prior to the microbead processing stage) was 20% w/w. It was found that 
microbead manufacture was possible for this formulation; however some 
precipitation of the drug was observed which suggested that a loading of 20% w/w 
CLX in the surfactant phase was excessive. Formulation CLX 098/B (Table 4.14) 
was produced containing a loading of 15% w/w of CLX in the ‘surfactant phase’ and 
a final concentration of 40% w/w gelatine in the final microbeads (i.e., the 
‘surfactant phase’: ‘gelatine phase’ ratio of 1:4 was maintained). There was only 
slight precipitation evident overtime. This was a major advance on the previous 
formulation produced. In Chapter 2, formulation CLX 032/B was presented in which 
the gelatine concentration was 65% w/w and the CLX loading was 9.8% w/w. In the 
case of CLX 032/B, this formulation could not be progressed to microbead 
manufacture as the CLX precipitated on impact of the ‘surfactant phase’ with the 
‘gelatine phase’. Formulation CLX 098/B had a drug concentration of 8.2% w/w 
(comparable to that of CLX 032/B), however in contrast to CLX 032/B, it was shown 
to be easily converted into microbeads. It was postulated that the improvement with 
respect to the precipitation of the drug was as a result of the reduced number of water 
molecules (in the gelatine phase) available for interaction with the drug. 
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Table 4.14 Composition of Formulations CLX 090/B and CLX 098/B 
 
Formulations CLX 090/B CLX 098/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 111.38 82.97 
Gelatine 399.69 400.76 
D-Sorbitol 45.19 46.54 
Solutol® HS-15 443.75 469.73 
 
4.4.2 Optimised CLX microbead formulations 
 
Based on the data and observations from all the formulations described above and 
Section 4.4.1.1.4 B in particular, optimised CLX microbead formulations were 
developed. This optimisation process is described below. 
 
4.4.2.1 Inclusion of SDS as a precipitation inhibitor 
 
Following the important findings presented in Section 4.4.1.1.4 B, all subsequent 
experiments focused on formulations containing gelatine in the range of 30-40% w/w. 
In an effort to eradicate the slight precipitation observed for formulation CLX 098/B 
(Table 4.14), another potential precipitation inhibitor, sodium dodecyl sulfate (SDS), 
was investigated. The inclusion of 3.2% w/w SDS resulted in a formulation 
(formulation CLX 099/B – Table 4.15) in which precipitation was initially absent. Part 
of the mixture was converted into microbeads, while the remaining fraction was kept 
stirring at 60°C for a period of 1 week. After 1 week the emulsion was examined and 
some precipitate was observed. A further formulation CLX 101/B (Table 4.15) was 
manufactured in which the concentration of SDS was increased to 5.3% w/w. No 
precipitation occurred initially but again some precipitate became evident over a 
prolonged period of time. 
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  Table 4.15 Composition of Formulations CLX 099/B, CLX 101/B, CLX 102/B, CLX 104/B,  
                     CLX 105/B and CLX 115/B 
 
Formulations CLX 099/B 
CLX 
101/B 
CLX 
102/B 
CLX 
104B 
CLX 
105/B 
CLX 
115/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 80.65 79.33 105.53 76.91 88.50 51.72 
Solutol® HS-15 456.99 449.15 420.46 435.46 501.07 293.10 
Gelatine 387.10 374.29 377.54 369.12 309.48 496.55 
SDS 32.26 52.81 53.69 76.22 65.54 103.45 
D-Sorbitol 43.01 44.42 42.78 42.28 35.41 55.17 
 
 
The CLX content of formulation CLX 101/B was determined by weighing quantities of 
microbeads equating to 5 mg doses of CLX and analysing for CLX following 
extraction. The average % entrapment was 91.77 % ± 0.04%. Formulations CLX 099/B 
and CLX 101/B both represented formulations in which the CLX loading in the 
‘surfactant phase’ was 15% w/w. In an effort to increase the overall loading of the drug, 
a formulation (CLX 102/B – Table 4.15) was attempted in which the loading of the drug 
in the surfactant phase was increased to 20% w/w. This formulation was however 
unsuitable as the drug was observed to precipitate. It was concluded that despite the 
reduction of the gelatine concentration and the inclusion of SDS as a precipitation 
inhibitor that there was still a maximum concentration of CLX that could be included in 
the formulation in order to avoid precipitation. Formulation CLX 104/B (Table 4.15) 
was prepared in which the SDS concentration was increased to 7.6% w/w. The 
concentration of CLX in the ‘surfactant phase’ was also reduced back to 15% w/w. 
There was some precipitation evident over time but was reduced compared to 
formulations that contained lower concentrations of SDS, confirming that the SDS level 
had an impact with respect to precipitation. The CLX content of formulation CLX 
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104/B was determined to be 93.21% ± 0.73%. In an effort to further increase the drug 
loading in the overall formulation, whilst keeping a constant drug concentration in the 
‘surfactant phase’ (i.e., 15% w/w), a further reduction of the gelatine concentration was 
attempted (Formulation CLX 105/B – Table 4.15). The gelatine concentration was 
reduced from an average of 37% w/w to approximately 30% w/w. Although it was 
possible to produce microbeads it was found that the mixture was viscous and difficult 
to process, indicating that a gelatine concentration of 37% w/w was the limit for the 
gelatine phase at this loading of CLX (15% w/w in the surfactant phase). Microscopic 
analysis was performed on microbead formulation CLX 104/B. The analysis was 
performed on beads produced prior to the onset of any visible precipitation. Thin slices 
of the beads were obtained by cutting the beads with a blade and these slices were 
viewed under the inverted microscope (Figure 4.6). This analysis revealed what 
appeared to be needle like crystals in the microbeads. These needles were characteristic 
of CLX needle crystals (Chawla et al., 2003) which suggests that some precipitation 
may have occurred that was not visible to the naked eye. This was an important finding 
in the context of the requirement for the formulation to present CLX in a solubilised 
state (i.e., no precipitation).  
 
  
Figure 4.6 Photographs (using Inverted Microscope (Nikon Eclipe Ti) of a ‘slice’ of formulation CLX 
104/B at (A) 10X magnification and (B) 40X magnification. 
 
A B 
CLX Needles Present 
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In order to assess the impact of including SDS in the formulation at the original gelatine 
concentration of 55%, formulation CLX 115/B (Table 4.15) was prepared. Significant 
precipitation was evident in this formulation which confirmed that a combination of 
reducing the gelatine concentration and the inclusion of SDS was required to eliminate 
precipitation. 
 
4.4.2.2 Impact of ‘surfactant phase excipients’ on reducing the gelatine phase 
concentration 
 
Following on from the important finding in section 4.4.1.1.4 B, regarding the reduction 
of the gelatine phase concentration, the role of the ‘surfactant phase’ excipients in these 
formulations was further investigated. A formulation similar to CLX 101/B (Table 4.15) 
was prepared in which the Solutol® HS-15 ‘surfactant phase’ was substituted with a 
‘surfactant phase’ containing 20% w/w CLX dissolved in a mixture of Transcutol® P, 
Cremophor® EL and Miglyol® 810 (Formulation CLX 119/B – Table 4.16). There was 
no precipitation for this formulation originally; however there was significant 
precipitation evident after a number of hours. It was noted that the level of precipitation 
was significantly less compared to a corresponding formulation (CLX 028/B – Chapter 
2) in which the gelatine concentration was 54% w/w. It should also be noted that there 
was no SDS in formulation CLX 028/B which may also have contributed to the 
improvement with respect to CLX 119/B. The most significant observation with respect 
to CLX 119/B was however regarding its processing conditions and the morphology of 
the resultant microbeads. It was found that it was very difficult to process the beads 
when Miglyol® 810N/Cremophor® EL/Transcutol® P were used instead of Solutol® HS-
15. In the case of the beads that were produced, they had a very irregular bead shape 
(not spherical) and appeared to be leaking oil. It was proposed that the waxy nature of 
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Solutol® HS-15 (solid at room temperature) helped to retain the integrity of the bead. 
This was a very important observation regarding the choice of excipients when 
attempting to formulate microbeads with low gelatine concentrations (i.e., in the region 
of 30–40% w/w).  
 
                 Table 4.16 Composition of Formulation CLX 119/B 
 
CLX 119/B 
Formulation Components mg/g 
Celecoxib 105.08 
Transcutol 220.47 
Cremophor EL 131.21 
Miglyol 810 68.38 
Gelatin 377.01 
SDS 54.91 
D-Sorbitol 42.95 
 
 
4.4.2.3  First generation CLX microbead formulations in which precipitation was 
eliminated 
 
The following formulations (CLX 123/B, CLX 125/B and CLX 127/B – Table 4.17) 
represent the first generation of CLX formulations which were produced on the basis of 
all the findings previously described and crucially in which there was no precipitation 
evident (immediately or overtime). The formulations containing SDS were transparent 
(both the original mixture and the resultant beads) which suggests that they were 
potentially micellar solutions. The formulation containing Opadry® White had a white 
appearance which was likely attributable to the Opadry® White powder forming a fine 
suspension.  
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Table 4.17 Composition of formulations CLX 123/B, CLX 124/B CLX 125/B and CLX 127/B 
Formulations CLX 123/B 
CLX 
124/B 
CLX 
125/B 
CLX 
127/B 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 54.68 88.61 56.79 58.49 
Solutol® HS-15 492.13 501.97 511.14 526.38 
Gelatine 396.71 282.52 298.56 305.75 
SDS - 95.36 99.80 75.35 
Opadry White 11.98 - - - 
D-Sorbitol 44.51 31.54 33.70 34.04 
 
Release analysis was performed on 50 mg doses of these three formulations (CLX 
123/B, CLX 125/B and CLX 127/B). The dissolution medium employed was PW. The 
reader is reminded that in the case of the Celebrex™ (marketed CLX product), the 
maximum % of CLX released in PW was 6 % (Refer to Chapter 2). In contrast the 
maximum % drug release for the three optimised formulations ranged between 69 and 
84 % release (Figure 4.7). It is important to note that the concentration of drug in the 
‘surfactant phase’ was reduced to 10% in all of these formulations. CLX 124/B 
(formulation containing 15% CLX in the ‘surfactant phase’) was produced in direct 
comparison to CLX 125/B and it was observed that precipitation occurred 2–3 h after 
the mixture was prepared which again emphasised the criticality of drug loading with 
respect to precipitation. 
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Figure 4.7 Percentage of CLX released from formulations CLX 123/B, CLX 125/B and 
CLX 127/B tested in PW. The data presented are mean values ± STDEV (n=3). 
 
4.4.3 Physical characterisation of optimised microbead formulations 
 
In order to compare and understand the performance of the formulations described 
above, it was required to characterise the internal structure of these formulations. 
Although image analysis had previously been performed on slices of microbeads (e.g., 
for formulation CLX 104/B - Figure 4.6), it was found that this method had the potential 
to be destructive (the integrity of the bead could be compromised as a result of the 
slicing process). An alternative approach involving the preparation of ‘thin films’ of the 
microbead formulations was attempted. A number of fluorescent dyes were 
incorporated into some of these formulations in an effort to distinguish between the 
‘surfactant phases’ and ‘gelatine phases’ of the formulations. These dyes are described 
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in Table 4.18 below. It was postulated that the amphiphilic dyes might have a higher 
affinity for the ‘surfactant phase’ whereas the water soluble dyes would have a higher 
affinity for the gelatine/water phase.  
 
        Table 4.18 List of amphiphilic and water soluble dyes incorporated into microbead formulations 
Amphiphilic Dyes Water Soluble Dyes 
Nile Red Dextran Alexa Fluor 546 
Bodipy 505/515 Dextran Rhodamine Green 
Sudan Orange Dextran Cascade Blue 
 
 
Based on a number of trials it was found that a combination of Dextran Alexa Fluor 546 
and Nile Red were found to be the best dyes in distinguishing between the two phases 
and therefore these dyes were incorporated into all formulations produced for the 
purpose of microscopic analysis. 
In order to understand the structure of optimised formulations such as CLX 125/B, a 
number of formulations were prepared to act as controls and/or to assess the impact of 
the addition and removal of certain formulation components (e.g., SDS). The 
formulations prepared are listed in Table 4.19 below. Two of these formulations (CLX 
130/B and olive oil formulation) were prepared as placebos (i.e., no CLX API was 
included). The purpose of the olive oil formulation was to assess the impact of 
employing no surfactant within the formulation whilst CLX 130/B was prepared to 
assess the impact of removing API from CLX 125/B. CLX 131/B was prepared to 
assess the impact of substituting SDS with an alternative surfactant/precipitation 
inhibitor (Vitamin E TPGS). Formulation CLX 134/B was prepared to assess the impact 
of removing SDS from the formulation and also the impact of employing a smaller 
concentration of the ‘surfactant phase’ in comparison to CLX 125/B (i.e., less Solutol® 
HS-15). 
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Table 4.19 Composition of Formulations; Gelatine Control Formulation, CLX 130/B, CLX 131/B, CLX 
134/B and olive oil formulation. 
Formulations 
Gelatine 
control 
formulation 
CLX 
130/B 
CLX 
131/B 
CLX 
134B 
Olive oil 
formulation 
C
o
m
po
n
en
t C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib - - 58.45 28.35 - 
Solutol® HS-15 - 412.32 526.08 255.15 - 
Gelatine 903.61 445.50 303.94 644.33 314.89 
SDS - 94.79 -   
D-Sorbitol 96.39 47.39 34.27 72.16 34.24 
Vit E TPGS - - 77.25 - - 
Olive Oil - - - - 520.29 
 
 
Thin films of each of these formulations were prepared and photographs of each film 
were taken using an inverted microscope (Nikon Eclipse Ti). The microscope was 
predominantly used in its light microscope setting as opposed to fluorescent light 
(greater clarity was observed using the light microscope). At this time, the measurement 
function on the microscope was not operational therefore it was not possible to take 
measurements, however images were taken at similar levels of magnification (where 
possible) to allow for direct comparisons to be made. In Figure 4.8 A, the structure of a 
film of the gelatine control formulation represented in Table 4.19 is shown. It appeared 
to have consistent matrix appearance in which there were distinct regions (light blue and 
dark blue regions). This was not unexpected as gelatine is a polydisperse system 
comprising different lengths of protein chains that in turn consist of long hydrophobic 
chain segments and short hydrophilic segments (i.e., it has amphiphilic properties). In 
this instance Figure 4.8 A was acting as a background control for comparison with the 
other films.  
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In Figure 4.8 B, the structure of formulation CLX 134/B is shown. This formulation is 
similar to that previously described for CLX 125/B with the exception that SDS is not 
included in the formulation and also the concentration of Solutol® HS-15 is reduced. 
Figure 4.8 B illustrated a system in which there was evidence of the presence of large 
polydisperse vesicles. Figure 4.8 C illustrated the internal structure of a film of CLX 
131/B, a formulation again similar to CLX 125/B but where SDS was substituted with 
Vitamin E TPGS.  In this instance, it was evident that there were large vesicles or oil 
droplets present in the formulation. Similarly, Figure 4.8 D (olive oil formulation) 
displayed evidence of large oil droplets. Figures 4.8 C and D were both taken at a lower 
magnification (10X), which illustrated the large size of their respective oil 
droplets/vesicles in comparison to formulation CLX 134/B (Photograph 4.8 B). In 
Figures 4.8 E (CLX 130/B) and F (CLX 125/B), there was no evidence of vesicles 
present which suggested that their sizes were too small to be visible (i.e., mixed 
micelles could be present). This was a very important finding as it suggests that 
formulation CLX 125/B was a micellar solution (which corresponds with the fact that 
the formulation is transparent) in comparison to other formulations such as CLX 134/B, 
CLX 131/B or the olive oil formulation which appeared to be emulsions (they had a 
milky appearance – refer to Chapter 2 for emulsion description). 
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Figure 4.8 Photographs of thin films of various formulations taken using an Nikon Eclipse Ti Inverted 
Microscope; A) 40X image of gelatine formulation, B) 40X image of CLX 134/B, C) 10X image of CLX 
131/B, D) 10X image of olive oil formulation, E) 40X image of CLX 130 and F) 40X image of CLX 
125/B. All formulations included a combination of Dextran Alexa Fluor 546 and Nile Red dyes. 
 
This is important as the in-vivo performance of formulations with a fine droplet size 
(e.g., microemulsions, micellar solutions etc.) have in cases been shown to be superior 
(better and more consistent absorption, less impact of food effects etc.) in comparison to 
equivalent large droplet formulations (e.g., emulsions). An example of this is the 
A B 
C D 
E F 
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improved performance of the Novartis® microemulsion Cyclosporine preparation 
Neoral® in contrast to the equivalent emulsion formulation Sandimmune® (Mueller et 
al., 1994).  
 
4.4.4 Selection of optimal CLX microbead formulation 
 
Following a review of formulations CLX 123/B, CLX 125/B and CLX 127/B, the 
development of an optimal formulation focused on formulations containing SDS (i.e., 
formulations similar to CLX 125/B and CLX 127/B). This decision was made on the 
basis that formulations containing SDS were transparent therefore it was definite that 
there was no precipitation evident. In addition the entrapment efficiency for CLX 125/B 
(97.55 % ± 0.85 %)) was higher than that for CLX 123/B (91.06 % ± 0.58 %) 
Formulation CLX 136/B (Table 4.20) was developed on the basis of CLX 125/B and 
CLX 127/B, with an enhanced drug loading (6%) and also a lower concentration of 
SDS. It was desirable to lower the quantity of SDS in the formulation given that the 
equivalent quantity of SDS in a 50 mg dose of formulation CLX 127/B (64.41 mg) was 
higher than the maximum quantity listed for SDS in a solid oral dosage form (51.69 mg) 
on the FDA’s IIG database (FDA IIG Database, 2014). In order to build on the 
characterisation studies outlined in Section 4.4.3, the impact of removing SDS from 
formulation CLX 136/B was assessed in formulation CLX 135/B (Table 4.20). Release 
analysis was performed on 50 mg doses of formulations CLX 135/B and CLX 136/B 
(Figure 4.9) to evaluate the impact of removing SDS with respect to in-vitro drug 
release (in addition to its impact with respect to precipitation). The removal of SDS 
resulted in a dramatic decrease in the release, with a maximum of 46% release for 
formulation CLX 135/B in comparison to 80% release for formulation CLX 136/B.  In 
order to gain a better understanding of the impact of removing SDS from the 
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formulation, thin films of these formulations (including Dextran Alexa Fluor 546 and 
Nile Red dyes) were prepared and photographs were taken using a Nikon Eclipse Ti 
inverted microscope (Figure 4.10). Similar to Figure 4.8A, in photograph A of figure 
4.10, the structure of a film of a gelatine formulation is again represented for 
comparison purposes as a background control. In photograph 4.10B, the structure of 
formulation CLX 135/B is represented. Photograph 4.10B illustrated a system in which 
there was evidence of the presence of large polydisperse surfactant phase 
droplets/vesicles. In photograph 4.10C, the structure of formulation CLX 136/B is 
represented. The image in photograph 4.10C was similar to that for the gelatine control 
in photograph 4.10A. It is again proposed that the surfactant phase droplets/vesicles 
present in formulation CLX 136/B were too small to be visible (i.e., mixed micelles 
could be present). Similar to the finding in Section 4.3.3, this is an important point as it 
suggests that formulation CLX 136/B was a micellar solution (which also corresponds 
with the fact that the liquid formulation was transparent) in comparison to formulation 
CLX 135/B which was opaque. It is suggested that the greater in-vitro release 
performance of formulation CLX 136/B in comparison to formulation CLX 135/B 
which contained less surfactant (i.e., no SDS) was related to the droplet size of the 
corresponding formulations.  
 
              Table 4.20 Composition of formulations; CLX 135/B and CLX 136/B  
Formulations CLX 135/B 
CLX 
136/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 63.06 60.63 
Solutol® HS-15 567.50 545.66 
Gelatine 396.71 316.13 
SDS - 42.51 
D-Sorbitol 38.05 35.07 
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Figure 4.9 Percentage of CLX released from formulations CLX 135/B, CLX 136/B and Celebrex® 
tested in PW. The data presented are mean values ± STDEV (n=3). 
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Figure 4.10 Photographs of thin films of three formulations taken using an Nikon Eclipse Ti Inverted 
Microscope; A) 10X image of gelatine formulation, B) 10X image of formulation 135/B and C) 10X 
image of formulation 136/B. All formulations included a combination of Dextran Alexa Fluor 546 and 
Nile Red dyes. 
A 
C 
B 
100 µm 
100 µm 
100 µm 
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Some further formulations were also produced to assess the impact of changing the 
Solutol® HS-15 concentration in the formulation. Formulation CLX 138/B (Table 4.21) 
was produced in which the Solutol® HS-15 concentration was decreased by 
approximately 50% in comparison to CLX 136/B (Table 4.20). It is noted that the 
decrease in the Solutol® HS-15  also results in a corresponding increase in gelatine 
concentration. Although the release profiles for both formulations were similar (Figure 
4.11), microscope analysis of a ‘thin film’ of CLX 138/B revealed the presence of large 
droplets/vesicles (Figure 4.12). Given that the drug concentration in CLX 138/B was 
relatively low at 2.8% w/w, it is not surprising that the release profile was similar to that 
of CLX 136/B, however the larger droplet/vesicle is indicative of a formulation in 
which release could pose problems at a higher drug loading. Formulation CLX 141/B 
(Table 4.21) was produced to test this theory. Release testing of CLX 141/B was 
performed in PW over a period of 6 h, with a maximum of 40 % release of CLX 
achieved (Figure 4.11). Formulation CLX 141/B had a milky white appearance 
therefore it was difficult to see vesicles/ droplets when viewed under the microscopic 
however needles of CLX were clearly visible (Figure 4.12 B). As a result of these 
findings, formulations with lower levels of Solutol® HS-15 (<45% w/w) were excluded 
from further assessment. 
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                  Table 4.21 Composition of formulations; CLX 138/B and CLX 141/B 
 
 
 
 
 
 
 
 
Figure 4.11 Percentage of CLX released from formulations CLX 136/B, CLX 138/B and CLX 138/B 
tested in PW. The data presented are mean values ± STDEV (n=3). 
 
Formulations CLX 138/B 
CLX 
141/B 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
(m
g/
g) 
Celecoxib 28.00 54.55 
Solutol® HS-15 252.01 218.18 
Gelatine 615.26 619.83 
SDS 36.30 38.02 
D-Sorbitol 68.43 69.42 
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Figure 4.12 Photographs of thin films of two formulations taken using an Nikon Eclipse Ti Inverted 
Microscope; A) 40X image of formulation CLX 138/B and B) 10X image of formulation CLX 141/B. All 
formulations included a combination of Dextran Alexa Fluor 546 and Nile red dyes. 
 
Following a review of all the formulations produced, CLX 136/B was considered to be 
the optimal formulation for progression to coating development and ultimately an in-
vivo animal study. The ‘surfactant phase’ of formulation CLX 136/B constituted the 
liquid formulation CLX 016/L described in Chapter 3 (i.e., 10% CLX dissolved in 
Solutol® HS-15). Given that the other formulation described in Chapter 3, CLX 021/L 
(6.7% CLX dissolved in Solutol® HS-15: Miglyol® 810 (2:1)), had out performed CLX 
016/L in the in-vitro cell study and subsequent release experiment (refer to Chapter 3), a 
final round of drug release experiments was conducted to understand the basis for this 
greater performance and to provide extra assurance that CLX 136/B (i.e., a formulation 
without Miglyol® 810N) was the optimal formulation for progression. Two liquid 
formulations, CLX 151/L and CLX 158/L (Table 4.22) were produced. The intention of 
formulation CLX 151/L (6.7% CLX dissolved in Solutol® HS-15) was to allow a direct 
comparison with formulation CLX 021/L in the absence of Miglyol® 810N, whereas 
CLX 158/L (10% CLX dissolved in Solutol® HS-15 and Miglyol® 810N (2:1) was 
A B 
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produced to allow for a direct comparison with CLX 016/L with the addition of 
Miglyol® 810N. 
 
Table 4.22 Composition of formulations; CLX 016/L, CLX 021/L, CLX 151/L and CLX 158/L  
 
Formulations CLX 021/L CLX 151/L CLX 016/L CLX 158/L 
C
o
m
po
n
en
t 
C
o
n
ce
n
tr
a
tio
n
 
 
(m
g/
g) 
Celecoxib 66.67 66.67 100.00 100.00 
Solutol® HS-15 600.00 933.33 900.00 600.00 
Miglyol® 810N 333.33 - - 300.00 
 
 
Release analysis in PW over a period of 12 h was performed on formulations CLX 
151/L and CLX 158/L and a comparison made to previous release experiments on 
formulations CLX 016/L and CLX 021/L (Figure 4.13). The results illustrated that 
although the inclusion of Miglyol® 810N in the formulation had some initial 
stabilisation effect, that the % of drug still in solution at 12 h was comparable for 
formulations CLX 016/L and CLX 158/L. The results also demonstrated that the 
primary difference in formulations CLX 016/L and CLX 021/L was the loading of CLX 
employed, as when the loading of CLX in Solutol® HS-15 was decreased to 6.7% w/w 
in formulation CLX 151/L, the % of drug release was comparable to CLX 021/L over a 
period of 12 h. These results provided an added assurance that formulation CLX 136/B 
(i.e., formulation excluding Miglyol® 810) was the correct formulation choice for the 
next phase of the project. 
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Figure 4.13 Percentage of CLX released from formulations CLX 021/L, CLX 016/L, CLX 151/L and 
CLX 158/L tested in PW. The data presented are mean values ± STDEV (n=3). 
 
 
4.4.5 CLX 136/B – optimal CLX microbead formulation 
 
Microbead formulation CLX 136/B represented the development of an optimal oral 
lipophilic drug delivery system for CLX. The inclusion of such a high level of 
surfactant (>50% w/w of the entire formulation) precludes the formulation from 
incorporation into conventional oral dosage forms such as soft gelatin capsules and also 
microencapsulation technologies such as shell/core microcaspules, due to interactions 
between the inner capsule contents and the capsule shell.  Lipophilic CLX formulations 
have previously been developed, such as the nanoemulsion formulation presented by 
Shakeel and Faisal (Shakeel and Faisal , 2010), however as nanoemulsions have a high 
water content they have been shown to be unsuitable for incorporation into soft gelatin, 
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hard gelatine or HPMC capsules for oral delivery. Also the high water content of these 
type of formulations promotes hydrolysis and/or precipitation of certain drugs on long-
term storage, which ultimately affects their utility in oral delivery (Date et al., 2010). 
Based on current marketed technologies, the only suitable mode of administration of 
such an emulsion would be as an oral solution, however oral solutions have an inherent 
disadvantage in that they are not amenable to further processing  to allow for targeted or 
sustained delivery (e.g., for colon delivery).  It is acknowledged that Self Emulsifying 
Drug Delivery Systems (SEDDS) and Self Micro-Emulsifying Drug Delivery Systems 
(SMEDDS) are suitable for incorporation into soft gelatine capsules and a number of 
CLX SEDDS/SMEDDS have been reported (Subramanian et al., 2004, and Song et al., 
2013). Although the delivery of CLX SEDDS/SMEDDS has many advantages 
including improved solubility and bioavailability, one of their primary disadvantages is 
that they are currently delivered as single dosage units (e.g., in soft gelatine capsules) 
and as eluded to in Section 4.2.4 there are a number of advantages of delivering drugs in 
a multiparticulate format and in the context of this project (delivery of CLX to the 
colon), a multiparticulate format is essential.  
Multiparticulate formulations containing CLX SMEDDS/SEDDS have been attempted, 
however entrapment efficiencies have ranged between 60-82% (Homar et al., 2009) in 
contrast to an entrapment efficiency of 97.02 % ± 0.99% in the case of CLX 136/B. It is 
also worth noting that the shape of CLX 136/B beads (robust spherical beads) compared 
favourably with dried CLX microcapsules reported by Homar and colleagues, in which 
the microcapsules produced were irregular in shape and in many cases were leaky 
resulting in a low % of entrapment efficiency. 
As shown in Figure 4.9, release analysis on 50 mg doses in PW resulted in a maximum 
release of 80% for formulation CLX 136/B over a period of 6 h. In addition to 
outperforming Celebrex®, this data also represents an increase in the release of CLX 
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from microcapsules compared to that reported in studies by Homar and colleagues 
(Homar et al., 2007 and 2009). In the latter study, CLX microcapsule formulations with 
a maximum release ranging from 9–16% were reported (the release experiments were 
performed on 3 mg doses). In the 2007 study, CLX microcapsule formulations with a 
maximum release in the range of 60–80 % were reported however the dissolution media 
employed contained a surfactant (2 % Tween 80) to facilitate the release of the drug and 
the release experiments were again performed on 3 mg doses. This data illustrates that 
the microbead approach presented here is advantageous to the microcapsule approach 
presented by Homar and colleagues. 
 
4.5 Conclusions 
 
Chapters 2 and 3 described the development of liquid CLX formulations which were 
tested in an in-vitro cell culture study and yielded positive results. In this phase of the 
project (Chapter 4), these liquid formulations were successfully translated into gelatine 
based microbeads via the use of a gravity ‘dripping’ technique. An optimal microbead 
formulation (CLX 136/B) with a commercially viable loading of 6% w/w CLX was 
produced. Formulation CLX 136/B produced spherical and robust microbeads with a 
high drug content of 97% and 80% drug release in PW, thereby meeting the formulation 
objectives set out at the start of the study. The viable drug loading of 6% w/w was 
ultimately achieved by eliminating the onset of precipitation in the formulations by 
including SDS as a precipitation inhibitor and also by reducing the gelatine 
concentration within the formulation. The inclusion of SDS was also shown to improve 
the in-vitro drug release performance of the formulation. CLX 136/B was demonstrated 
to have a greater drug release performance than the marketed CLX product Celebrex® 
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and is believed to represent a micellar solution based on the transparent appearance of 
the original liquid and image analysis of the resultant beads.   
The optimised beads produced in this phase of the study ultimately provided a platform 
for the treatment of CRC as it allowed the possibility of presenting CLX to the colon in 
a pre-solubilised multipariculate format, however the next challenge was to target these 
multiparticulates to the colon and to then to assess their potential for the treatment and 
prevention of CRC using an appropriate animal model. This challenge is described in 
Chapter 5. 
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4.6 Nomenclature 
 
Table 4.23 List of abbreviations which are listed according to their appearance in the text. 
 
Abbreviation Definition 
CLX  Celecoxib  
CRC Colorectal cancer 
HME Hot melt extrusion 
CQA Critical quality attribute 
PEG Polyethylene glycol 
API Active pharmaceutical ingredient 
HLB Hydrophilic lipophilic balance 
STDEV Standard deviation 
SDS Sodium dodecyl sulphate 
HPMC Hydroxypropyl cellulose 
HPC Hydroxypropyl cellulose 
COA Certificate of analysis  
HPLC High performance liquid chromatography  
UV Ultraviolet 
GI Gastrointestinal 
IIG Inactive ingredient 
PW Purified water  
TPGS Tocopherol polyethylene glycol succinate 
PVA Polyvinyl alcohol 
SEDDS Self-emulsifying drug delivery system 
SMEDDS Self-microemulsiying drug delivery system 
CLX xxx/L 
Celecoxib liquid formulation numbering system where xxx is a 
sequential number and L is liquid 
CLX xxx/B 
Celecoxib bead formulation numbering system where xxx is a 
sequential number and B is bead 
 
 
 
4.7 Acknowledgements 
I would like to express my gratitude to the analytical department at Sigmoid Pharma 
Ltd. for analytical support as part of this work. 
 
 175 
 
4.8 References 
 
Andrews, G.P., Jones, D.S., Diak, O.A., Margetson, D.N. & McAllister, M.S. 2009, 
"Hot-melt extrusion: an emerging drug delivery technology", Pharmaceutical 
Technology Europe, vol. 21, no. 1, pp. 18-23.  
Brandau, T. 2014, "Annular Jet-Based Processes" in Microencapsulation in the Food 
Industry: A Practical Implementation Guide, eds. A. Gaonkar, N. Vasisht, A. 
Khare & R. Sobel, Elsevier, San Diego, pp. 99-110.  
Brouwers, J., Brewster, M.E. & Augustijns, P. 2009, "Supersaturating drug delivery 
systems: the answer to solubility-limited oral bioavailability?", Journal of 
Pharmaceutical Sciences, vol. 98, no. 8, pp. 2549-2572.  
Cavallari, C., Rodriguez, L., Albertini, B., Passerini, N., Rosetti, F. & Fini, A. 2005, 
"Thermal and fractal analysis of diclofenac/Gelucire 50/13 microparticles obtained 
by ultrasound-assisted atomization", Journal of Pharmaceutical Sciences, vol. 94, 
no. 5, pp. 1124-1134.  
Chávarri, M., Marañón, I. & Villarán     , M.C. 2012, "Encapsulation Technology to 
Protect Probiotic Bacteria" in Probiotics, ed. E.C. Rigobelo, Intech, Winchester, 
pp. Ebook.  
Chawla, G., Gupta, P., Thilagavathi, R., Chakraborti, A.K. & Bansal, A.K. 2003, 
"Characterization of solid-state forms of celecoxib", European Journal of 
Pharmaceutical Sciencesvol. 20, no. 3, pp. 305-317.  
Colorcon Opadry® White 20A28380 product specification, 2010. 
Colorcon Opadry® II product specification, 2010. 
Date, A.A., Desai, N., Dixit, R. & Nagarsenker, M. 2010, "Self-nanoemulsifying drug 
delivery systems: formulation insights, applications and advances", Nanomedicine 
(London, England), vol. 5, no. 10, pp. 1595-1616.  
 176 
 
Gharsallaoui, A., Roudaut, G., Chambin, O., Voilley, A. & Saurel, R. 2007, 
"Applications of spray-drying in microencapsulation of food ingredients: An 
overview", Food Research International, vol. 40, no. 9, pp. 1107-1121.  
Ghosh, S.K. 2006, "Functional Coatings and Microencapsulation: A General 
Perspective" in Functional Coatings, ed. S.K. Ghosh, Wiley, New Jersey, pp. 1-28.  
Guzman, H.R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C.R., 
Chen, H., Moreau, J.P., Almarsson, O. & Remenar, J.F. 2007, "Combined use of 
crystalline salt forms and precipitation inhibitors to improve oral absorption of 
celecoxib from solid oral formulations", Journal of Pharmaceutical Sciences, vol. 
96, no. 10, pp. 2686-2702.  
Homar, M., Dreu, R., Kerc, J. & Gasperlin, M. 2009, "Preparation and evaluation of 
celecoxib-loaded microcapsules with self-microemulsifying core", Journal of 
Microencapsulation, vol. 26, no. 6, pp. 479-484.  
Homar, M., Ubrich, N., El Ghazouani, F., Kristl, J., Kerc, J. & Maincent, P. 2007, 
"Influence of polymers on the bioavailability of microencapsulated celecoxib", 
Journal of Microencapsulation, vol. 24, no. 7, pp. 621-633.  
Kalepu, S., Manthina, M. & Padavala, V. 2013, "Oral lipid-based drug delivery systems 
– an overview", Acta Pharmaceutica Sinica B, vol. 3, no. 6, pp. 361-372.  
Mackaplow, M.B., Zarraga, I.E. & Morris, J.F. 2006, "Rotary spray congealing of a 
suspension: effect of disk speed and dispersed particle properties", Journal of 
Microencapsulation, vol. 23, no. 7, pp. 793-809.  
Maniruzzaman, M., Boateng, J.S., Snowden, M.J. & Douroumis, D. 2012, "A review of 
hot-melt extrusion: process technology to pharmaceutical products", ISRN 
Pharmaceutics, vol. 2012, pp. 436763.  
Martinsa, R.M., Siqueiraa, S. & Freitasa, L.A.P. 2012, "Spray Congealing of 
Pharmaceuticals: Study on Production of Solid Dispersions Using Box-Behnken 
Design", Drying Technology: An International Journal, vol. 30, no. 9, pp. 935-945.  
 177 
 
Mueller, E.A., Kovarik, J.M., van Bree, J.B., Tetzloff, W., Grevel, J. & Kutz, K. 1994, 
"Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion 
formulation", Pharmaceutical Research, vol. 11, no. 2, pp. 301-304.  
Passerini, N., Albertini, B., Perissutti, B. & Rodriguez, L. 2006, "Evaluation of melt 
granulation and ultrasonic spray congealing as techniques to enhance the 
dissolution of praziquantel", International Journal of Pharmaceutics, vol. 318, no. 
1-2, pp. 92-102.  
Passerini, N., Perissutti, B., Moneghini, M., Voinovich, D., Albertini, B., Cavallari, C. 
& Rodriguez, L. 2002, "Characterization of carbamazepine-Gelucire 50/13 
microparticles prepared by a spray-congealing process using ultrasounds", Journal 
of Pharmaceutical Sciences, vol. 91, no. 3, pp. 699-707.  
Porter, S.C. 2013, "Coating of Tablets and Multiparticulates" in Aulton's 
Pharmaceutics, 4th Edition The Design and Manufacture of Medicines, ed. K. 
Taylor, Amsterdam, Elsevier, pp. 567-582.  
Rowe, R.C., Sheskey, P.J. & Owen, S.C. 2006, Handbook of Pharmaceutical 
Excipients, 5th Edition edn, Pharmaceutical Press, London.  
Saha, R.N., Sajeev, C., Jadhav, P.R., Patil, S.P. & Srinivasan, N. 2002, "Determination 
of celecoxib in pharmaceutical formulations using UV spectrophotometry and 
liquid chromatography", Journal ofPharmaceutical and Biomedical Analysis, vol. 
28, no. 3-4, pp. 741-751.  
Shakeel, F. & Faisal, M.S. 2010, "Nanoemulsion: A promising tool for solubility and 
dissolution enhancement of celecoxib", Pharmaceutical Development and 
Technology, vol. 15, no. 1, pp. 53-56.  
Singh, M.N., Hemant, K.S., Ram, M. & Shivakumar, H.G. 2010, "Microencapsulation: 
A promising technique for controlled drug delivery", Research in Pharmaceutical 
Sciences, vol. 5, no. 2, pp. 65-77.  
Song, W.H., Park, J.H., Yeom, D.W., Ahn, B.K., Lee, K.M., Lee, S.G., Woo, H.S. & 
Choi, Y.W. 2013, "Enhanced dissolution of celecoxib by supersaturating self-
 178 
 
emulsifying drug delivery system (S-SEDDS) formulation", Archives of Pharmacal 
Research, vol. 36, no. 1, pp. 69-78.  
Subramanian, N., Ray, S., Ghosal, S.K., Bhadra, R. & Moulik, S.P. 2004, "Formulation 
design of self-microemulsifying drug delivery systems for improved oral 
bioavailability of celecoxib", Biological & Pharmaceutical Bulletin, vol. 27, no. 
12, pp. 1993-1999.  
Umer, H., Nigam, H., Tamboli, A.M. & Nainar, M.S.M. 2011, "Microencapsulation: 
Process, Techniques and Applications", IJRPBS, vol. 2, no. 2, pp. 474-481.  
Whelehan, M. 2010, Liquid-core microcapsules: A mechanism for the recovery and 
purification of selected molecules in different environments. PhD Thesis, Dublin 
City University, Dublin, Ireland. 
FDA - Inactive Ingredients Database, 2014. Available: 
http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm [2014, Oct/13].  
Nisco- Gravity Dripping, 2014. Available: 
http://www.nisco.ch/working_principle_dripping_by_gravity.htm [2014, Oct/13].  
Particle Sciences Technical Brief – Encapsulation, 2010. Available: 
http://www.particlesciences.com/docs/technical_briefs/TB_2010_7.pdf           
[2014, Oct/13].  
 
 
 
 
 
 
 
 
 
 
 
 179 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5                                  
Colon targeting of microbeads for an 
in-vivo animal study 
 
 
Publication Status: Elements of the work presented in this chapter in 
addition to data from chapters 5 and 6 has been accepted for publication 
(02-11-14) in the Journal of Pharmacy and Pharmacology under the 
following title ‘In-vitro characterization of a novel celecoxib microbead 
formulation for the treatment and prevention of colorectal cancer’.  
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5.1 Abstract 
 
The purpose of this phase of the project was to develop a colon targeted celecoxib 
(CLX) microbead formulation, on the basis of formulation CLX 136/B (described in 
Chapter 4) for use in an AOM (azoxymethane)/DSS (dextran sodium sulphate) 
colorectal cancer (CRC) mouse model. One of the primary objectives of the project was 
to apply a sustained release coating polymer to the beads to allow for colon specific 
delivery to a mouse according to a defined target product profile (TPP). A diffusion 
based polymer coat (Surelease®) was applied to the microbeads at a weight gain (w/g) 
of 8% and despite not meeting the TPP, this partially colon targeted microbead 
formulation was selected for progression to the AOM/DSS CRC mouse model. In the 
murine model, the effect of the microbead formulation on the attenuation of CRC 
tumours was compared to that of Celebrex® and was found to be marginally better. The 
anti-inflammatory effects for both formulations were also assessed, with the microbead 
formulation being found to have a significant effect compared to the control in the case 
of colon length and histology scoring whereas, the effect of Celebrex® did not meet 
significance. 
 
5.2 Introduction 
5.2.1 Background 
 
At the conclusion of Chapter 4, CLX 136/B, a lipid based CLX microbead formulation 
was identified as having met all the desired critical quality attributes (CQAs) for an 
intermediate CLX product designed for the treatment and prevention of CRC. Details of 
all the CQAs for the intermediate product are detailed in Chapter 4, however one of the 
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key requirements was that the formulation would provide a suitable substrate for the 
application of controlled release polymers in order to allow for colon targeting. The next 
phase of the project focused on developing the intermediate product described in 
Chapter 4 to yield a colon specific finished product via the application of controlled 
release polymers to CLX 136/B microbeads. This phase of the project also involved the 
subsequent testing of the coated microbeads in an in-vivo CRC animal study to assess 
and compare their anti-cancer effects to that of the marketed CLX product Celebrex®.  
CRC development is a long term process beginning in normal epithelial cells via 
aberrant crypts and progressive adenoma stages to carcinomas in situ and then 
metastasis (De Robertis et al., 2011) (see Chapter 1 for further details). The goal of 
modelling human CRC in animals is to recapitulate the molecular etiology, pathology, 
and clinical progression of the disease and to provide a tool for advancing our 
understanding of the tumour response to novel chemopreventative and therapeutic 
strategies (Johnson and Fleet, 2013 and De Robertis et al., 2011). A variety of models 
of CRC have been developed that mimic human CRC, a summary of which is provided 
in Section 5.2.2. Colon delivery has for a long period of time been exploited for the 
topical treatment of intestinal pathological conditions such as irritable bowel disease 
(IBD) (Maroni et al., 2012). For example in the case of Crohn´s disease (CD) and 
ulcerative colitis (UC), dosage forms of mesalazine (a 5-aminosalicylic acid (5-
ASA) anti-inflammatory drug used to treat these conditions) have been designed to 
achieve high concentrations of the drug at the local inflamed areas (lower small 
intestine (SI) and colon) while minimizing release in the stomach and upper SI so as to 
avoid premature absorption and consequent drug wastage and systemic side effects 
(Klein et al., 2002). Given the requirement to target CLX to the colon in the treatment 
of CRC, a review of formulation options for colon targeting is included in Section 5.2.3. 
Finally the objectives for this phase of the project are detailed in Section 5.2.4.   
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5.2.2 Animal models for CRC 
 
The available animal models for CRC constitute three broad categories; a) spontaneous 
cancers in various animal species (e.g., dogs, sheep and rodents), b) chemically induced 
cancers in rodents and c) cancers resulting from genetically modified mice (Johnson and 
Fleet, 2013 and De Robertis et al., 2011). It is noted that there also exist other animal 
models which involve a cross over between these broad categories (e.g., chemical 
induction on genetically modified mice). 
Animal models involving spontaneous cancers are not widely used for a variety of 
reasons including, low prevalence of CRC in animals, long latency of carcinogenesis, 
cost and non-correlation with human CRC (e.g., tumours often occur in the SI of the 
animals described rather than the colon). This review of animal models for CRC is 
therefore restricted to chemically and genetically induced tumour models.  
5.2.2.1 Chemically induced tumour rodent models 
 
Given that spontaneous incidence of CRC in rodents is low (1–4%) (Karim and Huso, 
2013), many chemicals have been used to induce CRC. These carcinogens include (a) 
heterocyclic amines (HCAs) (b) aromatic amines (AAs), (c) alkylnitrosamide 
compounds and (d) dimethylhydrazine (DMH) and AOM (De Robertis et al., 2011). 
These four categories of carcinogens are described below in addition to a fifth category 
describing enhanced AOM models. 
A. Heterocyclic amines (HCAs) 
 
HCAs include 2-amino-1-methyl-6-phenylimidazol (4,5-b) pyridine (PhIP) and 2-
amino-33-methylimidazo[4,5-f] quinolone (IQ) which were identified in broiled and 
grilled meat and fish and have since been introduced into experimental CRC as they 
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have been demonstrated to be highly mutagenic and tumorigenic in rodent models, with 
respect to colon cancer induction. It has been also shown that the incidence of tumours 
in rodents arising from treatment with HCAs increases when co-administered with a 
high fat diet which is important given the links between CRC and dietary factors (De 
Robertis et al., 2011 and Rosenberg et al., 2009). Although much attention has been 
focused on the use of HCAs such as PhIP and IQ for chemically inducing CRC tumours 
in rodents, primarily due to the fact that epidemiologic evidence links PhIP from cooked 
meat to increased CRC risk (Johnson and Fleet, 2013), there are a number of 
disadvantages associated with the model. These disadvantages include; a) the 
carcinogens demonstrate multi-target-organ specificity resulting in prostate and 
mammary tumours in addition to colon tumours, b) tumour incidence is generally low 
(5–28% for 52 week studies), c) very lengthy studies (>100 weeks) are required for 
higher rates (43–55%) of tumour incidence, d) lengthy studies (>100 weeks) are 
associated with severe toxicity and e) the studies are not cost effective due to the length 
of the studies required (De Robertis et al., 2011 and Rosenberg et al., 2009). 
 
B. Aromatic amines (AAs) 
 
AAs such as 3,2'-dimethyl-4-aminobiphenyl (DMBA) have been shown to chemically 
induce both benign (adenomas) and malignant (adenocarcinomas) tumours in rodents. 
Similar to HCAs, the co-administration of AAs with a high fat diet results in a greater 
incidence of CRC in rodents (Rosenberg et al., 2009). There are a number of 
disadvantages of DMBA induced CRC rodent models inducing the following; a) a large 
number of injections (up to 20) are required to induce colonic tumours, b) similar to 
HCAs, DMBA demonstrates multi-target-organ specificity resulting in neoplasms in 
other tissues including mammary glands, the stomach and the bladder and c) the studies 
 184 
 
are not cost effective due to the number of injections required (Karim and Huso, 2013, 
De Robertis et al., 2011 and Rosenberg et al., 2009). 
C. Alkylnitrosamide compounds 
 
One of the features of both HCAs (e.g., PhIP) and AAs (DMBA) which was not 
described above is a requirement for these compounds to undergo metabolic activation 
prior to exerting their carcinogenic effect in-vivo. Methylnitrosourea (MNU) and N-
methyl-N-nitro-N-nitrosoguanidine (MNNG) are examples of directly acting alkylating 
agents that do not require metabolic activation and therefore are considered to be potent 
topical carcinogens (Rosenberg et al., 2009). The direct acting nature of these agents is 
considered to be the primary advantage with respect to use in CRC models as they 
enable the modifying effects of xenobiotics (e.g., chemotherapy drugs) to be studied 
without consideration of the metabolism of the initiating carcinogen (i.e., it removes an 
unwanted variable). The direct acting feature of these agents is however also a 
disadvantage as it is necessary to administer the carcinogen via an intrarectal injection 
which whilst ensuring local action, is a technically difficult procedure (Karim and Huso, 
2013 and Rosenberg et al., 2009). 
 
 
D. DMH and AOM 
 
DHM (1,2-dimethylhydrazine) or its metabolite azoxymethane (AOM) have been 
widely used to induce CRC in rodents. DMH is a precursor of methylazoxymethanol 
(MAM), a carcinogen found in cycad flour.  Both DMH and AOM require several 
metabolic activation steps, some of which are postulated to be favourable with respect 
to specifically targeting the colon (Rosenberg et al., 2009). The majority of recent 
studies have focused on the use of AOM rather than DMH due to a number of practical 
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advantages associated with AOM including the following; high potency, simple mode 
of application, excellent stability in solution and lower cost. The primary advantage of 
DMH or AOM CRC rodent models is that the chemically induced tumours share many 
of the histopathological features of human CRC and therefore are considered to be good 
models. Some disadvantages of the model include infrequent APC (adenomatous 
polyposis coli) or p53 gene mutations which are common in human CRC. The primary 
disadvantage of both DMH and AOM models is however the latency periods required 
prior to tumour formation which can range from 21 to 40 weeks and also as many as 10 
injections are required (De Robertis et al., 2011).  
E. Enhanced AOM models 
 
Based on the information described in Sections 5.2.2.1 A-D above, rodent models 
involving AOM are deemed among the most favourable models for a variety of reasons 
including the route of administration, relevance of tumours with respect to human CRC                                                                                            
tumours and the colon specific nature of the carcinogen. In an effort to circumvent the 
disadvantages of AOM-only models described in Section 5.2.2.1 D (namely long 
latency periods and multiple injections), a lot of attention has been focused on 
enhancing these AOM models by combining AOM with the inflammatory agent DSS, 
which has resulted in a dramatic shortening of the latency time and reduction in the 
number of intraperitoneal (i.p.) injections. In two studies, involving a single injection of 
AOM (7.4–10 mg/kg body weight) in combination with a) 3 cycles (7 day cycle) of 
administering 3% DSS in the drinking water and b) one cycle (7 day cycle) of 
administering 2% DSS in the drinking water, latency periods were demonstrated to be 
reduced to 12 weeks (De Robertis et al., 2011). AOM/DSS has also been shown to be a 
useful tool in the evaluation of CRC chemopreventative strategies (Karim and Huso, 
 186 
 
2013), including its use for assessing the chemopreventative effects of CLX (Lee et al., 
2005), which was of particular relevance in the context of this study.  
 
5.2.2.2 Genetic tumour models 
 
As discussed in Chapter 1, familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC) are two genetic conditions which are risk factors 
for the development of CRC. Strains of mice have been genetically modified in order to 
mimic cancers caused by FAP and HNPCC. These genetic models are discussed below.  
A. Genetic mouse model for FAP 
 
Patients with FAP carry a germline mutation in the APC gene.  They develop hundreds 
to thousands polyps within the large intestine and they are at high risk for developing 
CRC. A mouse model, referred to as APCMin mouse, which possess a similar mutation to 
that observed in FAP patients, has been extensively used to study the development, 
treatment and prevention of CRCs that contain somatic APC mutations (Johnson and 
Fleet, 2013). The primary disadvantage of the APCMin mouse model is with respect to 
tumour location, as APC mutant mice usually develop more adenomas in their small 
intestine than their large intestine and also only on rare occasions do the adenomas 
progress to invasive adenocarcinomas which is in stark contrast to FAP patients (i.e., 
large number of adenomas in the large intestine which progress to invasive ade-
nocarcinomas) (Karim and Huso, 2013). 
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B. Genetic mouse model for HNPCC 
 
In the case of HNPCC, patients possess mutations in one of the DNA mismatch repair 
(MMR) genes; MSH2, MLHJ, PMSJ, and PMS2. The development of mouse models for 
HNPCC has proved challenging as the heterozygous deletion of the MMR genes 
involved is not sufficient to predispose to cancer and as a result mice with homozygous 
deletions have been used as disease models for HNPCC-like cancers. Although these 
models do result in intestinal tumour formation, they also have a tendency to result in 
lymphoma development in which is not reflective of HNPCC (De Robertis et al., 2011). 
A novel mouse model has been developed in which MSH2 is knocked down in villin-
expressing tissues (i.e., the small and large intestine) but normal MMR activity is 
preserved in the rest of the mouse (Karim and Huso, 2013). Although this model is 
advantageous over the homozygous deletion models described in that the mice do not 
develop lymphomas, the disadvantage of the model is that tumour formation occurs 
predominantly in the small intestine (Johnson and Fleet, 2013).   
5.2.2.3 CRC model selection  
 
On the basis of the information described in Sections 5.2.2.1 and 5.2.2.2, the AOM/DSS 
mouse model was selected as the appropriate model for this study primarily on the basis 
that it was the model that most accurately recapitulated the histopathology and 
pathogenesis observed in sporadic human CRC but also because it represented an 
inflammation-driven CRC model which is important in the context of the links between 
inflammation (including colitis) and CRC as outlined in Chapter 1. Experimental details 
for the model are detailed in Section 5.3.2.5, however a detailed overview of the model 
focusing on its applicability with respect to CRC and intervention studies for COX-2 
inhibitors is provided below. 
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5.2.2.3.1 AOM/DSS mouse model  
 
As referred to earlier, a key advantage of the AOM/DSS mouse model is that the 
development of cancer in the model is highly reflective of that seen in humans. Aside 
from exhibiting histopathological features similar to human CRC, the tumours produced 
in the model also accurately reflect the pathogenesis observed in human CRC (e.g., 
tumours are very frequent in the distal part of the colon, which is also the predominant 
location of spontaneous CRC in humans). In addition, the AOM/DSS mouse model has 
been shown to be particularly applicable to tumour progression driven by colitis 
(Oshima and Oshima, 2012).  
By using a combination of AOM (tumour-inducing agent) and DSS (tumour-promoting 
agent), the AOM/DSS model reproduces colorectal carcinogenesis promoted by an 
initial acute inflammation phase (the DSS dissolved in drinking water is toxic to the 
epithelial lining of the colon and produces severe colitis), and has a much shorter 
latency period than models based on only AOM or DSS administration. AOM only 
models have already been described, however there also exists DSS-only models 
(widely used as IBD models). These DSS models typically require many cycles of DSS 
administration and also result in a low incidence of tumours (De Robertis et al., 2011 
and Becker et al., 2005). CRC development following DSS-induced inflammation 
supports the hypothesis that chronic inflammation in IBD plays a crucial role in 
malignant epithelial neoplasia in the colon (Rosenberg et al., 2009). 
In Chapter 1, the possible tumourigenic effect of cyclooxygenase-2 (COX-2) on the 
development of CRC tumours (in both sporadic CRC and CACRC (colitis associated 
CRC)) was discussed. In addition to displaying similar histopathological features and 
pathogenesis as human CRC, the tumours induced in the AOM/DSS model also display 
very similar characetristics to human CRC at a molecular level. Included among these 
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molecular similarities is an observation of increased levels of COX-2 enzymes in 
AOM/DSS induced tumours (De Robertis et al., 2011), which further vindicates its 
selection in the context of this project. It is noted however (as per Chapter 1) that other 
studies involving AOM/DSS treatment on COX-22/2- knockout mice (i.e., mice in which 
COX-2 is not expressed) have also resulted in tumour formation (Ishikawa and 
Herschman, 2010). 
Regardless of the role that COX-2 plays in CRC, as described in Chapter 1 there is a 
large body of evidence illustrating the anti-cancer effects of CLX including a number of 
chemopreventative studies for CLX using the AOM/DSS CRC model (Lee et al., 2005, 
Coudry et al., 2004 and Li et al., 2009).  
In summary, the AOM/DSS mouse model was selected as the model of choice for the 
CLX intervention studies on the basis that it is reflective of human CRC and also 
because it is considered to be a highly reproducible, potent and affordable model for 
studying colon carcinogenesis.  
 
5.2.3 Colon targeting  
 
With respect to colon delivery, several different formulations have been attempted, 
which largely rely on selected physiological parameters exhibiting typical variation 
patterns along the gastrointestinal (GI) tract to enable colon targeting. These 
physiological parameters include; composition of GI microflora, pH of intestinal fluids 
and transit/residence times within particular segments of the gut.  Although the primary 
purpose of this phase of the project was to develop a product to target the colon in the 
selected animal model (i.e., colonic targeting in a mouse), given that ultimate aim is to 
develop a product for human therapy, a comparison of the physiology of mouse vs 
human GI physiology is detailed below. A review of the various technologies available 
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for the colon targeting of multiparticulates and the decision making process regarding 
the selection of the most suitable technology is also included. Finally the TPP for the 
product to enable colonic targeting in the mouse model is described in the context of the 
current stage of this project. 
 
5.2.3.1 Comparison of human and mouse GI physiology 
 
Although intense research efforts have been focused on understanding human GI 
physiology, there is a lack of agreement with respect to some of the key parameters such 
as transit times, pH and microflora content as highlighted in a review by Mc Connell 
and colleagues (McConnell et al., 2008 A). This discord is largely as a result of 
variations due to food effects, diseased states and inter/intra subject variability 
(including gender). In the absence of a consensus in relation to these parameters, the 
information presented here in this review of human GI physiology represents median 
figures quoted by Mc Connell and others. In contrast to human physiology, based on a 
review of the literature, there is very limited research and data in relation to murine GI 
physiology. The information presented here summarises a review of the literature that is 
available in relation to mouse GI physiology. 
 
A. Transit times in human and murine GI tracts 
 
Gastric emptying in humans (i.e., emptying of stomach contents into the small intestine) 
of dosage forms is a highly variable process which primarily depends on whether the 
subject is fed or fasted and on the properties of the dosage unit (e.g., size and density). 
Whilst there are a large number of studies which reference different times for gastric 
emptying, a median figure of 2 h (<1 h (fasted) and >3 h (fed)) is most often quoted for 
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multiparticulate formulations (Patel et al., 2011, Garbacz and Klein 2012 and Asghar 
and Chandran, 2006). In contrast to gastric residence time, transit time in the small 
intestine has been shown to be more consistent and less dependent on food intake. The 
transit time of dosage forms is predominantly quoted at 3–4 h regardless of the dosage 
form (pellets or tablets) (Garbacz and Klein 2012, McConnell et al., 2008 A, Patel et 
al., 2011, Varum et al., 2010 and Asghar and Chandran, 2006). Prior to entering the 
colon, both single-unit and multiple unit dosage forms accumulate and stagnate at the 
ileocaecal junction for a variable period of time which is affected by food intake. In 
contrast to small intestine transit times, transit times in the colon do vary with respect to 
the dosage form with longer transit times being quoted for multiparticulates (Varum et 
al., 2010). Although there is evidence of colon transit times ranging from 6 h to greater 
than 70 h (Varum et al., 2010), the transit time is often quoted to be in the region 20-30 
h (Patel et al., 2011, Oh and Lee, 2014). Disease can also impact on GI transit times, for 
example, patients with UC have been shown to have significantly faster colon transit 
times compared to controls (McConnell et al., 2008 A). 
In the case of mice, the reporting of transit times is very limited and in addition 
published GI transit times vary considerably. In the work presented by both 
Padmanabhan (Padmanabhan et al., 2013) and Ashok (Ashok et al., 2012), the total GI 
transit time is estimated at 6 h, whereas in the case of work presented by Bellier (Bellier 
et al., 2005) the total transit time is estimated at 10–12 h. Padmanabhan and colleagues 
also reported residence transit times of 1 h for the stomach and 3 h for the SI.  
 
B. pH of human and murine GI tracts 
 
Similar to transit times, the pH in the different regions of the human GI tract is subject 
to variation and is heavily reliant on inter/intra subject variability but also on food 
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effects. In addition it has been reported that pH changes in disease (McConnell et al., 
2008 A). In the case of healthy subjects, the predominant reported pH range for the 
various regions of the human GI tract (fed and fasted) is as follows; stomach (pH: 1–5) 
duodenum/jejunum (5.5–7) and the ileum/colon (pH 7–8) (Patel et al., 2011 and 
McConnell et al., 2008 A). In the case of mice, pH values across the murine GI was 
measured as part of a comprehensive study by McConnell and colleagues (McConnell 
et al., 2008 B). The results of study reported pH ranges for the various regions of the 
murine GI tract (fed and fasted) as follows; stomach (pH: 3.0–4.0) duodenum/jejunum 
(pH 4.7–5.0) and the ileum/colon (pH 4.4–5.2). A comparison of the pH profiles of 
humans and mice illustrate that the mouse has a much lower intestinal pH which has 
implications with respect to in-vivo testing (discussed later). 
 
C. Microflora of human and murine GI tracts 
 
Bacteria are ubiquitous along the human GI tract, although some regions (e.g., the 
colon) are more heavily colonised than others. The high bacterial content of the colon (1 
x 1012 CFU/g contents) distinguishes it from other regions of the GI tract (e.g., stomach 
and SI bacterial content ranges from 1x103 to 1 x104 CFU/g contents) (McConnell et 
al., 2008 A). The difference between bacterial concentrations in the upper and lower gut 
can be exploited with respect to colon specific drug delivery (discussed in Section 
5.2.3.2 C). As in the case of both pH and transit times, intra and inter individual 
variability does occur with respect to microflora populations and levels. These 
fluctuations can also be caused as a result of disease, either by the disease itself (e.g., in 
UC and CD) or due to drug therapy (e.g., antibiotics in the case of infections) 
(McConnell et al., 2008 A). 
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Although the GI physiology of mice and humans are quite different, as are their dietary 
habits, a common feature of both species is that anaerobic bacteria (e.g., bacteroides, 
and eubacterium) are the predominant populations in the colonic flora. It has also been 
shown that lactic acid bacteria (e.g., bifidobacteria and lactobacilli), enterobacteria (e.g., 
E. coli) and enterococci are common to the colon of both species (Haeberlin and Friend, 
1992). It is notable that the levels of bacteria in mice (including most of the species 
listed above) are however much higher in the SI and stomach compared to humans. This 
is due to the fact that mice are coprophagic (i.e., eat their own faeces) and therefore they 
ingest large numbers of bacteria (Haeberlin and Friend, 1992). 
5.2.3.2 Technologies for colonic targeting of multiparticulates 
 
As described earlier, the common approaches available for colon-specific delivery of 
multiparticulates include; a) design of time dependent delivery systems, b) coating with 
pH-dependent polymers and c) the use of polymers that are degraded exclusively by 
colonic bacteria (Krishnaiah et al., 2002). A review of these three approaches is detailed 
below. 
A. Time dependent delivery systems  
 
The time dependent approach to colon delivery relies on the relatively consistent transit 
time through the SI (3–4 h in humans - Section 5.2.3.1 A). By combining this consistent 
SI transit time with the use of multiparticulates, which allow for a shorter gastric 
residence time (<1 h – Section 5.2.3.1 A), it is possible to design a time based colon 
delivery system that preserves the release of the drug from the formulation through the 
stomach and SI until reaching the ileum/colon (i.e., a lag time of 4–6 h).  There are a 
number of mechanisms through which time delayed release can be achieved including 
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erodible systems, rupturable systems and diffusive systems. All of these systems can be 
used to achieved a delayed release (i.e., lag period), however diffusive systems may be 
considered advantageous over erodible and rupturable systems in that they also allow 
for sustained release of the drug over a prolonged period of time following the initial 
delay which results in a sigmoidal release pattern (Maroni et al., 2012). Diffusion 
controlled systems are based on the application of a diffusive coating to the dosage 
form. The lag time achieved is reliant on the thickness of the coat as it corresponds to 
the time required for media (e.g., GI fluid) to penetrate the coat to reach the core via 
channels created in the polymer coat. The sigmoidal profile is achieved on the basis of 
the coat becoming more permeable over time as more channels are created. The most 
common diffusion based polymer coats are Eudragit® RS and RL (pH independent 
polymethacrylates manufactured by Evonik) and Surelease® (ethylcellulose based 
coating manufactured by Colorcon). Surelease® is used as the time dependent control 
mechanism for Pentasa® (marketed Mesalamine product for the treatment of UC and 
CD) (Klein et al., 2002). 
B. pH dependent delivery systems 
 
As described in Section 5.2.3.1 B, the pH in the ileum and colon is higher than in any 
other region of the GI tract. Based on this physiology, dosage forms that disintegrate at 
high pH levels (e.g., pH 7) have the potential for colon specific delivery. The most 
commonly used pH dependent coating polymers for oral delivery are methacrylic acid 
copolymers, Eudragit L100 and Eudragit S100, which dissolve at pH 6 and 7 
respectively. It has been reported that the use of Eudragit S alone may not be suitable 
for colon delivery as studies in healthy subjects have shown a pH drop from 7 at the 
terminal ileum to pH 6 in the ascending colon and as a result such systems sometimes 
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fail to release the drug (e.g., if the dosage form is not exposed to pH 7 for a sufficient 
length of time). In order to overcome this problem, a combination of these two 
polymers at various ratios can be used to release drug within a pH range of 6–7 (Asghar 
and Chnadran, 2006). There are a number of products on the market for the treatment of 
IBD that rely on pH as their mechanism for release. These products include the 
following; Asacol® and Salofac® (coated Mesalamine tablets) which dissolve at pH 7 
(Eudragit-S) and pH 6 (Eudragit-L) respectively (Klein et al., 2002). 
 
C. Microflora dependent delivery systems 
 
Microflora dependent delivery systems exploit the ability of colonic bacteria to catalyse 
enzymatic reactions on substrates that undergo no major dissolution, degradation or 
absorption phenomena in the GI tract. Included in this approach are the use of prodrugs, 
such as that described by Ruiz and colleagues (Ruiz et al., 2011) in which prednisone 
(steroid used for the treatment of UC) is released from a prodrug as a result of colon 
specific azoreductase-activated mechanism. Given that the use of prodrugs was not 
considered for this project (due to the regulatory implications of developing new 
chemical entities), the assessment of the use of microflora dependent delivery systems 
solely focused on coating systems. These coating systems are based on the use of 
naturally occurring polymer materials (e.g., amylose, pectin, guar gum and chitosan) 
which are susceptible to selective degradation in the lower GI tract based on microflora 
catalysed enzymatic reactions (Maroni et al., 2012). The use of polysaccharides for 
coating purposes has been tried with limited success due to the poor film properties of 
the majority of non-starch polysaccharides but also due to their tendency to swell in the 
GI tract resulting in porosity and consequent early drug release (Asghar and Chnadran, 
2006). Some of these problems can however be overcome by the combination of the 
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polysaccharides with other polymers, such as a combination of amylose and 
ethylcellulose (Siew et al., 2000 and Freire et al., 2010). One of the disadvantages of 
microflora dependent coating polymers is the lack of commercially approved products 
which rely on this mechanism of release. Alizyme’s COLAL-PRED® technology which 
involves a prednisone multipartculate coated with Amylose/Surelease® for the treatment 
of UC represents the only such product that has progressed to Phase III clinical trials, 
however it did not meet one of its primary clinical endpoints (Alizyme Product 
Information, 2014). 
 
D. Selection of most suitable technology 
 
The decision making process for selecting the most suitable technology for the colonic 
delivery of the CLX multiparticulates was based on three key criteria; 
 
1. That the technology selected would be directly applicable for colon delivery in 
the mouse model but also for colon delivery in humans (on the basis that the 
ultimate aim of the research was to act as a stepping stone towards the 
development of a commercial product). 
 
2. That the technology had a proven track record of use in humans (i.e., that there 
are approved products using the technology on the market). 
 
3. That the technology could circumvent the potential for the diseased state of 
patients to affect GI physiology to such an extent as to compromise the release 
of the drug. 
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Table 5.1 Comparison of coating technologies with respect to technology requirements 
 
Coating Technology 
Technology Requirement 
Directly applicable to  
both mouse and 
humans 
Track record 
of use in 
humans 
Drug release not  
affected by disease 
state  
pH dependent delivery systems [1]  [4] 
Time dependent delivery systems [2]    [4] 
Microflora dependent delivery systems [3]   [4] 
 
[1] The technology was not considered to meet this requirement as the pH dependent polymers required 
for colonic delivery in humans (i.e., dissolve at pH >7) were unlikely to dissolve across the pH range in 
the mouse GI tract (i.e., a different pH dependent polymer that dissolved in the pH range of 4.5–5 would 
be required). 
[2] Although the transit times in mice and humans are different, the technology was considered to be 
directly applicable to both given that the same polymer could be used albeit probably at different weight 
gains (i.e., higher weight gains likely required to achieve required lag for humans). 
[3] Given that differences in stomach and upper SI microflora in mice compared to humans, this 
technology was not considered to be appropriate given the likelihood of early drug release in mice due to 
the action of microflora. 
[4] Disease in patients has the potential to affect pH, microflora content and transit time in the GI tract 
therefore none of the technologies were considered to meet this requirement.  
 
Following a review of Table 5.1, it was concluded that a time dependent delivery 
system was the most appropriate system for investigation. Although there is evidence to 
suggest that disease (e.g., UC) could result in faster transit times in patients, the impact 
was considered to be less than with pH or microflora dependent delivery systems due to 
the use of multiparticulates which by default allow for both longer colon residence 
times and a greater distribution across the colon, thereby negating some of the impacts 
of rapid transit times caused by disease.  
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5.2.3.3 TPP for mouse model 
 
Given that the primary aim for this stage of the project was to develop a product 
suitable for colon delivery to a mouse, a TPP was designed prior to the initiation of 
coating studies. The TPP for the product to allow for maximum colonic targeting in the 
mouse was as follows; <10% release at 2 h and >50% release at 6 h. The TPP was based 
on published GI transit times for mice described in Section 5.3.2.1 A. On this basis, a 
two point TPP was stipulated to a) ensure minimal drug release in the stomach and SI 
prior to reaching the colon (i.e., <10% release at 2 h) and b) to ensure sufficient drug 
was released prior to expulsion of the multiparticulate (i.e., >50% release at 6 h).  
 
5.2.4 Objectives 
 
As described in Section 5.2.1, the primary goal of this phase of the project was to 
develop a colon specific targeted CLX microbead formulation and to assess and 
compare the anti-cancer effect of the targeted microbead to that of the marketed CLX 
product Celebrex® in an in-vivo CRC animal study. The aims/objectives set out to meet 
this goal were as follows: 
 
A. The first objective was to apply a controlled release polymer to the 
microbeads with the intention of meeting the TPP described in Section 
5.2.3.3 and to select the preferred coated microbead formulation for 
progression to an animal study using the AOM/DSS CRC mouse model 
(refer to Section 5.2.2.3.1 for details). 
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B. The second objective of the study was to assess and compare the effects of 
the selected CLX microbead formulation to that of Celebrex® on the 
attenuation of CRC tumours in the AOM/DSS CRC mouse model. 
C. Given the association of CRC and in particular CACRC with inflammation, 
the third objective involved an assessment of the anti-inflammatory effects 
of both the CLX microbead formulation and Celebrex® in the mouse model 
as a means of further monitoring their effects with respect to CRC 
pathology. 
 
5.3 Materials and Methods 
5.3.1 Materials 
5.3.1.1 Formulation materials  
 
CLX microbeads (formulation CLX 136/B) were made using the following materials; 
Solutol HS-15® (BASF, Germany), Miglyol® 810N (Sasol, South Africa), porcine 
gelatin (Nitta Gelatin, Japan), sorbitol (Neosorb® - Roquette, France) and Sodium 
Dodecyl Sulphate (SDS) (Merck, Germany). Coating trials were performed with the 
following sustained release coating polymers; Surelease® (Colorcon®, USA), Eudragit® 
RS30D/RL30D (Evonilk®, Germany). A sample of CLX active pharmaceutical 
ingredient (API) was kindly provided by Erregierre (Italy). The purity of the API was 
99.6% based on the COA (cert of analysis) provided by the supplier. All chemicals used 
for the release experiments and HPLC (high performance liquid chromatography) 
testing were of laboratory grade. Celebrex® was manufactured by Pfizer (USA). 
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5.3.1.2 In-vivo model materials  
 
Azoxymethane (AOM), methylene blue (MB), formalin, ethanol, eosin, Phosphate-
buffered saline (PBS) and hematoxylin were obtained from Sigma-Aldrich (USA). 
Dextran sodium sulphate (DSS) was purchased from MP Biomedicals (UK). 
 
5.3.2 Methods 
5.3.2.1 In-vitro release testing 
 
Release testing of coated CLX microbeads was performed (n=3) at 37°C using a two-
step release method (2 h in 0.1 M HCl (750 ml) followed by 10 h in phosphate buffer, 
pH 6.8 (1000ml)). Release experiments were carried out using either a Varian/Vankel 
VK7010 dissolution apparatus (VanKel, USA) or a Distek Evolution 6300 (Distek, 
USA) equipped with standard glass vessels and USP type II paddles. Paddle rotating 
speed in all experiments was 75 rpm. Microbeads equating to 25 mg of CLX were 
weighed and added to the media. At specified times 1.8 mL samples were withdrawn, 
filtered through a 70 µm pore filter (QLA, USA) and analysed using the HPLC method. 
The % of drug released at particular time points was determined from peak areas which 
were calculated against a single point external reference standard. The % of drug release 
was adjusted to take into account the content assay of the formulation. Release analysis 
of Celebrex® (25 mg doses) was also performed using the method described above. 
5.3.2.2 HPLC analysis 
 
The HPLC method for the analysis of the release and assay samples was adapted from 
Saha and colleagues (Saha et al., 2002). The HPLC column used was a reverse phase 
4.6 x 250 mm Inertsil® C8 column (Inertsil, The Netherlands) with a particle size of 5 
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µm.. The mobile phase was acetonitrile:water (65:35). The isocratic method used a flow 
rate of 1.25 ml/min and ultraviolet (UV) detection at 230 nm. The injection volume was 
20 µl and the retention time was 8 min. The HPLC apparatus that was used for the 
analysis were Thermo Finnigan (Thermo Electron Corporation, USA) and Waters 
(Waters, USA) HPLC systems (and associated Chromquest and Empower software).  
5.3.2.3 Content assay  
 
The content of CLX in coated microbead formulations was determined. A quantity of 
beads (n=2) with a theoretical potency of 5 mg wassonicated for 2 h in a mixture of 
acetonitrile:water 65:35 to extract the drug from the microbeads. The resultant solution 
was passed through a 0.45 µm filter prior to absorbance analysis. Where required the 
samples were diluted prior to analysis. The concentration of CLX was determined by 
absorbance measurements at 230 nm via the HPLC method described above. CLX 
content (%) was determined from peak areas which were calculated against a single 
point external reference standard.  
 
5.3.2.4 Fluid bed coating of microbeads 
 
Coating solutions/suspensions of Surelease® and Eudragit® RS30D/RL30D were 
prepared as per the manufacturer’s instructions. The starting weight of microbeads 
(CLX 136/B) for coating was approximately 6 g. Given that the substrate microbeads 
were manually produced, there was limited availability of material for coating trials; 
therefore approximately 5 g of coloured placebo beads were added to 1 g of active 
microbeads to enable a batch size that was sufficient for coating.  An MFL01 fluid bed 
system (Vector Corporation, USA) equipped with a Wurster insert was used for coating. 
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Microbeads were coated at an inlet air temperature setting of 65°C and a product 
temperature of 40°C. The volume of fluidizing air was maintained at 179 LPM (litres 
per minute) to ensure optimum fluidizing of microcapsules. A nozzle air pressure of 1.7 
bar and a solution flow rate of 3-4 g/min was applied. At the end of the coating process, 
the coated microbeads were dried for 5 min in the fluid bed system at a product 
temperature of 40°C. The weight gain of the beads was calculated based on the starting 
(pre-coating) and end (post- coating) weights of the beads.  
 
5.3.2.5 AOM/DSS-induced CRC model 
 
Six week-old female C57BL/6 mice, purchased from Jackson Laboratories (Bar Harbor, 
USA), were housed in a specific pathogen-free (SPF) facility in individually ventilated 
and filtered cages (Tecniplast, Italy) under positive pressure. All animal experiments 
were performed in compliance with the Irish Department of Health and Children 
regulations and approved by the Trinity College Dublin’s BioResources ethical review 
board (Ref:B100/325 Feb 2012). CRC was induced by the co-administration of AOM 
and DSS using a hybrid of the methods described in Section 5.2.2 E. Briefly, colon 
tumours were induced by i.p. injection of 10 mg/kg AOM at day 0 and day 14. After 
both injections, mice underwent two cycles of 2 % DSS in drinking water for 5 days 
(week 1 and week 3). AOM and DSS were administered as per the protocol described 
by Neufert and colleagues (Neurfert et al., 2007). Mice were treated with vehicle (PBS) 
or drug three times per week for the following 12 weeks, and monitored daily for 
morbidity/mortality (Figure 5.1). Mice were randomly divided into experimental groups 
receiving the following treatments: Group 1) PBS (0.1 ml/mouse) (n=10), Group 2) 
Celebrex® (0.25 mg/mouse) (n=10), Group 3) Coated CLX microbeads (1 bead/mouse) 
(n=10). Group 4 (n=6), the negative control, did not receive AOM/DSS administrations, 
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but only PBS (0.1 ml/mouse). Celebrex® powder (0.25 mg/mouse) was suspended in 0.1 
ml PBS and administered orally using a stainless steel gavage needle. Coated CLX 
microbeads were administered orally by means of a modified gavage needle (Figure 
5.2). One microbead containing the same dose of CLX present in 0.25 mg of Celebrex® 
powder (i.e., 0.1 mg) was loaded in the PVC tube fixed on the needle and a 1 ml-syringe 
pre-loaded with 0.1 ml PBS and 0.9 ml air. PBS was used as a delivery medium for easy 
passage through the oesophagus.  
 
 
 
Figure 5.1 Experimental protocol for AOM/DSS CRC model. Colon tumours were induced by i.p. 
injection of 10 mg/kg AOM at day 0 and day 14. After both injections, mice underwent two cycles of 2 % 
DSS in drinking water for 5 days (week 1 and week 3). Mice were treated with vehicle (PBS) or drug 
three times per week for the following 12 weeks. At the termination of the study (week 15), mice were 
euthanized by cervical dislocation. 
 
 
Figure 5.2 Modified gavage needle for administering coated CLX beads to the mice in AOM/DSS 
CACRC model 
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5.3.2.6 Assessment of inflammation (body weight, colon length and histology 
scoring) 
 
Body weight was recorded weekly as index of pathology by using a digital scale (VWR, 
UK). Body weight change was expressed in percentage (%) and calculated for each 
mouse according to the formula: BWn/BWi*100 where BWi is the initial body weight 
(week 0) and BWn is the n-th body weight recorded every week for 15 weeks.  
At the termination of the study (week 15), mice were euthanized by cervical dislocation 
and colon length were measured as a macroscopic index of tissue inflammation (Diaz-
Granados et al., 2000). The entire colon (from ileocecal junction to the anus) was 
excised and the length was measured and expressed in mm.  
Histology scoring was also performed as an assessment of inflammation. 
Approximately 1 cm segments of excised distal colonic tissue were fixed in 10% 
buffered formalin (pH, 7.4; PBS buffered) and embedded in paraffin. Sections (5 μm) 
were cut and stained with heamatoxylin and eosin (H&E) and graded blind using a 
cumulative score ranging from 0 to 3–4 (Aveillo et al., 2014). An arbitrary maximum 
combined score of 10 was determined on the basis of the following parameters: severity 
of inflammatory cell infiltration, extent of injury, and crypt damage. Photomicrographs 
were taken using a Leica® microscope (Leica® DM 3000 LED) equipped with Leica® 
DFC495 camera (Leica® Microsystem, Germany). Images were visualized by LAS v4.0 
and ultra-scanned with ScanScope® (Aperio® ePathology Solutions, Oxford, UK).  
 
5.3.2.7 Tumour assessment (tumour number, tumour size and tumour location) 
 
The formation of tumours in the colon was evaluated as described by Aviello and 
colleagues (Aviello et al., 2012). Colons were excised, fixed flat in 10% buffered 
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formalin for 24 h and then stained with 0.2% MB. The total number of tumours per 
mouse was scored stereo-microscopically (5X magnification) using a Leica® 
microscope equipped with Leica® DFC495 camera. Focal lesions of the colonic mucosa 
were easily detectable prior to MB staining of fixed whole-mount preparations of colon 
as they presented enlarged dysmorphic crypts, compression of surrounding epithelium, 
darkly coloured staining and raised circle-like masses. The size of each tumour mass 
identified was measured by a micrometer system included in the Leica Application 
Suite (LAS) version 4.0 (Laboratory Instruments & Supplies Ltd., Ashbourne, Ireland) 
software used for the visualization of tumours. Tumour size was used as an indicator of 
disease progression, in that smaller tumours would be indicative of a positive effect of 
the treatment on tumour progression. In order to study the anatomic tumour distribution, 
after being fixed flat, colons where cut in three segments (approximately 3 cm long), 
namely proximal, central and distal (referred to the distance from the ileo-cecal valve 
junction). The location of each tumour identified was recorded.  
 
5.3.2.8 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism (La Jolla, USA). Results are 
presented as mean ± SEM (standard error of the mean) (6–10). Differences, indicated as 
two-tailed P values, were considered significant when P < 0.05 as assessed by unpaired 
Student’s t test.  
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5.4 Results and Discussion 
5.4.1 Coated CLX microbead formulations 
As described in the introduction, microbead formulation CLX 136/B was chosen for 
progression for coating trials and ultimately for the AOM/DSS CRC murine study. A 
fluid bed wurster coating process was used to apply sustained release polymers with the 
intention of targeting the beads to the colon of the mouse. A number of attempts were 
made to apply Eudragit RS30D/RL30D sustained release coating polymers to the beads 
however these attempts proved unsuccessful due to blocking of the spray gun by the 
coating suspensions. An ethyl cellulose dispersion (Surelease®) was attempted and was 
successfully applied to the beads without any gun blocking issues. The TPP for the 
product to allow for maximum colonic targeting in the mouse was as follows; <10% 
release at 2 h and >50% release at 6 h. Formulation CLX 136/B was initially coated to 
yield two formulations (Table 5.2); formulation C-01 (CLX 136/B C-01 - 5% w/g of 
Surelease®) and C-02 (CLX 136/B C-02 - 8% w/g of Surelease®). Despite the use of a 
pH independent polymer (Surelease®), a two-step pH change release method was 
employed to mimic the transition from the stomach (acid step) to the SI/colon 
(phosphate buffer step). It can be seen from Table 5.2 and Figure 5.3 (in-vitro release 
data and profiles for formulation C-01 and formulation C-02) that neither formulation 
met the desired TPP at the 2 h time point. Given that the availability of sufficient 
material for coating trials was limited (formulation CLX 136/B was manually 
produced), formulation C-02 was chosen as a partially colonic targeted CLX microbead 
formulation for progression to the in-vivo AOM/DSS model of murine CRC. The 
processing conditions for formulations C-01 and C-02 are detailed in Table 5.3 below. 
The drug release of Celebrex® 25 mg capsules was also performed using the two-step 
release method for comparison purposes (see Figure 5.3). 
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Table 5.2 Percentage CLX released (± standard deviation (STEDV) from release testing of formulations 
C-01 and C-02 (two-step release method: 2 h in 0.1 M HCl (750 ml) followed by 10 h in phosphate 
buffer, pH 6.8 (1000ml)).  
Time point (h) 
% CLX Released 
C-01 
(5% weight gain of 
Surelease®) 
C-02 
(8% weight gain of 
Surelease®) 
0 0 0 
1 36.35 (± 0.77) 20.09 (± 0.28) 
2 70.63 (± 1.48) 39.78 (± 0.21) 
4 86.46 (± 1.13) 62.65 (± 0.56) 
6 86.72 (± 1.34) 71.34 (± 1.76) 
12 85.08 (± 0.70) 78.61 (± 0.98) 
 
 
                      Table 5.3 Fluid bed processing conditions for formulations C-01 and C-02 
Parameter C-01 C-02 
Product temperature  (°C) 
 
59–63 59–60 
Exhaust temperature  (°C) 
 
37–41 37–41 
Atomisation pressure (Bar) 
 
1.7 1.7 
Air flow (LPM) 
 
196–197 196–198 
Average spray rate (g/min) 
 
4 4 
Coating time (min) 
 
37 52 
Oven curing temperature (°C) 
 
40 40 
% Weight gain after curing 
 
5.4 8.3 
 
 
 208 
 
 
 
 
Figure 5.3 Percentage of drug released from release testing of formulations C-01, C-02 and Celebrex® 
(two-step release method: 2 h in 0.1 M HCl (750 ml) followed by 10 h in phosphate buffer, pH 6.8 
(1000ml)). The data presented are mean values ± STDEV (n=3). 
 
5.4.1.1 Effects of CLX formulations on extent of inflammation 
 
Mean body weight (index of pathology) and colon length (index of tissue inflammation) 
of mice administered Celebrex® (group 2) and CLX microbeads (group 3 - formulation 
C-02) were compared to that of group 1 (PBS) and/or group 4 (untreated). The body 
weight change of groups 1, 2 and 3 was not significantly different (Figure 5.4).  
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Figure 5.4 Average percentage body weight change of mice (±SEM) from each group (untreated negative 
control (n=6), PBS (n=10), Celebrex® (n=10) and coated microbead formulation C-02 (n=10)) from 
weeks 0–15 of the study.  
 
On the contrary, at autopsy mice treated with formulation C-02 for 12 weeks showed a 
significant (p=0.0330) reduction in colon length compared to the PBS treated mice 
(Figure 5.5). In Celebrex® treated mice, although the colons were shortened, this 
difference was not statistically significant (p=0.2470).  
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Figure 5.5 The effect of CLX on inflammation in the AOM/DSS CRC murine model included an 
assessment of colon length. The entire colon was excised and the length was measured and expressed in 
mm. The average colon length (±SEM) for each group (untreated negative control (n=6), PBS (n=10), 
Celebrex® (n=10) and CLX microbead formulation C-02 (n=10)) are shown. Statistics were performed 
relative to PBS for formulations C-02 and Celebrex®. 
 
Histology scoring was also performed as an assessment of inflammation. It can be seen 
from Figure 5.6 that whilst histology scores for formulation C-02 and Celebrex® were 
comparable, the histology score for formulation C-02 was statistically significant (p= 
0.0446),  compared to the PBS control, in contrast Celebrex® was not significant (p= 
0.0628).  
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Figure 5.6 The effect of CLX on inflammation in the AOM/DSS CRC murine model included an 
assessment of colon histology. Excised distal colonic tissue (1 cm-segments) of were fixed in 10% 
buffered formalin (pH, 7.4; PBS buffered) and embedded in paraffin. Sections (5 μm) were cut and 
stained with H&E and graded blind using a cumulative score ranging from 0 to 3–4 (Aveillo et al., 2014). 
The average histology score (±SEM) for each group (untreated negative control (n=6), PBS (n=10), 
Celebrex® (n=10) and CLX microbead formulation C-02(n=10)) are shown. Statistics were performed 
relative to PBS for formulations C-02 and Celebrex®. 
5.4.1.2 Effects of CLX formulations on CRC tumour attenuation 
 
The effect of CLX microbeads (group 3 – formulation C-02) and Celebrex® (group 2) 
on tumour size, tumour location and number were compared to that of group 1 (PBS) 
and/or group 4 (untreated).  Figure 5.7 illustrates a representative pictomicrograph of 
normal cells (A) and a tumour mass (B). There was no difference in tumour size among 
groups 1–3 (Figure 5.8) with tumour masses observed to have been homogenously 
distributed along the colon tissues. 
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Figure 5.7 Photomicrographs of (A) normal cells and (B) tissue mass, taken using a Leica® microscope 
equipped with Leica® DFC495 camera (Leica® Microsystem, Germany). Images were visualized by LAS 
v4.0 software.  
 
Figure 5.8 The effect of CLX on tumour size in the AOM/DSS CRC murine model was assessed. 
Following identification of tumours (see Figure 5.9 for details), the size of each tumour mass identified 
was measured by a micrometer system included in the LAS version 4.0 software used for the visualization 
of tumours. The average size (±SEM) of tumours for each group (untreated negative control (n=6), PBS 
(n=10), Celebrex® (n=10) and CLX microbead formulation C-02(n=10)) are shown. 
 
 
 
A B 
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Mice treated with formulation C-02 did however show a reduction in the number of 
AOM/DSS-induced tumours compared to the PBS control group approaching a 
statistical significance (p=0.0558) (Figure 5.9). In contrast, the p value for Celebrex® 
compared to the control was 0.1500 (i.e., it did not approach statistical significance).  
 
Figure 5.9 The effect of CLX on tumour number in the AOM/DSS CRC murine model was assessed. 
Colons were excised, fixed flat in 10% buffered formalin for 24 h and then stained with 0.2% MB. The 
total number of tumours per mouse was scored stereo-microscopically (5X magnification) using a Leica® 
microscope equipped with Leica® DFC495 camera. The average number of tumours for each group 
(untreated negative control (n=6), PBS (n=10), Celebrex® (n=10) and CLX microbead formulation C-02 
(n=10)) are shown. Statistics were performed relative to PBS for formulations C-02 and Celebrex®. 
 
5.4.1.3 Formulation analysis of in-vivo animal results 
 
As described in Section 5.2.3.3, the TPP for the coated formulation included a 
requirement for <10% release at 2 h in order to ensure minimal drug release in the 
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stomach and SI prior to reaching the colon. Due to the limited quantity of manually 
produced microbeads available for coating trials, a partially colonic targeted  
formulation comprising a sustained release polymer coat, which allowed in the region of 
50% of the drug to be available in the colon, was chosen for the subsequent in-vivo 
animal study (Figure 5.3 – formulation C-02). 
 
In this phase of the project the therapeutic efficacy of the partially colonic targeted 
microbead formulation (formulation C-02) was evaluated compared to Celebrex® with 
respect to the attenuation of colonic inflammation and the development of colorectal 
tumours in the AOM/DSS murine model of CRC. Relative to the control, the CLX 
microbead formulation was found to score significantly better compared to Celebrex® 
with respect to the level of indicators for inflammation (Figures 5.5 and 5.6) and whilst 
the level of tumour attenuation was comparable between the CLX microbead 
formulation and Celebrex®, the CLX microbead formulation approached significance 
(p=0.0558) whereas Celebrex® did not (p=0.150) (Figure 5.9).  
As described in Chapter 1, whilst it is generally accepted that the GI side effects of 
NSAIDs (Non-steroidal anti-inflammatory drugs) are mainly caused by 
cyclooxygenase-1 (COX-1) inhibition, which blocks the production of the protective 
mucus at the epithelial layer in the GI tract, COX-2 inhibitors such as CLX are still 
associated with GI toxicity (Silverstein et al., 2000). This GI toxicity is partly 
attributable to local effects on the GI tract, including local irritation (Halen et al., 2009). 
Multiparticulate drug delivery systems have been shown to be less likely than single 
unit dosage forms to cause local irritation (Tang et al., 2005) as they allow for a greater 
distribution of the drug. Similarly, micelle formulations allow for an even distribution 
of drug in the GI tract and can reduce the toxicity caused by the administration of a neat 
drug (Lui et al. 2008). The results obtained in this phase of the project represented a 
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significant step forward in that it allowed the possibility of presenting CLX in a micellar 
format within a multiparticulate, a combination that has the potential to minimize GI 
side effects whilst maintaining the effectiveness of the treatment. 
A further analysis of the data obtained from the in-vivo study highlighted the potential 
for the microbead formulation to have an even more enhanced effect than Celebrex® 
over that presented in Figures 5.5, 5.6 and 5.9. The release profile for formulation C-02 
(Figure 5.3) shows that in the region of 50% of CLX is likely to have been released 
prior to the microbead formulation reaching the colon based on a 3 h SI transit time 
(Padmanabhan et al.,  2013). A number of in-vivo studies conducted in both animals and 
humans have shown that when CLX is delivered in a soluble form that the extent of 
drug absorption is significantly greater when compared to Celebrex® (Paulson et al., 
2001 and Subramanian et al., 2004). The study by Paulson and colleagues also 
demonstrated that when a CLX solution was delivered directly to the stomach and the 
duodenum, that the Tmax (time at which serum levels of drug are at their highest) for 
drug absorption was approximately 0.69 and 1.13 h respectively. Based on these 
studies, it could be hypothesied in this study that in the region of 50% of the CLX from 
formulation C-02 could have been rapidly absorbed within 3 h of administration and 
therefore may not have been available in luminal side of the colon. In contrast, the low 
solubility of CLX in Celebrex® has been shown to prolong the absorption process, with 
a terminal half life of 11 h being reported (FDA Clinical Pharmacology and 
Biopharmaceutics Review for Celebrex®, 1998). Based on this information and the 
release profile for Celebrex® shown in Figure 5.3, it is also reasonable to assume that 
the majority of the Celebrex® dose administered in this study would have been available 
to the colon 3 h after administration. A hypothesis is therefore presented that the 
chemopreventative effects of the CLX microbead formulation achieved in this study 
may have been achieved with a lower concentration of drug locally available in the 
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lumen of the colon than that which may have been locally available (in the colon lumen) 
in the case of Celebrex®. Should this hypothesis be proven in future studies (i.e., by 
repeating the study using a CLX microbead formulation that meets the desired TPP), it 
would represent a significant breakthrough for the use of CLX in the treatment and 
prevention of CRC as it would afford the opportunity to administer CLX at lower doses 
and thereby reduce the incidence of cardiovascular (CV) and GI side effects associated 
with high doses of Celebrex® (Soloman et al., 2005 and FDA labelling Revision for 
Celebrex Capsules, 2008).  
 
5.5 Conclusions 
 
Chapter 4 described the development of an optimised CLX microbead which 
culminated in formulation CLX 136/B, a formulation which met all the CQAs required 
for the intermediate product (i.e., a robust microbead which contained a sufficient 
loading of dissolved CLX). In this phase of the project (Chapter 5), a sustained release 
polymer (Surelease®) was applied to CLX 136/B microbeads with the intention of 
meeting a defined TPP to allow for colon specific delivery in a mouse model. Despite 
the successful application of Surelease® to the microbeads at 5% (C-01) and 8% (C-02) 
w/g, the TPP at 2 h time point was not achieved for either formulation. Due to the 
limited quantity of product available for coating optimisation studies, coated microbead 
formulation C-02, which represented a partially colonic targeted formulation, was 
selected for progression to an AOM/DSS CRC murine model. In the murine model, the 
effect of formulation C-02 on the attenuation of CRC tumours was compared to that of 
Celebrex® and was found to have a marginally greater effect. The anti-inflammatory 
effects of both formulations were also assessed with formulation C-02 exhibiting a 
significant effect compared to the control in the case of colon length and histology 
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scoring whereas Celebrex® did not achieve significance. A hypothesis was also 
presented to suggest that the anti-cancer and anti-inflammation effects of formulation C-
02 may have been achieved with a lower concentration of drug locally available in the 
lumen of the colon than that which may have been available in the case of Celebrex®.. 
The results for the partially colonic formulation presented here (C-02) enables the 
possibility of presenting CLX in a micellar format within a multiparticulate, a 
combination that has the potential to minimize GI side effects whilst maintaining the 
effectiveness of the treatment. In order to build upon these results, a next generation 
fully colonic targeted formulation was required in order to allow for hypothesis 
described to be tested in a future animal study. Chapter 6 describes the development of 
this next generation product.  
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5.6 Nomenclature 
Table 5.4 List of abbreviations which are listed according to their appearance in the text. 
Abbreviation Definition 
AOM Azoxymethane 
DSS Dextran sodium sulphate 
CLX  Celecoxib  
CACRC Colitis associated colorectal cancer 
TPP Target product profile 
w/g Weight gain 
CRC Colorectal cancer 
CQA Critical quality attribute 
IBD Irritable bowel disease 
CD Crohn´s disease  
UC Ulcerative colitis 
5-ASA 5-aminosalicylic acid  
SI Small intestine 
HCAs Heterocyclic amines  
AAs Aromatic amines 
DMH Dimethylhydrazine 
PhIP 2-amino-1-methyl-6-phenylimidazol (4,5-b) pyridine  
IQ 2-amino-33-methylimidazo[4,5-f] quinolone 
DMBA 3,2'-dimethyl-4-aminobiphenyl 
MNU Methylnitrosourea  
MNNG N-methyl-N-nitro-N- nitrosoguanidine 
DMH 1,2-dimethylhydrazine  
MAM methylazoxymethanol 
i.p. Intraperitoneal 
APC  Adenomatous polyposis coli  
FAP Familial adenomatous polyposis 
HNPCC Hereditary non-polyposis colorectal cancer 
MMR mismatch repair 
COX-2 cyclooxygenase-2 
GI Gastrointestinal  
SDS Sodium dodecyl sulphate 
API Active pharmaceutical ingredient 
COA Certificate of analysis  
HPLC High performance liquid chromatography  
MB methylene blue  
PBS Phosphate-Buffered Saline 
UV ultraviolet 
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Abbreviation Definition 
LPM  Litre per minute 
H&E Heamatoxylin and eosin  
SEM Standard error of the mean 
STDEV Standard deviation 
NSAIDs Non-steroidal anti-inflammatory drugs  
COX-1 cyclooxygenase-1 
Tmax  Time at which serum levels of drug are at their highest 
CV cardiovascular  
CLX xxx/B 
Celecoxib bead formulation numbering system where xxx is a 
sequential number and B is bead 
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CHAPTER 6                       
Encapsulation scale-up, coating 
optimisation and application of 
formulation platform to other actives 
 
 
Publication Status: Elements of the work presented in this chapter in 
addition to data from chapters 3 and 5 has been accepted for publication 
(02-11-14) in the Journal of Pharmacy and Pharmacology under the 
following title ‘In-vitro characterization of a novel celecoxib microbead 
formulation for the treatment and prevention of colorectal cancer’.  
 
 
 
 
 227 
 
6.1 Abstract 
The primary purpose of this phase of the project (Chapter 6) was to overcome the 
limitations of the partially colonic targeted microbead celecoxib (CLX) formulation 
described in Chapter 5 by scaling-up microbead production and subsequently 
optimising the coating applied to the microbeads. Microbead production scaled-up was 
achieved via automated prilling (using an Inotech IE-50 R encapsulator) which resulted 
in robust microbeads with a very narrow size distribution, a high % entrapment 
efficiency and, critically, a high and consistent level of drug release in release 
experiments using purified water (PW) as the dissolution media. Subsequent coating 
optimisation studies resulted in a microbead formulation coated with 20% weight gain 
(w/g) of Surelease® (SR) that was deemed suitable for use in a future colorectal cancer 
(CRC) mouse study. Further coating optimisation was performed which included the 
deployment of a HPMC (hydroxypropyl methylcellulose) based sub-coat (Opadry® 
White) resulting in a product suitable for human colon delivery. Finally a screening 
study was performed which illustrated that the optimised CLX microbead formulation 
(CLX 136/B) was suitable as a platform formulation for a range of alternative actives 
with similar physicochemical characteristics.  
6.2 Introduction 
6.2.1 Background 
 
Chapter 5 described the application of a sustained release polymer (SR) to CLX 136/B 
(the optimised CLX microbead formulation developed in Chapter 4) and an assessment 
of the anti-cancer and anti-inflammatory effects of the coated formulation versus that of 
Celebrex® in an AOM (azoxymethane)/DSS (dextran sodium sulphate) CRC murine 
model. It was intended that the coating applied to the microbead would result in a 
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product capable of specifically targeting the colon of a mouse, however the target 
product profile (TPP) for the product was not met, with the consequence that the coated 
microbead formulation (C-02) used for the animal study was partially rather than fully 
colonic targeted due to an early release of the drug, with approximately 50% of the drug 
being released after 3 h (i.e., before reaching the colon). Whilst formulation C-02 was 
observed to have out-performed Celebrex® with respect to both its anti-tumorigenic and 
anti-inflammatory effects, it was postulated in the conclusion to Chapter 5 that the use 
of the partially colonic targeted formulation (C-02) may have resulted in a sub-optimal 
result for formulation CLX 136/B. The focus of this phase of the project (Chapter 6) 
was therefore to optimise the SR coating applied to formulation CLX 136/B with the 
intention of developing a next generation coated CLX microbead formulation to meet 
the TPP for colon specific delivery to a mouse for use in a repeat of the AOM/DSS 
CRC mouse model in the future (Note: the repeat of this animal study is outside the 
scope of the current project).  
It was necessary to use formulation C-02 for the animal study described in Chapter 5 
due to the limited availability of substrate beads for coating optimisation as the beads 
were manually produced via a manual gravity dripping method (see Chapter 4 for 
details). In order to produce sufficient quantities of substrate microbeads for the 
required coating optimisation studies, the first phase of this stage of the project involved 
the automated scale-up of microbead production using a suitable mechanically-aided 
dripping technology. A review of available mechanically aided dripping technologies 
are included in Section 6.2.2 below.  
As previously described, the primary aim of this phase of the project was to develop an 
optimised coating formulation in order to meet the TPP for colon targeting in a mouse 
(Section 6.2.3.1). Given that the ultimate objective for this formulation is the 
development of a commercial product for use in human therapy, the TPP for a human 
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product is also described (Section 6.2.3.2). In order to meet the TPP for human 
administration and in particular to ensure sufficient release at the latter end of the 
release profile, a number of possible formulation approaches to help achieve this target 
are described (Section 6.2.3.3). 
Finally, although the primary focus of the project was on the development of a CLX 
formulation suitable for the treatment and prevention of CRC, it is desirable for any 
formulation/technology to be broadly applicable to a range of actives, therefore as a 
final step in the project, the suitability of the core formulation for the incorporation of a 
range of APIs (active pharmaceutical ingredients), in a solubilised form, across a broad 
physicochemical spectrum was assessed (See section 6.4.4 for details).  
A summary of the objectives of the final phase of the project (Chapter 6) are detailed in 
section 6.2.4.  
 
6.2.2 Mechanical-aided dripping techniques 
 
As described in Chapter 4, dripping involves a technique where a single liquid (mixture 
of core and shell/matrix materials) is extruded through a nozzle resulting in a matrix 
droplet in which the core material is homogenously dispersed within the matrix. The 
principle of this process is based on gravity whereby when the liquid passes through the 
tip of the nozzle, a droplet grows and separates from the stream before falling into the 
hardening solution. Gravity dripping represents the simplest method of making 
microbeads, however it has a number of limitations including very slow flow rates 
(refer to Chapter 4 for further details). The disadvantages associated with gravity 
dripping can be overcome by increasing the flow rate to the nozzle and via the 
application of a mechanical force to break-up the stream of liquid as it flows from the 
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nozzle (i.e., droplet formation is no longer reliant on the force of gravity). These 
mechanical forces give rise to the following techniques based on the principle of 
dripping; jet cutting technology, rotating (spinning) disc atomisation, electrostatic 
extrusion, coaxial air flow and prilling. A review of these mechanically aided dripping 
techniques detailed below and a diagram depicting the techniques is shown in Figure 
6.1. 
             
Figure 6.1 Schematic diagram of different mechanically aided dripping techniques; (a) Jet cutting 
technology, (b) spinning disc atomisation, (c) coaxial air flow, (d) electrostatic extrusion and (e) prilling. 
Diagram adapted from Krasaekoopt (Krasaekoopt, 2013). 
 
6.2.2.1 Jet cutting technology 
 
High throughput production of microbeads can be achieved by cutting the jet of liquid 
extrudate (from the nozzle) into cylindrical segments via a rotating micrometric cutting 
tool (i.e., cutting wire) (Figure 6.1 (a)).  Due to surface tension, these cylindrical 
segments then form spherical droplets/beads when passing through the air before 
dropping into the hardening solution. The JetCutter® from (GeniaLab®, Germany) is 
 231 
 
based on this technology (GeniaLab® Technology overview, 2014). The primary 
advantage of the JetCutter® are a) an ability to process very viscous liquids, b) high flow 
rates (up to 5L/h), c) ability to produce microbeads across a wide range of bead sizes 
and d) a very narrow bead size distribution. Despite these advantages, the technology 
also poses a number of challenges, namely; a) a high loss percentage associated with the 
cutting technique and b) scaling up to a multi nozzle process is difficult (Chavarri et al., 
2012). In addition to these technical challenges, the author could not find any references 
for the use of the JetCutter® with respect to either gelatine or for pharmaceutical 
production.  
 
6.2.2.2 Spinning disk atomisation 
 
Spinning disk atomization constitutes a technique in which the liquid extrudate is fed 
onto a high velocity spinning disc, which in turn produces droplets due to the 
centrifugal force at the edge of the disc. Similar to the jet cutting technology, these 
droplets are then dropped into a hardening solution thereby forming solid beads (Figure 
6.1 (b)). The method is capable of producing beads in a size range of a few hundred 
microns up to several millimetres (Krasaekoopt, 2013), however bead deformation is 
high due to the impact speed of the droplets into the hardening solution and satellite 
beads (i.e., a second population of very small beads) are also known to form resulting in 
a wider bead size distribution (Teunou and Poncelet, 2005).  
 
6.2.2.3 Coaxial air flow 
 
Coaxial air flow technology involves applying a stream of compressed air around the 
extrusion nozzle with the result of pulling the liquid droplets away from the nozzle at a 
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faster rate than that achieved for gravity dripping (Figure 6.1 (c)). Coaxial air flow is 
also referred to as the concentric air-jet technique as the equipment consists of a 
concentric nozzle; an inner orifice (through which the liquid flows) and an outer orifice 
(through which the air flows). An ability to produce beads with a diameter from a few 
microns to 1mm is considered to be the main advantage of the technology (Chavarri et 
al., 2012). Interestingly however, this generally perceived advantage is actually 
considered to be a disadvantage in the context of this project as the target bead size is in 
the region of 1–2 mm (suitable bead size for fluid bed coating). Another disadvantage of 
the technology is a very slow flow rate (< 30 ml/h) which poses challenges on scale-up 
(Chavarri et al., 2012).  
 
6.2.2.4 Elecrostatic extrusion 
 
Similar to coaxial air flow, the principle of electrostatic extrusion is based on a force 
pulling liquid droplets off the orifice at a faster rate than that achieved for gravitational 
dripping, however an electrostatic force is applied rather than air flow. The electrical 
potential is applied to the extruded polymer solution by passing it through a charged 
nozzle (usually a hypodermic needle) with the produced droplets subsequently falling 
into a hardening solution which has been earthed or holds an opposite charge, thereby 
creating electrostatic potential between the nozzle and the hardening bath and hence 
drawing droplets from the nozzle (Figure 6.1 (d)) (Dormer, Berkland and Singh, 2014). 
The technology is capable of producing beads across a wide size range (1 µm to several 
millimetres), however its limitations include the following; a) low production rates, b) a 
wide size distribution and c) safety concerns due to the use of electrostatic charge 
(personal injury and fire hazard) (Dormer, Berkland and Singh, 2014). 
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6.2.2.5 Prilling  
 
Prilling, which is also referred to as the vibrating-jet, vibrating nozzle, vibrational drip 
casting technique or annular jet, is one of the most widely used methods for the 
production of microspheres/microbeads and microcapsules (Whelehan and Marison, 
2011). The technique involves extruding a liquid through a nozzle at a given flow rate 
to create a laminar jet. The laminar jet is then broken up into short lengths by the 
application of a vibrational frequency with defined amplitude (i.e., a sinusoidal force) to 
the jet. The short segments, in turn, form spherical droplets in the air due to the surface 
tension of the extruded liquid. The characteristics of the drops formed are dependent on 
the nozzle diameter, the flow rate of the laminar jet, the size of the frequency at defined 
amplitude and the viscosity of the extruded liquid. The most common application of the 
sinusoidal force involves either vibrating the nozzle (vibrating nozzle technique) or by 
pulsating the polymer before passing through the nozzle (vibrating liquid technique) 
(Whelehan and Marison, 2011, Brandau 2014).  Based on a review of the literature there 
is no collective agreement with respect to the terminology used to describe the laminar 
jet break-up techniques, however the term prilling is being increasingly used with 
respect to pharmaceutical applications (Vervaeck et al., 2014 and Pivette et al., 2012) 
and therefore is the term being employed here. A diagram depicting prilling is shown in 
Figure 6.2. 
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Figure 6.2 Schematic diagram depicting microbead formation via a prilling technique. Microbead 
formation is achieved by applying a sinusoidal force to the extruded jet, in this case by mechanically 
vibrating the nozzle at a set frequency with a defined amplitude. Diagram adapted from Whelehan and 
Marison (Whelehan and Marison, 2011). 
 
 
 
There are a number of advantages associated with prilling processes. Compared to other 
microencapsulation techniques and indeed other dripping techniques, prilling results in 
perfect regular shaped microbeads with a smooth surface and excellent flow properties 
and which are capable of 100% drug encapsulation (Vervaeck et al., 2014 and Pivette et 
al., 2012). The process also allows for continuous manufacture and can be easily scaled-
up using multiple nozzle configurations (Brandau, 2014). The primary disadvantage 
associated with the technology is that processing is usually restricted to low viscosity 
liquids, however in terms of gelatine formulations this can usually be circumvented via 
the addition of water. Given that most of the water is eventually removed during drying 
of the microbeads, the addition of extra water to facilitate processing does not impact on 
the final formulation composition. 
dd = droplet diameter 
Vj = jet velocity 
dn = nozzle diameter 
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Compared to the other mechanically aided dripping technologies described, a distinct 
advantage of prilling processes is the availability of both lab scale and commercial scale 
equipment. In terms of lab scale equipment, the options include the Var-D series of 
encapsulators from Nisco Engneering (Switzerland), Inotech encapsulators from Encap 
Biosystems (now Buchi, Switzerland) and the Spherisator series from Brace GmBH 
(Germany). Brace GmbH also supply commercial scale equipment as does the Freund 
Corporation (Japan).  
Based on the advantages associated with prilling processes and also access to one of the 
pieces of lab scale equipment described (i.e., an Inotech IE-50 R encapsulator), prilling 
was selected as the process of choice for the scale-up manufacture of formulation CLX 
136/B. 
 
6.2.3 Coating Optimisation 
 
As described in the introduction, the primary intention of the coating optimisation study 
was to develop a next generation fully colon targeted CLX microbead formulation that 
would meet the TPP for colon specific delivery in a mouse model. As a reminder for the 
reader, the TPP for delivery in the mouse is repeated in Section 6.2.3.1 below and a 
brief outline of the intended formulation approach to meet the desired TPP is described. 
Given that the ultimate aim of this research is the development of a product for human 
therapy, a secondary aim of the coating optimisation study was to develop the release 
profile of the product to meet a TPP for human administration. Section 6.2.3.2 outlines 
the TPP for human dosing and also highlights the challenges of meeting the TPP based 
on the data generated up to this point (i.e., Chapter 5). Finally some formulation 
approaches to facilitate the regulatory requirements associated with the human TPP are 
described in Section 6.2.3.3. 
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6.2.3.1 Mouse TPP 
 
The TPP for the product to allow for maximum colon targeting in the mouse described 
in Chapter 5 was as follows; <10% release at 2 h and >50% release at 6 h. The TPP was 
based on published GI transit times for mice (described in Chapter 5). On this basis, the 
two point TPP described intended to a) ensure minimal drug release in the stomach and 
small intestine  prior to reaching the colon (i.e., <10% release at 2 h) and b) to ensure 
sufficient drug was released prior to expulsion of the multiparticulate (i.e., >50% release 
at 6 h). A review of the release profiles for the two coated formulations produced up to 
this point (Figure 6.3) illustrated that neither formulation met the desired TPP at the 2 h 
timepoint. Following a review of the data presented in Figure 6.3, it was clear that by 
increasing the w/g of SR that a longer lag time could be achieved therefore the primary 
focus of the initial coating optimisation work involved the application of increasing 
levels of SR. 
 
Figure 6.3 Percentage of drug released from release testing of formulations C-01 and C-02 (two-step 
release method: 2 h in 0.1 M HCl (750 ml) followed by 10 h in phosphate buffer, pH 6.8 (1000ml)). Note: 
This is a repeat of Figure 5.5 from Chapter 5. The figure is presented again here for the benefit of the 
reader. 
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6.2.3.2 Human TPP  
 
When defining a TPP for human administration there are two key points for 
consideration; a) the TPP to enable a maximum therapeutic/clinical effect and b) a TPP 
to meet regulatory requirements for the quality control testing of the final product. It is 
possible to define two separate TPPs to meet these dual requirements, however this 
usually requires the development of two separate analytical methods with associated 
cost implications therefore where possible it is desirable to have a TPP that meets both 
sets of requirements. With respect to this product, the clinical TPP was defined on the 
basis of the description of human gastrointestinal (GI) physiology described in Chapter 
5.  The primary focus was therefore to develop a formulation that would preserve the 
formulation during its passage through the stomach and small intestine, to start release 
of the drug at the ileocecal junction and thereafter to release drug in a sustained release 
manner to enable maximum exposure throughout the colon. On the basis of the transit 
times described in Chapter 5, it was considered that this clinical TPP would equate to 
the following; < 10% release at 2 h (to minimise release in the stomach), < 30% release 
at 4 h (to minimise release in the small intestine), approximately 50% release at 6 h (to 
ensure that sufficient drug is released as the beads start to move through the ascending 
colon and > 80% release after 18 h (to ensure full release of the drug prior to exiting the 
colon/rectum). In terms of a regulatory TPP, the FIP (International Pharmaceutical 
Federation) guideline and the European Pharmacopeia require at least 3 specifications 
points when setting a drug release specification for a sustained/extended release 
product. These specifications points are as follows; 1) NMT (not more than) 20–30% 
after 1–2 h (to provide an assurance against premature drug release), 2) a second 
specification at approximately 50% release to define the release pattern and 3) > 80% 
release at the end of the release profile (to ensure almost quantitative release) (Sievert 
 238 
 
and Siewert, 1998). Based on a review of the clinical and the regulatory TPPs described 
above, an overall TPP was derived to meet all requirements. The number of 
specification points was limited to three to meet commercial pressures to keep the 
number of time points to a minimum (i.e., less time points means less samples to be 
tested and also less opportunity to generate out of specification results). The overall 
human TPP derived was as follows; < 20% release at 2 h, 40-60% release at 6 h and > 
80% release after 18 h. 
 
6.2.3.3 Functional excipients to enhance drug release 
 
In section 6.2.3.1, a strategy of applying increasing levels of SR was presented as a 
means of achieving the 2 h lag time required. It is a well-known phenomenon that 
applying greater levels of SR can in some cases result in difficulties in achieving full 
release (i.e., > 80%) at the latter end of the release profile (Rege et al., 2005 and Levina 
et al., 2007). Some of the strategies that can be employed to modulate the release profile 
to order to achieve full release when using increasing levels of SR are described below. 
 
A.  Pore formers  
 
Functional coatings (e.g., SR) are applied to multiparticulate drug delivery systems to 
achieve desired release profiles. These release profiles can be controlled by varying the 
composition and levels of the sustained release polymer. One method of varying the 
release profile from polymers is via the inclusion of a pore former which on contact 
with liquid results in the formation of channels in the polymer and hence enhanced 
release (Teng and Qui, 2010). Pore formers can act on the basis of a number of different 
principles including the following; a) an ability to dissolve at a specified pH, b) 
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enzymatic activation and c) water solubility. A review of enzymatic and solubility 
activated pore formers is included below. Pore formers activated via pH changes were 
omitted from consideration due to GI pH fluctuations (particularly in disease) as 
previously described in Chapter 5. 
A1. Solubility activated pore formers 
 
The primary component of SR is ethyl cellulose (EC). EC is a water-insoluble polymer, 
having a relatively small degree of swelling due to its hydrophobicity. Incomplete drug 
release, as well as a long lag time, has been reported in some instances from EC coated 
multiparticulates, even at low coating weight gains. As a result there have been a 
number of studies performed to assess the use of HPMC as a water soluble pore-former 
to enhance the release of drugs form dosage forms coated with SR (Dias et al., 2010 and 
Levina et al., 2007). It has been shown in the studies cited that by including various 
concentrations of HPMC as pore formers resulted in an enhancement of both the rate 
and extent of release from dosage forms over a period of 24 h and ultimately ensured 
complete terminal release. It was postulated that the HPMC in the coat hydrated thereby 
producing water-logged regions (pores) within the film. Some of the HPMC was then 
believed to have migrated into the dissolution medium, thereby creating regions with 
higher film permeability to the drug. 
 
A2. Enzymatic activated pore formers 
 
As described in Chapter 5, colon microflora is recognised as a triggering component in 
the design of colon specific drug delivery systems. For a number of reasons the use of a 
predominantly enzymatic activated coating system was not pursued for this project 
(refer to Chapter 5 for details), however it was felt that the use of enzymatic pore 
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formers did warrant investigation on the basis of a lower risk than that associated with 
systems that primarily relied on enzymatic activation. The risk is considered to be less 
due to the purpose of the pore former in such formulations, in that the primary function 
of the pore former is ensure maximum release at the end of the release cycle. For 
example in the case of a diseased patient in which the necessary colonic microflora is 
not present to activate the pore former then it is reasonable to expect that the patient 
might still receive a minimum of 70–80% of the intended dose assuming the purpose of 
the pore former was to ensure release of the remaining 20–30%. As referred to in 
Chapter 5, there are a number of polysaccharides that have been studied in the context 
of colon specific delivery. Of these polysaccharides, the use of pectin as a pore former 
has been the focus of a number of studies involving SR (Wei et al., 2007, Wei et al., 
2008, Ahmed, 2005 and Wakerly et al., 1997). Since pectin is water soluble, it is not 
considered to be an ideal carrier for colon delivery (when used alone), however it is 
deemed suitable for use as a pore former when used in combination with an insoluble 
polymer (e.g., ethylcellulose).  In this context an added benefit of pectin is that in the 
event of the failure of pectin to breakdown enzymatically (e.g., in the absence of 
sufficient levels of Bacteroides thetaiotaomicron (bacteria primarily involved in 
breaking down of dietry pectin (Dongowski et al., 2000)), the pectin may form pores in 
the coat as a result of its water solubility in a similar fashion to that postulated for 
HPMC (Section 6.2.3.3 A1).  
 
B. Sub-coats 
 
A second strategy to modulate the release profile to achieve full release of active when 
using increasing levels of SR involves the application of an Opadry® (HPMC) sub-coat 
underneath the functional SR layer (i.e., the outer EC coat). This strategy has previously 
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been shown to be successful in achieving full release of active drug from microbeads 
coated with SR in an unpublished patent from Sigmoid Pharma (Coulter, 2013). HPMC 
sub-coats have previously been employed in combination with EC outer coats in 
rupturable pulsatile drug delivery systems where it is postulated that the release of the 
drug at the end of the release cycle corresponds with a rupturing of the EC coat perhaps 
due to an interaction between the inner coat and/or the core on the outer coat. There are 
many examples in the literature of rupturable systems (Maroni et al., 2012 and Yadav et 
al., 2011), however the system described in the Sigmoid Pharma patent is unique in that 
it 1) allows for the maintenance of a significant lag period (<10% release over 2 h), 2) it 
allows for drug release to be modulated across the entire release profile (i.e., the burst 
effect seen in pulsatile delivery systems is not observed) and 3) it has been shown to 
improve batch to batch repeatability (Coulter, 2013). 
 
6.2.4 Objectives 
 
As described in the introduction (Section 6.2.1), the primary goal of this phase of the 
project was to optimise the SR coating applied to formulation CLX 136/B with the 
intention of developing a next generation coated CLX microbead formulation that meet 
the TPP for colon specific delivery to a mouse for use in a repeat of the AOM/DSS 
CRC mouse model in the future. A secondary goal was to develop the coating 
formulation with respect to its ultimate use as a finished product for human therapy. The 
final goal was to assess the suitability of the core formulation for incorporation of a 
range of APIs (in a solubilised form) across a broad physicochemical spectrum. The 
objectives set out to fulfil these three goals were as follows: 
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A. Firstly to scale-up the manufacture of formulation CLX 136/B using an 
Inotech IE-50 R encapsulator to allow for a sufficient quantity of beads for 
coating optimisation studies. 
B. Secondly to apply increasing levels of SR to CLX 136/B beads with the 
intention of securing a 2 h lag time and therefore meeting the mouse TPP. 
C. In the expectation that by applying increasing levels of SR that > 80% 
release would not be achieved at the latter end of the release profile, the third 
objective was to incorporate release enhancers (e.g., pore formers) in the 
coating composition in order to meet the human TPP. 
D. The fourth and final objective was to screen the solubility of a range of 
actives in the surfactant phase of formulation CLX 136/B and attempt to 
manually manufacture beads of actives deemed to be soluble in an effort to 
assess the broader application of the platform formulation. 
 
6.3 Materials and methods 
6.3.1 Materials 
 
CLX microbeads (formulation CLX 136/B) were made using the following materials; 
Solutol HS-15® (BASF, Germany), Miglyol® 810N (Sasol, South Africa), porcine 
gelatin (Nitta Gelatin, Japan), sorbitol (Neosorb® - Roquette, France) and Sodium 
Dodecyl Sulphate (SDS) (Merck, Germany). Coating trials were performed using 
Surelease®, Methocel® E5, Opadry® White 20A28380 (all Colorcon®, USA) and Apple 
Pectin USP (Sigma Aldrich, USA). A sample of CLX API was kindly provided by 
Erregierre (Italy). A solubility screening study was performed using the following APIs; 
Nimodipine (Allchem, India), Budesonide (Crystal Pharma, Spain), Zolpidem Tartrate 
(Farmak, Czech Republic), Naproxen Sodium (Teva, Israel), Cyclosporine (Euticals, 
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Italy), Tacrolimus (Biocon, India) Aspirin, Ibuprofen, Sulindac, Naproxen, Tramadol 
HCl, Diclofenac Sodium salt and Theophyline (all Sigma Aldrich, USA). All chemicals 
used for the release experiments and HPLC (high performance liquid chromatography) 
testing were of laboratory grade. Aspergillus niger pectinase (Sigma Aldrich, USA) was 
used for release testing of some formulations comprising pectin. 
 
6.3.2 Methods 
6.3.2.1 Automated microbead manufacture 
 
A vibrating nozzle, jet break-up encapsulator (Inotech model IE-50 R, Switzerland) 
equipped with a 1 mm diameter single nozzle, an air pressure solution delivery system 
and a temperature controlled nozzle jacket was used to prepare microbeads. The details 
of the formulation preparation, the cooling oil used and the cooling oil temperature were 
as previously described for manual microbead production in Chapter 4. The nozzle 
jacket was set to 65°C. Heat wire set at 65°C was wrapped around the solution tube to 
maintain the solution at 65°C.  Microbeads were produced at a solution flow rates of 8-
10 g/min. Microbeads were removed from the cooling oil and were allowed to dry at 
ambient temperature for 18-24 hours before being sieved. Batch sizes in the region of 
50 g were produced. 
6.3.2.2 Fluid bed coating of microbeads 
 
The following coating solutions were prepared with PW as per the manufacturer’s 
instructions; SR (15% solids), SR:Pectin (98:2 w/w – 15% solids), SR: Methocel® 
(90:10 w/w – 15% solids) and Opadry® White 20A28380 (10% solids). The starting 
weight of microbeads for all coating trials was approximately 6 g. Microbeads with an 
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average size range of approximately 1.4 mm were used for coating trials. An MFL01 
fluid bed system (Vector Corporation, USA) equipped with a Wurster insert was used 
for coating. Microbeads were coated at an inlet air temperature setting of 65–70°C and a 
product temperature of 39–45°C. The volume of fluidizing air was maintained at 179 
LPM (litres per minute) to ensure optimum fluidizing of microbeads. A nozzle air 
pressure of 1.7 bar and solution flow rates of 3–4 g/min were applied. At the end of the 
coating process, the coated microbeads were dried for 5 min in the fluid bed system at a 
product temperature of 40°C. The weight gain of the beads was calculated based on the 
starting (pre-coating) and end (post- coating) weights of the beads.  
 
6.3.2.3 In-vitro release testing 
 
Release testing of uncoated CLX microbeads (50 mg doses) was performed (n=3) at 
37°C in PW. Release of coated CLX microbeads (25 mg doses) were performed (n=3) 
at 37°C using a two-step release method (2 h in 0.1 M HCl (750 ml) followed by 16 h in 
phosphate buffer, pH 6.8 (1000 ml)). For some formulations containing pectin, 
pectinase (0.02 %) was added to the dissolution media after approximately 16 h. 
Release experiments were carried out using either a Varian/Vankel VK7010 dissolution 
apparatus (VanKel, USA) or a Distek Evolution 6300 (Distek, USA) equipped with 
standard glass vessels and USP type II paddles. Paddle rotating speed in all experiments 
was 75 rpm. Microbeads equating to 25 or 50 mg of CLX were weighed and added to 
the release media. At specified times 1.8 ml samples were withdrawn, filtered through a 
70 µm pore filter (QLA, USA) and analysed using a HPLC method. The % of drug 
released at particular time points was determined from peak areas which were calculated 
against a single point external reference standard. The % of drug release was adjusted to 
 245 
 
take into account the content assay (coated beads)/entrapment efficiency (uncoated 
beads) result for the formulation.  
6.3.2.4 HPLC analysis 
 
The HPLC method for the analysis of the release and assay samples was adapted from 
Saha et al. (2002). The HPLC column used was a reverse phase 4.6 x 250 mm Inertsil® 
C8 column (Inertsil, The Netherlands) with 5 µm particles. The mobile phase was 
acetonitrile:water (65:35). The isocratic method used a flow rate of 1.25 ml/min and 
ultraviolet (UV) detection at 230 nm. The injection volume was 20 µl and the retention 
time was 8 min. The HPLC apparatus that was used for the analysis was a Waters 
(Waters, USA) HPLC systems (and associated Empower software).  
 
6.3.2.5 Evaluation of entrapment efficiency 
 
The amount of incorporated CLX was determined in selected CLX microbead 
formulations produced using the Inotech encapsulator.  A quantity of beads (n=2) with 
a theoretical potency equating to 5 mg were sonicated for 2 h in a mixture of 
acetonitrile:water 65:35 to extract the drug from the microbeads. The resultant solution 
was passed through a 0.45 µm filter prior to absorbance analysis. Where required the 
samples were diluted prior to analysis. The concentration of CLX was determined by 
absorbance measurements at 230 nm via the HPLC method described. CLX content (%) 
was calculated as the amount of determined CLX with respect to the total mass of dried 
microbeads.  The entrapment efficiency (%) of CLX was expressed as a percentage of 
the determined CLX with respect to the total amount of CLX used in the preparation of 
the microbeads. 
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6.3.2.6 Particle size analysis 
 
Particle size analysis (PSA) was performed for selected CLX microbead formulations 
produced using the Inotech encapsulator.  The entire batch size of dried microbeads 
produced was sieved using 100 mm stainless steel sieves (Retsch, Germany). The sieve 
sizes used were as follows; 1 mm, 1.25 mm, 1.4 mm, 1.6 mm, 2 mm and 2.5 mm. The 
resultant fractions were separated and weighed. Approximate determinations of the size 
of selected wet beads was also performed using a calibrated vernier calipers (Sigma 
Aldrich, USA).  
6.3.2.7 Content assay 
 
The content of CLX in coated microbead formulations was determined via the same 
method described in Section 6.3.6. The concentration of CLX in the beads tested was 
determined by absorbance measurements at 230 nm via the HPLC method previously 
described. CLX content (%) was determined from peak areas which were calculated 
against a single point external reference standard.  
 
6.3.2.8 API solubility screening 
 
The solubility of a range of APIs in Solutol® HS-15 was investigated. API was added to 
a measured quantity of Solutol® HS-15 at concentration of 10% w/w (minimum of n=2 
measurements). These mixtures were stirred at approximately 35°C on a 
hotplate/magnetic stirrer.  Mixtures that appeared cloudy after overnight stirring were 
categorised as ‘insoluble’ whereas those which resulted in transparent solutions were 
categorised as ‘soluble’.  
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6.3.2.9 Manual manufacture of microbeads 
 
Following on from the API solubility screening described above, the feasibility of 
manufacturing microbeads using selected APIs was performed via the manual 
manufacturing method described for CLX microbeads in Chapter 4. The microbead 
formulation was identical to that employed for CLX 136/B with the exception of the 
API. 
6.4 Results and discussion 
6.4.1 Encapsulation scale-up  
 
A total of 9 batches of CLX 136/B were made on an Inotech IE-50 R vibrating jet 
encapsulator. The batch numbers for these batches were CLX 136/B IN (Inotech) 01–
09. The composition for all batches was as outlined in Table 6.1 below. 
 
                                      Table 6.1 Composition of scaled-up formulation CLX 136/B 
 
 
 
 
 
 
 
The processing conditions for these batches are outlined in Tables 6.2 and 6.3 below. 
The first batches attempted were CLX 136/B IN-01 and CLX 136/B IN-02 and although 
it was possible to make beads, the process was very inefficient (process yields of 32.4% 
CLX 136/B Scale-up 
Components g mg/g 
Celecoxib 2.86 60.43 
Solutol® HS-15 25.70 543.88 
Gelatin 15.00 317.39 
SDS 2.00 42.32 
D-Sorbitol 1.70 35.97 
Total 47.26 - 
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and 34.3% respectively) with the nozzle blocking on numerous occasions as a result of 
the solution not being sufficiently hot by the time it reached the nozzle. For all 
subsequent experiments, heated wire was wrapped around the solution tube to ensure 
that the solution remained at approximately 65°C prior to reaching the nozzle. Where 
processing was possible, the mechanism of jet ‘break-up’ was observed to be a 
‘dripping’ process in the case of these two batches (IN-01 and IN-02) which resulted in 
large beads (all of the beads were >2 mm after drying). The next batch produced, CLX 
136/B IN-03, proved more efficient with a process yield of 69.3 % but again the process 
was characterised as ‘dripping’. CLX 136/B IN-04 represented the first batch in which 
‘prilling’ was observed and it was noted that a very fine adjustment in the flow rate 
resulted in a change from a ‘dripping’ process to a ‘prilling’ process. The adjustments to 
the flow rate resulted in a very low process yield (17.7 %) as it proved difficult to find 
the correct combination of process conditions that were amenable to prilling-induced 
‘break-up’ of the liquid stream. Importantly, IN-04 represented the first batch in which 
dried beads with a diameter of < 2 mm were produced.  
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               Table 6.2 Processing conditions for Inotech batches IN-01, IN-02, IN-03 and IN-04 
Parameter IN-01 IN-02 IN-03 IN-04 
Heat wire set point (°C) N/A N/A 65 °C 65 °C 
 
Cooling oil temperature (°C) 
 
8–10 °C 8–10 °C 8–10 °C 8–10 °C 
Air Pressure (bar) NR NR 0.5 0.5 
 
Nozzle jacket temperature  
(°C) 
 
65 °C 65 °C 65 °C 65 °C 
 
Liquid flow 
observations/ 
recordings  
 
Liquid break 
up 
process 
Dripping Dripping Dripping Dripping/Prilling 
Approximate 
Flow rate  
NR NR NR NR 
Nozzle 
vibration 
Frequency 
(Hz) 
NR NR NR 45 
Amplitude 
 
NR NR NR 7 
 
Distance from nozzle to cooling 
bath (cm) 
 
NT NR NR NR 
Size of wet beads produced 
(mm) 
NR NR NR NR 
 
Size of dried beads produced  
(mm) 
2-2.5  2-2.5 2-2.5 1-2.5 
% Yield 32.4 34.3 69.3 17.7 
NR = Not recorded or not measured 
 
 
 
Following the observations for batch CLX 136/B IN-04, two further batches (CLX 
136/B IN-05 and IN-06) were produced to examine the impact of adjusting the flow rate 
and ultimately, the size of the beads produced. IN-05 and IN-06 were the first batches 
for which the flow rate of the delivery solution was measured. IN-05 was manufactured 
via a ‘dripping’ process with a recorded flow rate of approximately 8 g/min. As with 
previous dripping processes, all the beads (dried) produced were >2 mm. A sample of 
wet beads were also measured for IN-05 and were found to be within the size range of 
3-3.5 mm. The flow rate for batch IN-06 was increased and measured to be 
approximately 8.5 g/min. It was observed that the process alternated between ‘dripping’ 
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and ‘prilling’ with the flow rate adjusted throughout the process in an attempt to 
maintain a ‘prilling’ process. The resultant dried beads were found to be within a range 
of 1–2.5 mm which was reflective of the dual process. A sample of wet beads were also 
measured for IN-06 and were found to be within the size range of 1.5–3 mm. For the 
next two batches produced, CLX 136/B IN-07 and CLX 136/B IN-08, the flow rate 
increased toapproximately  10 g/min and although both processes were observed to be 
predominantly ‘prilling’ processes, the process flow rate required continual adjustment 
throughout the run to ensure that ‘prilling’ was maintained. These fine adjustments 
resulted in a variation in the size of beads (dried) produced as illustrated in Figure 6.4. 
In the case of IN-08, a phenomenon of ‘doubling’ was observed in which wet beads 
were colliding in the cooling oil and therefore resulted in a larger faction of beads > 
2mm. Based on a review of the processing parameters the ‘doubling’ phenomenon was 
attributed to a reduced nozzle height been employed (height from the nozzle tip to the 
top of the cooling bath). The process yields for batches IN-07 and IN-08 (71.1% and 
73.1% respectively) were higher than that previously achieved which was indicative of 
the increased level of control compared to the six previous batches.   
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           Table 6.3 Processing conditions for Inotech batches IN-05, IN-06, IN-07, IN-08 and IN-09 
Parameter IN-05 IN-06 IN-07 IN-08 IN-09 
Heat wire set point (°C) 65 °C 65 °C 65 °C 65 °C 65 °C 
 
Cooling oil temperature 
(°C) 
 
8–10 °C 8–10 °C 8–10 °C 8–10 °C 8–10 °C 
Air Pressure (bar) 0.5 0.5 0.5 0.5 0.5 
 
Nozzle jacket temperature  
(°C) 
 
65 °C 65 °C 65 °C 65 °C 65 °C 
 
Process/ 
flow rate 
Process type Dripping Dripping/ Prilling Prilling Prilling Prilling
 
Approximate 
Flow rate 8 g/min 8.5 g/min 10 g/min 10 g/min 10 g/min
[1]
 
Nozzle 
vibration 
Frequency 
(Hz) 45 45 45 45 45 
Amplitude 
 
7 7 7 7 7 
 
Distance from nozzle to 
cooling bath (cm) 
 
29 29 29 20 29 
Size range of wet beads 
produced (mm) 3–3.5 1.5–3 NR NR NR 
Size of dried beads 
produced  
(mm) 
2–2.5  1–2.5 See Figure 6.4 
See Figure  
6.4 
See Figure  
6.4 
% Yield NR NR 71.1 73.1 NR 
NR = Not recorded or not measured  
[1] = Flow rate regulator with enhanced sensitivity used for this trial 
 
The final batch produced was CLX 136/B IN-09. In the case of IN-09, the optimal 
process conditions from the previous batches were employed. Crucially a flow rate 
regulator with enhanced sensitivity was fitted for the manufacture of this batch which 
resulted in a much tighter control of the delivery flow rate of the solution to the nozzle 
and which consequently did not require adjustment during the process. The consistency 
introduced to the process as a result of this change resulted in a much tighter 
distribution of dried micobeads with 98.6% of microbeads being within the desired 
1.25–2 mm size range (Figure 6.4). 
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Figure 6.4 Fractions (%) of beads <1.25 mm, 1.25–2 mm and > 2mm following sieving of batches IN-07, 
IN-08 and IN-09. 
 
Further PSA was performed on IN-09 (Figure 6.5) which revealed a very narrow size 
distribution with 98.6% of the beads falling with a size range of 1.25–1.6 mm and 
73.4% being with a 1.25–1.4 mm. 
 
 
Figure 6.5 Fractions (%) of beads 1–1.25 mm, 1.25–1.4 mm, 1.4–1.6 mm and > 1.6 mm following 
sieving of batch IN-09. 
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All of batches produced (with the exception of batch IN-05) were tested with respect to 
their entrapment efficiency. In the case of batches IN-06, IN-07, IN-08 and IN-09, the 
fraction of beads with the smallest diameter were used for entrapment efficiency testing 
in order to preserve quantities of beads with diameters greater than 1.25 mm for coating 
trials. A comparison of the bead size used for analysis against the % entrapment 
efficiency revealed that larger beads (> 2mm) had a higher % entrapment which is 
likely attributable to a smaller surface area compared to small beads. This highlights a 
requirement to tightly control the bead size on scale-up to ensure that the entrapment 
efficiency is optimal. It is noted that for batch IN-09 that the % entrapment of the 
fraction tested (i.e., 80.4%) was at the higher end of that reported by Homar and 
colleagues for the encapsulation of CLX (Homar et al., 2009 – See Chapter 4 for further 
details). 
 
Table 6.4 % Entrapment efficiency and bead size used for analysis for batches IN-01 to IN-09 (excluding 
IN-05).  
Batch Number 
% Entrapment 
Efficiency (± % STDEV 
(n=2)) 
Fraction of bead size 
analysed 
CLX 136/B IN-01 92.08 ± 1.0% > 2 mm 
CLX 136/B IN-02 91.9 ± 0.1% > 2 mm 
CLX 136/B IN-03 93.70 ± 0.6% > 2 mm 
CLX 136/B IN-04 89.70 ± 0.8% > 2 mm 
CLX 136/B IN-06 75.6 ± 0.6% < 1.25 mm 
CLX 136/B IN-07 69.3 % ± 0.5% < 1.25 mm 
CLX 136/B IN-08 75.0% ± 1.3% < 1.25 mm 
CLX 136/B IN-09 80.4% ± 0.2% 1.25–1.4 mm 
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Release analysis in PW over a period of 24 h was performed on IN-09. The release 
profile shown in Figure 6.6 illustrates that the % release of formulation CLX 136/B 
described in Chapter 4 was maintained after scale-up on the Inotech IE-50 R. 
 
 
Figure 6.6 Percentage of drug released from release testing of formulation IN-09 in PW. The data 
presented are mean values ± STDEV (n=3). 
 
6.4.2 Coating optimisation to meet mouse TPP 
 
As described in the introduction, the formulation used for the mouse model study (CLX 
136/B C-02) did not meet the desired TPP requirement of <10% release at 2 h. As a 
result of the successful scale-up of formulation CLX 136/B (Section 6.4.1), there was 
now a sufficient quantity of beads available to allow for a coating optimisation study 
with the aim of meeting the mouse TPP.  This coating optimisation study involved the 
application of increased levels (weight gains) of SR in order to extend the lag time.  
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6.3.3.1 Increased levels of Surelease®  
 
Chapter 5 described the application of SR to formulation CLX 136/B at weight gains of 
5% (C-01) and 8% (C-02). Neither formulation met the TPP with in excess of 40% of 
the drug being released before 2 h. The primary challenge of this coating optimisation 
study was therefore to achieve a 2 h lag time in which of <10% of drug would be 
released. In an attempt to meet this challenge, four coating trials were performed in 
which SR weight gains of 17% (CLX 136/B C-03), 20% (CLX 136/B C-04), 27% (CLX 
136/B C-05) and 32% (CLX 136/B C-06) were achieved. It can be seen from Table 6.5 
and Figure 6.7 (in-vitro release data and profiles for formulations C-03 – C-06) that in 
excess of 30% of CLX was released from formulation C-03 (17% w/g SR) after a period 
of 2 h and therefore did not meet the TPP at the 2 h time point. In contrast, formulations 
C-04 (20% w/g SR), C-05 (27% w/g SR) and C-06 (32% w/g of SR) did not release any 
CLX (0%) after 2 h and therefore met the TPP at this time point (in addition to meeting 
the 6 h specification). The processing conditions for formulations C-03 to C-06 are 
detailed in Table 6.6 below. 
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Table 6.5 Percentage CLX released (± standard deviation (STDEV) from release testing of formulations 
C-03, C-04, C-05 and C-06 (two-step release method: 2 h in 0.1 M HCl (750 ml) followed by 16 h in 
phosphate buffer, pH 6.8 (1000 ml)).  
Time point (h) 
% CLX Released 
C-03 C-04 C-05 C-06 
0 0  0  0  0  
1 2.67 (±0.60) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
2 33.87 (±0.15) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 
4  61.00 (±0.60) 44.23 (±1.06) 29.95 (±0.83) 12.06 (±0.94) 
6 69.07 (±0.22) 72.65 (±0.07) 56.02 (±0.65) 53.53 (±1.32) 
12 67.74 (±0.15) 70.71(±0.38) 69.44 (±0.18) 71.33 (±0.54) 
18 64.58 (±0.07) 65.59 (±0.15) 66.71 (±0.18) 66.0 (±0.36) 
 
                  Table 6.6 Fluid bed processing conditions for formulations C-03, C-04, C-05 and C-06 
Parameter C-03 C-04 C-05 C-06 
 
Product temperature  (°C) 
 
41–42 40–41 40–41 39–40 
 
Inlet temperature  (°C) 
 
65 65–70 65–72 65–70 
 
Atomisation pressure (Bar) 
 
1.7 1.7 1.7 1.7 
 
Average spray rate (g/min) 
 
3–4 3–4 3–4 3–4 
 
Coating time (min) 
 
100 105 117 134 
 
Curing temperature (°C) 
 
40 40 40 40 
 
% Weight gain after curing 
 
17.3 20.8 27.2 32.4 
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Figure 6.7 Percentage of drug released from release testing of formulations C-03, C-04, C-05 and C-06 
(two-step release method: 2 h in 0.1 M HCl (750 ml) followed by 16 h in phosphate buffer, pH 6.8 (1000 
ml)). The data presented are mean values ± STDEV (n=3).  
Note: Only 12 h of the release profile is represented on the graph as the transit time in mice extends to a 
maximum of 12 h. 
 
It was concluded that whilst formulations C-04, C-05 and C-06 all met the mouse TPP, 
that formulation C-04 (20% w/g SR) was the most suitable for use in a follow on animal 
study as it represented the highest percentage release at the 6 h time point (72.65%) 
which would ensure a maximum possible release in the event of a shorter transit time. 
 
6.4.3 Coating optimisation to meet human TPP 
 
Having produced a product which met the desired mouse TPP, the focus of the coating 
optimisation study turned towards developing a product to meet the human TPP 
outlined in Section 6.2.3.2, that is, < 20% release at 2 h, 40-60% release at 6 h and > 
 258 
 
80% release after 18 h. Based on a review of Table 6.5, it was observed that none of the 
formulations met the human TPP at the 18 h time point, that C-05 (27% w/g SR) and C-
06 (32% w/g SR) met the TPP at the 6 h and 2h, that C-04 (20% w/g SR) only met the 
TPP at 2 h and that C-03 (17% w/g SR) did not meet the TPP at any of the specification 
points. Based on the observation that none of the formulations met the 18 h 
specification, the primary focus was to include excipients into the formulation that 
would enhance release at the end of the cycle. 
 
6.5.3.1 Inclusion of pore formers 
 
The initial attempts to enhance release at the latter end of the release profile involved 
the incorporation of pore formers into the SR coating. Two pore formers, Apple Pectin 
USP and Methocel® E5 were investigated. The details of these attempts are described 
below. 
 
A. Pectin 
 
In an attempt to assess the suitability of pectin as a pore former to meet the TPP at the 
18 h time point, a coating solution comprising 98:2 SR:pectin (SR:P) solids was 
prepared and applied to CLX 136/B. This ratio was chosen based on previous 
experiences at Sigmoid Pharma. The target weight gain for the formulation was 20% on 
the basis that the effect of the pore former might be more evident in an initial trial for a 
product with a lower overall percentage weight gain of SR than that for those weight 
gains that more closely reflected the desired human TPP (i.e., 27% and 32% w/g SR). 
Due to a lower coating efficiency for this coating solution, an even lower actual weight 
gain of 15% was achieved (CLX 136/B C-07). Formulation C-07 (15% w/g SR:P) was 
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compared to formulation C-03 (17% w/g SR) given that C-03 was the closet 
formulation to C-07 with respect to the coating weight gain. Formulation C-07 was also 
tested in the presence of pectinase. It can be seen from Figure 6.8 below, that the 
inclusion of pectin as a pore former at this concentration did not have any effect with 
respect to enhancing the % drug released at 18 h. 
 
 
Figure 6.8 Percentage of drug released from release testing of formulations C-03 and C-07 (two-step 
release method: 2 h in 0.1 M HCl (750 ml) followed by 16 h in phosphate buffer, pH 6.8 (1000 ml) ± 
addition of pectinase at 16 h). The data presented are mean values ± STDEV(n=3). 
 
B. Methocel® E5 
 
The use of Methocel® E5 as a pore former to meet the TPP at the 18 h time point was 
also investigated. Methocel® is a grade of HPMC widely used in the pharmaceutical 
industry and is recommended by Colorcon® for use as a pore former with SR coatings. 
A coating solution comprising 90:10 SR: Methocel® E5 (SR:M) solids was prepared 
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and applied to CLX 136/B. This ratio was chosen based on a recommendation from the 
manufacturer (Colorcon®). In this case, a target weight gain of 27% was set for this 
formulation, given that formulation C-05 (27% w/g SR) met the TPP at the 2 h and 6 h 
time points and that less coating polymer was required in comparison to formulation C-
06 (which also met the TPP at 2 h and 6 h). A slightly higher coating efficiency for this 
coating dispersion, resulted in an actual weight gain of 29% (CLX 136/B C-08). C-08 
(29% w/g SR:M) compared to formulation C-05 (27% w/g SR). It can be seen from 
Figure 6.9 below, that whilst formulation C-08 did result in enhanced % drug released 
at 18 h, the use of the pore former at this ratio resulted in a much higher rate of drug 
release and consequently the ability of the formulation to meet the 2 h and 6 h 
specifications was lost. 
 
 
Figure 6.9 Percentage of drug released from release testing of formulations C-05 and C-08 (two-step 
release method: 2 h in 0.1 M HCl (750 ml) followed by 16 h in phosphate buffer, pH 6.8 (1000ml)). The 
data presented are mean values ± STDEV(n=3). 
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6.5.3.2 Inclusion of Opadry® sub-coat 
 
Although the use of pore formers to meet the desired TPP had not been conclusively 
deemed unviable, for example, it is possible that the TPP could have been achieved by 
altering the concentrations of pectin or Methocel® employed, however the investment of 
time to assess this possibility was not warranted at this stage. Instead an alternative 
approach involving the application an Opadry® sub-coat to achieve the TPP at 18 h was 
investigated. A subcoat of 8% w/g Opadry® (OP) was applied to CLX 136/B beads prior 
to the application top coat of 27% w/g SR which yielded formulation C-09 (10% w/g 
OP + 27% w/g SR). A w/g of 27% SR was selected for the same reasons as outlined in 
Section 6.4.3.1 B. The % weight gain of Opadry® was based on previous experiences 
from Sigmoid Pharma. Formulation C-09 (8% w/g OP + 27% w/g SR) was compared to 
formulation C-05 (27% w/g SR) given that C-05 was the closest formulation to C-09 
with respect to SR coating weight gain. It can be seen from Figure 6.10 and Table 6.7 
below, that the inclusion of the Opadry® sub-coat modulated the release profile at both 
ends of the release profile and ultimately resulted in a product that met the desired 
human TPP at all three specification points. The processing conditions for both the 
Opadry® and SR coatings for C-09 are outlined in Table 6.8 below.  
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Figure 6.10 Percentage of drug released from release testing of formulations C-05 and C-09 (two-step 
release method: 2 h in 0.1 M HCl (750 ml) followed by 160 h in phosphate buffer, pH 6.8 (1000 ml)). 
The data presented are mean values ± STDEV(n=3). 
 
 
Table 6.7 Percentage CLX released (± standard deviation (STDEV) from release testing of formulations 
C-05 and C-09 (two-step release method: 2 h in 0.1 M HCl (750 ml) followed by 16 h in phosphate 
buffer, pH 6.8 (1000 ml)).  
 
Time point (h) 
% CLX Released 
C-05 C-09 
0 0  0  
1 0.00 (±0.00) 0.0 (±0.00) 
2 0.00 (±0.00) 0.2 (±0.00) 
4  29.95 (±0.83) 12.1 (±1.84) 
6 56.02 (±0.65) 50.2 (±2.26) 
12 69.44 (±0.18) 84.2 (±1.13) 
18 66.71 (±0.18) 84.0 (±1.13) 
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Table 6.8 Fluid bed processing conditions for Opadry® and SR coating of formulation C-09  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.4 Application of the platform formulation to other APIs 
 
As described in the introduction, the final objective of the project was to assess the 
broader application of microbead formulation CLX 136/B with respect to other APIs. 
As the name suggests, formulation CLX 136/B was the 136th formulation produced in 
this study which ultimately resulted in a robust spherical microbead in which 
precipitation of the drug was not evident during processing and which yielded both a 
good release performance in PW and a high % entrapment efficiency. Given that the 
latter two quality attributes would require the development of API-specific analytical 
methods, a high throughput API screening experiment was designed to focus on critical 
quality attributes at the point of manufacture. The first critical quality attribute (CQA 1) 
involved an assessment as to whether Solutol® HS-15 (major component of CLX-
Parameter Opadry® Coating SR Coating 
 
Product temperature  (°C) 
 
39–41 45 
 
Inlet temperature  (°C) 
 
65––70 70 
 
Atomisation pressure (Bar) 
 
1.7 1.7 
 
Average spray rate (g/min) 
 
3 4 
 
Coating time (min) 
 
110 90 
 
Curing temperature (°C) 
 
40 40 
 
% Weight gain after curing 
 
8.0 26.9 
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136/B) had the ability to dissolve the given APIs at a concentration of 10% w/w (i.e., 
10% drug/90% Solutol® HS-15 – surfactant phase concentration of CLX 136/B). The 
second CQA (CQA 2) involved an assessment of the ability of those actives which were 
deemed to be ‘soluble’ in Solutol® HS-15 to be translated into robust (non-leaking) 
spherical microbeads in which precipitation was not evident during processing. The 
composition of the beads attempted was identical to CLX 136/B with the exception of 
the API.  Finally a review of the formulations attempted was performed in an effort to 
predict the type of actives that might be suitable for incorporation into the platform 
formulation. 
 
6.5.4.1 Solubility assessment in Solutol® HS-15 
 
The following APIs were screened with respect to their solubility in Solutol® HS-15 at 
10% w/w; Nimodipine, Aspirin, Ibuprofen, Busedonide, Sulindac, Diclofenac Sodium 
salt Naproxen, Zolpidem Tartrate, Naproxen-Sodium, Theophylline, Tacrolimus, 
Cyclosporine and Tramadol-HCl. The actives were selected from those available in the 
laboratory in addition to some anti-inflammatory agents which were specifically 
purchased for the screening study. The categorisation of the actives with respect to 
being ‘soluble’ or ‘insoluble’ is detailed in Table 6.9 below. An active which was 
‘soluble’ was considered to have met CQA 1 as described in Section 6.4.4. 
Table 6.9 List of actives that were deemed ‘soluble’ or ‘insoluble’ at 10% w/w in Solutol® HS-15 
Soluble Actives Insoluble Actives 
Nimodipine 
Aspirin 
Ibuprofen 
Busedonide 
Sulindac 
Diclofenac Sodium salt 
Naproxen 
 
Zolpidem Tartrate  
Naproxen-Sodium 
Theophylline 
Cyclosporine  
Tramadol-HCl 
Tacrolimus 
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The first observation based on a review of Table 6.9 is that out of 14 actives (including 
CLX) that 8 (i.e., >50%) were ‘soluble’ at 10% w/w which illustrates the powerful 
solubilising potential of Solutol® HS-15 and its suitability as a first line solubility 
screening agent for future projects. It is also noted that one of the other actives in the 
‘insoluble’ category (Tacrolimus) was almost fully solubilised in Solutol® HS-15 at 
10% w/w. 
 
6.5.4.2 Microbead feasibility manufacture 
 
All of the actives categorised as ‘soluble’ in Table 6.9, were progressed to a microbead 
feasibility study with the aim of assessing their ability to meet CQA 2 described in 
Section 6.4.4. A summary of these microbead formulation attempts is provided in Table 
6.10. 
 
Table 6.10 List of actives which were successful and unsuccessful in achieving CQA 2 
Active Comment CQA 2 Achieved? 
Naproxen 
 
Robust spherical white beads formed  
Ibuprofen 
 
Beads produced had poor bead shape  
Nimodipine 
 
Robust spherical yellow beads formed  
Busedonide 
 
Robust spherical yellow beads formed  
Diclofenac Sodium Salt Robust spherical transparent beads formed  
 
Aspirin 
 
Leaky beads formed, poor bead shape  
Sulindac 
 
Leaky beads formed, poor bead shape  
 
 
The initial observation based on a review of Table 6.10 is that out of 8 actives 
(including CLX) that 6 (75%) were successfully translated into microbeads which 
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illustrates the broad application of the formulation developed. It is also noted that it was 
possible to translate Tacrolimus (almost soluble in Solutol® HS-15 at 10% w/w – Refer 
to Section 6.4.4.1) into microbeads. 
 
6.5.4.3 Formulation review/predictability assessment 
 
The results outlined in Sections 6.4.4.1 and 6.4.4.2 describe a high throughout two-step 
screening tool for the assessment of the platform formulation (CLX 136/B) with respect 
to other APIs. Given the high success rate of the platform illustrated, in that 75% of 
actives which were shown to be ‘soluble’ in Solutol® HS-15 were subsequently 
successfully translated into microbeads, there does not exist a strong case for a 
theoretical prediction tool for assessing the use of the platform formulation. The 
physicochemical characteristics of all the actives were however analysed in order to 
elucidate whether any correlations exist. This assessment was based on two key 
questions; a) are there any physicochemical similarities between the actives that met 
CQA 1 and b) are there any physicochemical similarities between the actives that met 
CQA 2? A review of the physicochemical properties (including their chemical 
structures) of all the actives tested (including CLX) is provided in Tables 6.11 and 6.12 
below. Table 6.11 includes all the actives that were ‘soluble’ in Solutol® HS-15 whereas 
Table 6.12 includes all the actives that were ‘insoluble’ in Solutol® HS-15. Unless 
otherwise indicated the references for this table were from either the European 
Pharmacopeia (European Pharmacopeia, 2014), the United States Pharmacopeia (United 
States Pharmacopeia, 2010) or the Drug Bank database (Drugbank, 2014).  
 
 267 
 
     Table 6.11 Comparison of the physicochemical properties of all actives that were ‘soluble’ in Solutol® HS-15 
Active 
(including CQA status) 
Molecular 
weight Log P pKa 
Water 
Solubility 
Molecular 
Formula Chemical Structure 
Celecoxib 
CQA 1  
CQA 2  
381.37 3.9 11.1 
Practically 
insoluble in 
water 
(3.3 mg/L) 
C17H14F3O7N3 O2S 
 
 
Naproxen 
CQA 1  
CQA 2  
 
 
230.25 3.18 4.15 
Practically 
insoluble in 
water 
(15.9 mg/L) 
 
C14H14O3 
Ibuprofen 
CQA 1  
CQA 2  
 
 
206.28 3.97 4.91 
Practically 
insoluble in 
water 
(21 mg/L) 
C13H18O2 
 
       Note: USP and EP definition of ‘practically insoluble in water’:  ≥ 10,000 parts solvent required to dissolve 1 part solute
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Table 6.11 contd. Comparison of the physicochemical properties of all actives that were ‘soluble’ in Solutol® HS-15 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Santa Cruz Biotech Product Datasheet, 2014 N/A = Not available 
Note: USP and EP definition of ‘sparingly soluble in water’: 30–100 parts solvent required to dissolve 1 part solute 
Active 
(including CQA status) 
Molecular 
weight Log P pKa 
Water 
Solubility 
Molecular 
Formula Chemical Structure 
Busedonide 
CQA 1  
CQA 2  
 
 
430.53 1.9 N/A 
Practically 
insoluble in 
water 
 
C25H34O6 
 
Nimodipine 
CQA 1  
CQA 2  
 
 
418.44 3.05 N/A 
Practically 
insoluble in 
water 
(24 mg/L) [1] 
C21H26N2O7 
 
Diclofenac Sodium Salt 
CQA 1  
CQA 2  
 
296.14 4.57 4.15 
Sparingly 
soluble in 
water 
 
C14H10Cl2NO2 . 
Na 
 
 269 
 
 
 
Table 6.11 contd.  Comparison of the physicochemical properties of all actives that were ‘soluble’ in Solutol® HS-15 
 
 
Active 
(including CQA status) 
Molecular 
weight Log P pKa 
Water 
Solubility 
Molecular 
Formula Chemical Structure 
Aspirin 
CQA 1  
CQA 2  
 
180.15 1.19 3.49 
Slightly 
soluble in 
water 
(4600mg/L) 
C9H8O4 
 
Sulindac 
CQA 1  
CQA 2  
 
 
356.41 3.42 4.7 
Very slightly 
soluble in 
water 
 
C20H17FO3S 
 
 
Note: USP and EP definition of ‘slightly soluble in water’: 100–1000 parts solvent required to dissolve 1 part solute 
          USP and EP definition of ‘very slightly soluble in water’: 1000–10,000 parts solvent required to dissolve 1 part solute  
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     Table 6.12   Comparison of the physicochemical properties of all actives that were ‘insoluble’ in Solutol® HS-15 
Active 
(including CQA status) 
Molecular 
weight Log P pKa 
Water 
Solubility 
Molecular 
Formula Chemical Structure 
Naproxen Sodium 
CQA 1  
 
252.24 3.18[1] N/A 
Soluble in 
water 
(250 g/L[1]) 
C14H13NaO3 
 
 
 
 
 
Zolpidem Tartrate 
CQA 1  
 
 
764.82 3.85 [2] 6.2 [2] 
Slightly 
soluble in 
water 
 
[C19H21N3O]2 
. C4H6O6 
 
Tramadol-HCl 
CQA 1  
 
 
299.83 2.4 9.41 Freely soluble in water C16H25ClNO2 . HCl 
 
      [1]Roche Product Datasheet, 2014 [2] Soine, 2008  N/A = Not available 
      Note: USP and EP definition of ‘soluble in water’: 10–30 parts solvent required to dissolve 1 part solute 
                USP and EP definition of ‘freely soluble in water’:  1–10 parts solvent required to dissolve 1 part solute 
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Table 6.12 contd. Comparison of the physicochemical properties of all actives that were ‘insoluble’ in Solutol® HS-15 
Active 
(including CQA status) 
Molecular 
weight Log P pKa 
Water 
Solubility 
Molecular 
Formula Chemical Structure 
Theophylline 
CQA 1  
 
 
180.12 -0.02 8.81 
Slightly 
soluble in 
water 
(7360 mg/L) 
C7H8N4O2 
 
Tacrolimus 
CQA 1  
 
 
804.01 3.3 N/A 
Practically 
insoluble in 
water 
 (4–
12mg/L)[1] 
C44H69NO12  
 
Cyclosporine 
CQA 1  
 
 
1202.61 4.12 Non-ionizable 
Practically 
insoluble in 
water 
 
C62H111N11O12 
 
     [1] Patel et al., 2012 N/A = Not available 
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In terms of CQA 1 (i.e., the ability of Solutol® HS-15 to dissolve the active) it is 
important to refer back to the structure of Solutol® HS-15 as described in Chapter 2. 
Solutol® HS-15, is a PEG (polyethylene glycol) fatty acid ester consisting of PEG 
mono- and di-esters of 12 hydroxystearic (primary lipophilic component) and of about 
30% free PEG. In Chapter 2, the solubility of CLX in stearic acid and a range of PEGs 
(i.e., the primary components of Solutol® HS-15) was examined and it was found that 
CLX was 40–95 times more soluble in the range of PEGs tested in comparison to stearic 
acid therefore it is reasonable to assume that the solubilising power of Solutol® HS-15 
in relation to CLX is predominantly PEG related. In spite of its name, PEG has 
hydroxyl groups only at each end of the polymeric chain, therefore, except for these 
ends, the polymer is essentially non-polar and hence is more amenable for dissolving 
non-polar compounds. 
Based on a review of the ‘insoluble’ compounds in Table 6.12, it was noted that three 
out of six of the insoluble compounds are salts. These are highly polar compounds with 
pure ionic bonds and therefore would not readily dissolve in PEG or PEG 15 
hydroxystearate (i.e., Solutol® HS-15). Of the remaining ‘insoluble’ compounds, 
Tacrolimus and Cyclosporine are much larger molecules than any of the other actives 
screened (aside from Zolpidem tartrate (another ‘insoluble’ compound) and therefore it 
is proposed that they are too bulky to interact with the hydrophobic structure of Solutol® 
HS-15 (i.e., the molecules of the active and the solvent are too big to have an 
interaction). It is notable that Tacrolimus which is smaller and less bulky than 
Cyclosporine had a better solubility in Solutol® HS-15.  Finally in the case of 
Theophylline, it has a pKa of 8.8 and therefore is also quite polar and will become 
ionized at pH<8 and hence is unlikely to solubilise in Solutol® HS-15. With respect to 
the actives that were ‘soluble’ in Solutol® HS-15 (Table 6.11), it would appear that the 
majority of these compounds are pushing towards the non-polar side of the spectrum 
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and therefore are suitable for dissolving in PEG or PEG 15 hydroxystearate. This 
includes CLX, which is unionized between pH 1-11 and would only lose a proton from 
the sulfonamide group at a very high pH. The main exception in Table 6.11 to the 
theory proposed would appear to be the one salt in the list (i.e., Diclofenac Sodium salt), 
however when compared to the other salts that were ‘soluble’ in Solutol® HS-15 (Table 
6.12), Diclofenac Sodium salt (sparingly soluble in water) has a lower water solubility 
than Tramadol HCl (freely soluble in water) or Naproxen Sodium (soluble in water) 
therefore one could reasonably argue that it is still a very non-polar compound and 
hence soluble in Solutol® HS-15. It is also noted that it is a much smaller compound 
compared to Zolpidem Tartrate. 
In terms of CQA 2, as previously stated 75% of the actives that were ‘soluble’ were 
found to be suitable for conversion into microbeads. A review of the suitable versus 
unsuitable actives with respect to CQA 2 (Table 6.11) highlighted that the two 
unsuitable actives had a higher water solubility compared to the other six actives. 
In summary, it is concluded that the platform formulation is very versatile but that non-
polar small molecules with very poor water solubility are most suited to the application. 
 
6.5 Conclusions 
 
Whilst Chapter 5 described the assessment of the anti-cancer and anti-inflammatory 
effects of a coated microbead formulation in a CRC murine model, the limitation of the 
formulation, that is that it was not fully colon targeted was also identified. The primary 
focus of this phase of the project (Chapter 6) was therefore to overcome these 
limitations by scaling-up microbead production and subsequently optimising the coating 
applied to the microbeads. Microbead production was successfully scaled-up via 
automated prilling (using an Inotech IE-50 R encapsulator) which resulted in robust 
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microbeads with a very narrow size distribution, a high % entrapment efficiency and 
critically a high and consistent level of drug release in release experiments using PW as 
the dissolution media. Importantly the scaled-up encapsulation process allowed for 
batch sizes in the region of 50 g which made significant coating optimisation studies a 
possibility. These coating optimisation studies initially focused on optimising the 
coating in order to meet the desired TPP for colon delivery in a mouse. This target was 
achieved by applying increased levels of the SR polymer (20%, 27% and 32% weight 
gains). The focus of the project then switched to meeting the desired TPP for human 
colon delivery and specifically to enhance release at the end of the release cycle to meet 
clinical and regulatory needs. This aim was achieved by applying a HPMC based sub-
coat (Opadry® White) under the SR coat.  The final aspect of the project focused on 
assessing the broader application of the platform formulation using alternative actives to 
CLX. This assessment illustrated the versatility of the formulation in that out of a total 
of 14 actives tested (including CLX), 50% were successfully converted into robust 
spherical microbeads in which there was no evidence of precipitation during processing. 
A review of the physicochemical characteristics of all the actives also identified that 
non-polar, poorly water soluble small molecules were most suited to the platform 
formulation. 
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6.6 Nomenclature 
 
Table 6.13 List of abbreviations which are listed according to their appearance in the text. 
Abbreviation Definition 
CLX  Celecoxib  
CRC Colorectal cancer 
w/g Weight gain 
PW Purified water 
HPMC Hydroxypropyl methylcellulose 
AOM Azoxymethane 
DSS Dextran sodium sulphate 
API Active pharmaceutical ingredient 
TPP Target product profile 
GI Gastrointestinal  
FIP International Pharmaceutical Federation 
NMT Not more than 
EC Ethylcellulose 
HPLC High performance liquid chromatography  
SDS Sodium dodecyl sulphate 
LPM  Litres per minute 
PSA Particle size analysis 
SR Surlease® 
STDEV Standard deviation 
SR:P Surelease®:Pectin 
SR:M Surelease®:Methocel E5 
OP Opadry® 
PEG Polyethylene glycol 
CQA Critical quality attribute 
CLX xxx/B 
Celecoxib bead formulation numbering system where xxx is a 
sequential number and B is bead 
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7.1 Conclusion and perspectives 
 
Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide 
with an estimated 1,360,000 new cases of CRC diagnosed worldwide in 2012, (Cancer 
Research UK, 2013).  In Ireland, CRC is the second most common type of cancer (as it 
is in Europe) and it is predicted that the number of cases of colorectal cancer will double 
between 2015 and 2040 (National Cancer Registry Ireland 2013 and 2014).  
 
As with other cancers, currently, the most effective treatments for colorectal cancer 
(combinations of surgical resection, radiation, and/or chemotherapy) depend on the 
detection of the cancer at a very early-stage. Despite the more widespread use of 
colorectal cancer screening (e.g., via colonoscopy procedures for patinets presenting 
with positive faecal occult blood tests), unfortunately, it has not been possible to 
identify all individuals at the earliest stages of disease. In fact, most patients present to 
their physician with advanced cancer when standard treatments for solid malignancies 
result in a much lower 5-year survival (Wang and Dubois, 2010). Thus, an effective 
approach for this disease must include prevention and targeted therapy. It is generally 
agreed that an effective way to control cancer is to find better ways of preventing it 
and/or detecting the disease at its earliest stage (Wang and Dubois, 2010). This is 
particularly important in the case of colitis associated cancer as the entire colon is 
considered to be at a heightened risk of dysplasia which ultimately requires surgical 
removal of the entire colon, therefore chemopreventive approaches present obvious 
benefits. Since elevated cyclooxygenase-2 (COX-2) expression was found in most 
colorectal cancer tissue and is associated with worse survival among CRC patients, 
investigators have sought to evaluate the effects of nonsteroidal anti-inflammatory 
drugs (NSAIDs) for CRC prevention and treatment. The epidemiologic studies, clinical 
trials and animal experiments indicate that NSAIDs are among the most promising 
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chemopreventive agents for this disease. NSAIDs exert their anti-inflammatory and 
anti-tumour effects primarily by reducing prostaglandin production via inhibition of 
COX-2 activity, therefore there has been a particular focus on the use of COX-2 
inhibitors for CRC prevention and treatment (Wang and Dubois, 2010). As described in 
Chapter 1, there is a significant body of research illustrating the anti-CRC effects of 
COX-2 inhibitors such as Celecoxib (CLX). The significant drawbacks of current 
therapy with the marketed CLX product Celebrex®, that is the serious cardiovascular 
(CV) and gastrointestinal (GI) side effects associated with the drugs, were also outlined. 
Chapter 1 revealed that the unwanted side effects of Celebrex® are a) dose related (CV 
and GI side effects) and b) dosage form related (GI side effects) (Sacchetti, 2013, 
Soloman et al., 2005 and FDA labelling Revision for Celebrex Capsules, 2008). The 
core objective of this project was to develop a more effective CLX formulation in which 
the solubility issues associated with the drug would be addressed, thereby ultimately 
allowing for the unwanted side effects associated with Celebrex® to be eliminated or 
reduced. A five step plan was developed to meet this core objective. These five steps 
were as follows; 
 
1. Development of a lipid-based formulations to enhance the solubility of CLX 
 
2. An assessment of the anti-cancer effects of selected lipid-based formulations in 
an in-vitro cell culture model and a comparison to the anti-cancer effects of 
Celebrex® 
 
3. The translation of the optimal lipid-based formulation into a multiparticulate 
lipid-based drug delivery system (LBDDS), a microbead formulation, and the 
optimisation of the same microbead formulation 
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4. The application of controlled release polymers to the optimal microbead 
formulation to enable colonic delivery in a mouse, an assessment of the anti-
cancer effects of the colonic targeted formulation a comparison to the anti-
cancer effects of Celebrex® 
 
5. The optimisation of the coated microbead formulation to allow for the 
development of a more colon specific formulation for use in future in-vivo 
mouse and human studies. The phase of the project also involved a scale-up of 
microbead manufacture and the application of the platform formulation to other 
active ingredients. 
 
The primary conclusions from each of these phases of the project are outlined below. 
References are also made to links between these conclusions and the various stages of a 
‘parallel screening model’ which was unexpectedly developed through the course of this 
work and which is described later in the chapter. 
 
In the first phase of the project (Chapter 2), lipid-based liquid formulations were 
produced, formulations CLX 016/L and CLX 021/L, which were demonstrated to have 
a greater drug release performance to that of Celebrex®. These liquid formulations were 
based on the non-ionic surfactant Solutol® HS-15 and the semi-synthetic medium chain 
triglyceride Miglyol® 810N (parallel screening - stage 2). An initial feasibility study 
also illustrated that these formulations were amenable to translation into spherical and 
robust gelatine based microbeads. This result was an important first step in the project 
as it demonstrated the potential to meet the two key critical quality attributes (CQAs) of 
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the desired formulation outlined in Chapter 1; 1) A LBDDS in which CLX was fully 
dissolved and 2) the translation of the LBDDS into a multiparticulate form..  
 
The second phase of the project (Chapter 3) involved testing a hypothesis that the lipid-
based CLX formulations had the potential for a more efficacious inhibitory effect than 
Celebrex® in a CRC cell line on the basis that pre-dissolving the drug would enable 
direct interaction with colon cancer cells (parallel screening – stage 3). The testing of 
this hypothesis demonstrated that CLX liquid formulations (CLX 016/L and CLX 
021/L) performed significantly better than the marketed CLX product Celebrex® with 
respect to their ability to prevent the proliferation but also motility of a HT29 CRC cell 
line in-vitro. The CLX liquid formulations were also shown to significantly reduce the 
motility (a marker for the metastatic potential of cancer cells) of the HT29 CRC cell 
line, whereas Celebrex® did not have a significant effect. One of the key findings of this 
phase of the project involved a demonstration that the liquid CLX formulations 
employed had an early apoptotic effect on HT29 cells, whereas CLX alone had both a 
necrotic and an early apoptotic effect, which was a very significant finding as it 
presented the opportunity for targeted CLX therapy with reduced GI side effects on the 
basis that the GI side effects related to Celebrex® are as a result of direct epithelial 
toxicity and are associated with the current presentation of the drug as a powder filled 
capsule (refer to Chapters 1 and 3 for further details).  A correlation between the drug 
release performance of CLX formulations in PW and their ability to affect HT29 cells 
was also observed, thereby presenting an effective tool for formulation screening 
(parallel screening - stage 2). CLX liquid formulations were used for this in-vitro cell 
study as they represented a precursor to microbead formulations and were also 
amenable for direct application to the cells.  
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In the third stage of the project (Chapter 4), the CLX liquid formulations developed in 
the first stage of the project and tested in the second stage of the project were used a 
precursor for the development of gelatine based microbead formulations using a gravity 
‘dripping’ technique. A spherical robust microbead formulation (CLX 136/B) with an 
entrapment efficiency of 97% and a maximum drug release in PW of 80% was 
produced, which represented a formulation that had the potential to consistently deliver 
CLX in a pre-solubilised state (parallel screening - stage 4). CLX 136/B was 
demonstrated to have a greater drug release performance to that of Celebrex®. A 
correlation between the droplet size and drug release performance was also established 
for optimal and sub-optimal formulations (parallel screening - stage 5). 
 
The proposition for the fourth stage of the project (Chapter 5) was to target the optimal 
microbead formulation developed in the previous phase of the project (CLX 136/B) to 
the colon of a mouse and to assess their potential, and that of Celebrex® for the 
treatment and prevention of CRC using an AOM (azoxymethane)/DSS (dextran sodium 
sulphate) mouse model for CRC. Surelease® (ethylcellulose polymer) was applied to the 
microbeads (batch size of 6 g) at a weight gain of 8% and despite not meeting a pre-
defined target product profile (TPP) for colonic specific delivery in a mouse (parallel 
screening stage 5), the partially colonic targeted formulation (C-02) was progressed to 
the CRC model (parallel screening stage 6). The effect of formulation C-02 on the 
attenuation of CRC tumours was compared to that of Celebrex® and was found to be 
marginally better. The anti-inflammatory effects of both formulations were also 
assessed, with formulation C-02 being found to have a significant effect compared to 
the control in the case of colon length and histology scoring (markers for inflammation) 
whereas Celebrex® did not meet significance. A hypothesis was also presented to 
suggest that the anti-cancer and anti-inflammatory effects of formulation C-02 may 
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have been achieved with a lower dose that that required to exert the effect seen for 
Celebrex® given that in the region of 50% of the drug from C-02 was likely released 
before the microbead reached the colon and therefore would not have been available in 
the colon to interact with colonic tissue.  
 
Given the limitations of the formulation tested in the mouse model, with respect to it 
being only partially colonic targeted, the focus of the fifth and final phase of the project 
was to optimise the coating applied to formulation CLX 136/B with the aim of 
producing a fully colonic targeted final product. This coating optimisation study 
necessitated the automated scale-up of microbead manufacture to allow for a sufficient 
quantity of microbeads for the coating. Microbead production was successfully scaled 
up via an automated prilling process (using an Inotech IE-50 R encapsulator) which 
resulted in robust microbeads with a very narrow size distribution, a high % entrapment 
efficiency and critically, a high and consistent level of drug release in release 
experiments using PW as the dissolution media. The application of increased levels of 
the Surelease® polymer (20%, 27% and 32% weight gains) resulted in a product that 
met the predefined mouse TPP. Having achieved the primary objective of the fifth phase 
of the project, the focus of the project then switched to meeting the desired TPP for 
human colonic delivery and specifically to enhance release at the latter end of the 
release profile to meet clinical and regulatory needs. This aim was achieved by applying 
a HPMC (hydroxypropyl methylcellulose) based sub-coat (Opadry® White) under the 
Surelease® coat.  The final part of the project focused on assessing the broader 
application of the platform formulation using alternative actives to CLX. A total of 14 
actives tested with 50% of these successfully converted into microbeads thereby 
illustrating the versatility of the platform formulation.  
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Parallel screening is defined as a cost-effective approaching for selecting a suitable drug 
delivery system to enhance the chances of achieving the required effects (e.g., 
bioavailability) for a given drug in the clinic (Chow and Kane, 2011). The requirement 
for parallel screening approaches is as a result of a major change in the types of new 
chemical entities (NCEs) being presented to formulation scientists. Literature shows 
that there is an increasing number of poorly soluble compounds in the drug discovery 
pipeline with BCS (biopharmaceutical classification system) Class II drugs (poorly 
soluble/highly permeable drugs such as CLX) and Class IV drugs (poorly 
soluble/poorly permeable representing 90% of NCEs, whereas BCS Class II and Class 
IV drugs only account for approximately 36% of the existing top 200 marketed drugs 
(Figure 7.1) (Chow and Kane, 2011 and Hauss, 2007). Current discovery programmes 
have the potential to create a significant loss of economic and therapeutic opportunity 
due to product attrition resulting from poor bioavailability (primarily due to poor 
solubility), however it is believed that applying suitable technologies and approaches to 
increase the bioavailability of poorly soluble molecules will reduce the attrition rate, 
will increase the number new drugs getting to the market and consequently will bring 
better healthcare to patients (Chow and Kane, 2011). 
 
 
Figure 7.1 Breakdown of NCEs and existing drugs with respect to their BCS classification.  
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Class I: highly soluble/highly permeable, Class II: poorly soluble/highly permeable, Class III: highly 
soluble/poorly permeable and Class IV: poorly soluble/poorly permeable. (Adapted from Chow and 
Kane, 2011) 
 
As outlined in Chapter 1, there are a number of formulation approaches which can be 
utilised to address the poor solubility of drug candidates and historically pharmaceutical 
companies have assessed the available technologies in an uncertain fashion that has 
resulted in a significant investment of time and money (See Figure 7.2). 
                
Figure 7.2 Uncertain pathway historically adopted by pharmaceutical companies to assess available 
technologies which has resulted in a drain on resources (Adapted from Chow and Kane 2011). 
A parallel screening strategy is advocated by Chow and Kane in order to increase the 
speed of screening drug candidates and to identify a suitable technology to progress the 
molecule to a proof-of-concept stage. The parallel screening strategy proposed by Chow 
and Kane involves the six steps outlined in Table 7.1 below. The equivalent six steps 
executed in the development of the CLX formulation are also described for comparison 
purposes. 
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Table 7.1 Six step parallel screening strategy advocated by Chow and Kane (Chow and Kane, 2011) and 
comparison to equivalent CLX formulation development steps 
Parallel 
Screening 
Step 
Chow and Kane Equivalent CLX Formulation Development Steps 
1 
Upfront scientific assessment 
including an assessment of the 
physicochemical characteristics of 
the drug 
 
Documentation of CLX API physicochemical 
characteristics (Chapter 1) and latterly the 
physicochemical characteristics of the various APIs 
screened (Chapter 6) 
2 
Screening experiments including 
solubility screening, thermal 
analysis etc. 
 
Excipient solubility screening (Chapter 2) and drug 
release screening experiments in PW 
3 
In-vitro assessments such as 
permeation studies involving Caco-
2 cell lines  
 
Cell proliferation studies involving HT29 cell lines 
and correlation with drug release performance in PW 
(Chapter 3) 
 
4 
Preparation of pilot formulations 
using inexpensive miniaturised (API 
sparing) equipment 
 
Manual preparation of microbeads (Chapter 4) and 
latterly encapsulation using lab scale Inotech 
encapsulator (Chapter 6). Coating of small batches of 
microbeads on MFL01 fluid bed coater (Chapters 5 
and 6). 
5 
Predictive analytical test methods to 
select pilot formulation for 
bioavailability studies 
 
Release studies on coated microbeads using two step 
release media (acid followed by phosphate buffer to 
mimic GI conditions) and development of model 
specific TPPs (Chapters 5 and 6). 
6 
Suitable animal model for 
bioavailability assessment 
 
Attenuation of CRC tumours in studies involving 
AOM/DSS induced mice (Chapter 5) 
 
 
As eluded to earlier, it was not an intended aim of this project to develop a parallel 
screening model, however based on the results presented and in particular the API 
screening study described in Chapter 6, it is clear that a very robust model has been 
developed for the screening of molecules linked to the prevention and treatment of 
CRC. In addition to a CRC parallel screening model, despite increased bioavailability 
not being a focus of this project, stages 1, 2, 4 and 5 of the model are deemed to be 
directly transferable to a model screening for enhanced bioavailability whereas stages 3 
(in-vitro cell model) and 5 (in-vivo animal model) could easily be adapted to suitable 
models where bioavailability enhancement is the aim of an alternative project (i.e., this 
model has the potential for a much broader application than CRC). 
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In terms of the next stages of development for the CLX product, a number of key 
milestones have been identified. These include; 
 
• Modulation of the release profiles for the formulations designed for colonic 
targeting in a mouse (formulations C-04, C-05 and C-06) in order to ensure 
>80% release at 12 h to guarantee the maximum possible dose of drug is made 
available. 
 
• A repeat of the AOM/DSS CRC mouse model described in Chapter 5 using a 
fully colonic targeted microbead formulation. It is also recommended that this 
study would involve an assessment of CLX levels in the blood (i.e., a 
pharmacokinetic (pK study)) for both CLX microbeads and Celebrex®. This is 
important so as to verify that the CLX released from the microbead formulation 
is exerting its effect via luminal interaction rather than via systemic delivery but 
also to understand if CLX in the microbeads has an alternative mode of action 
compared to Celebrex®. It is known that CLX is rapidly eliminated from the 
blood which thereby might limit its therapeutic concentration at the tumour site 
(Paulson et al., 2000).  It is also recommended that tissue samples be taken as 
part of any animal study to assess levels of markers such as PGE2 
 
• It is also recommended to perform a pK study on the uncoated CLX formulation 
to assess its potential to improve the bioavailability of CLX compared to 
Celebrex® for the treatment of osteoarthritis, adult rheumatoid arthritis and 
ankylosing spondylitis.  
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• Performance of a drug loading study for formulation CLX 136/B to assess the 
boundaries of the formulation with respect to its physicochemical performance 
(e.g., will a higher drug loading affect its release performance). 
 
• Performance of excipient compatibility studies in order to establish an impurity 
profile for the product. 
 
• Performance of a packaging study to elucidate the optimal packaging (e.g., 
bottles, blister packaging) for the product. 
 
• Performance of stability studies at ICH (International Conference on 
Harmonization) conditions in order to establish the stability of the formulation 
and ultimately to set a shelf-life for the product. 
 
• Performance of clinical studies to assess the efficacy and safety of the 
formulation. 
 
Although the focus of clinical cancer research and indeed of this project with CLX has 
predominantly been on chemoprevention, the potential chemotherapeutic use of CLX in 
cancer is also attracting considerable attention. Chemotherapeutic agents and radiation 
therapy have been shown to enhance COX-2 protein expression in human cancer cells, 
which in turn results in resistance to therapy, therefore there is a desire to determine 
whether CLX enhances the chemo-sensitivity and radio-sensitivity of tumour cells 
(Wang and Dubois, 2010). Preclinical studies have shown that CLX potentiates the 
effects of radiotherapy (Davis et al., 2004) and that a combination treatment of CLX 
with oxaliplatin had synergistic effects on inhibition of tumour growth in a mouse 
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xenograft model of human colon cancer (Zhao et al., 2009). Combination products in 
general are in fact an area of increased attention both from a chemotherapeutic but also 
a chemopreventative perspective with recent evidence illustrating that a combination of 
CLX and erlotinib (an EGFR tyrosine kinase inhibitor) had more effective prevention of 
polyp formation in APCMin/+ mice and more significant inhibition of tumour growth in a 
xenograft model than either drug individually (Buchanan et al., 2007). The combination 
therapies cited leverage on the principle that by combining CLX with the synergistic 
effects of other drugs that a lower dose of CLX may be used thereby reducing the 
undesired side effects associated with CLX (Wang and Dubois, 2010). 
 
In conclusion, despite a large body of evidence illustrating the chemopreventative 
effects of CLX, the identification of adverse CV side effects associated with the drug 
has understandably made it difficult for the development of new formulations in this 
field, however to ignore the potential benefits of chemoprevention with CLX is to 
continue to accept a higher than necessary death rate from colorectal cancer is patients 
who do not have access to or are not fully compliant with colorectal cancer screening 
and it also ignores the needs of a subset of patients for whom routine colorectal cancer 
screening is not as an effective detection mechanism (i.e., patients with colitis 
associated dysplasia) (Wang and Dubois, 2010). It is unlikely that chemoprevention will 
completely replace screening, but its success may lead to fewer screening exams and to 
fewer cancer-related deaths, especially in high risk groups (Arber, 2008). This project 
has resulted in the development of a colonic targeted microbead formulation in which 
CLX is presented in a pre-dissolved micellar format within a multiparticulate, a 
combination that has been shown to greater than the marketed CLX formulation 
Celebrex® from a physicochemical perspective (in-vitro release testing), from an anti-
inflammatory perspective (in-vivo CRC animal study) and an anti-cancer perspective 
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(in-vitro CRC cell line study and in-vivo CRC animal study). Importantly this 
combination (i.e., pre-dissolved micellar format within a multiparticulate) has the 
potential to minimize GI and CV side effects associated with the current marketed 
formulation and thereby presents the prospect of a formulation that can capitalise on the 
anti-adenoma and anti-cancer effects described in previous clinical studies whilst 
addressing the serious side effects that ultimately led to the discontinuation of these 
studies. In summary the formulation developed here has the potential to put colorectal 
cancer prevention, using a safer more effective CLX formulation, back on the table for 
consideration. 
7.2 Nomenclature 
 
Table 7.2 List of abbreviations which are listed according to their appearance in the text. 
 
Abbreviation Definition 
CRC  Colorectal cancer  
NSAIDs  Non-steroidal anti-inflammatory drugs 
COX-2 Cyclooxygenase-2 
CLX Celecoxib 
GI Gastrointestinal 
CV Cardiovascular 
LBDDS Lipid-based drug delivery system 
PW Purified water 
SDS Sodium dodecyl sulphate 
AOM Azoxymethane 
DSS Dextran sodium sulphate 
TPP Target product profile 
HPMC Hydroxypropyl methylcellulose 
ICH International conference on harmonisation 
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